diclofenac and Ache
diclofenac has been researched along with Ache in 429 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of intra-articular injection of diclofenac etalhyaluronate (DF-HA) in patients with osteoarthritis (OA) of the hip, ankle, shoulder, or elbow." | 9.51 | Diclofenac-hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial. ( Ikegami, H; Kano, K; Kubo, T; Kumai, T; Nishii, M; Seo, T, 2022) |
| "To compare the efficacy and safety of ketoprofen plasters and diclofenac plasters after 3 weeks of administration in patients with osteoarthritis-related knee pain." | 9.41 | Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial. ( Cha, JE; Ershova, O; Hyun, BJ; Kastanayan, A; Krechikova, D; Nikulenkova, N; Polyakova, S; Shvarts, Y; Vinogradova, I; Yakushin, S, 2021) |
| "To compare the effectiveness of suppository diclofenac (100mg), cervical lidocaine 25mg -prilocaine 25mg cream (5% EMLA) and placebo in pain relief for hysterosalpingography." | 9.41 | Pain Relief for Hysterosalpingography: A Randomized Controlled, Double Blinded Trial Comparing Suppository Diclofenac, Prilocaine/Lignocaine (EMLA) Cream And Placebo. ( Agboghoroma, OC; Babandi, RM; Durojaiye, KW; Essiet, EA; Jimoh, KO, 2021) |
| "The application of topical diclofenac has been suggested as a possible treatment for Achilles tendinopathy." | 9.41 | Topical diclofenac vs placebo for the treatment of chronic Achilles tendinopathy: A randomized controlled clinical trial. ( Bovard, J; Bussin, E; Cairns, B; Fredericson, M; Gerschman, T; Scott, A, 2021) |
| "Both diclofenac and tramadol are equally effective in controlling pain in AP with similar safety profile." | 9.34 | Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study. ( Dhaka, N; Gupta, V; Kochhar, R; Kumar, NS; Muktesh, G; Samanta, J; Samra, T; Sarma, P; Sinha, SK; Yadav, TD, 2020) |
| "Immediately post-IVI, patients in Group 2 reported significantly lower VAS pain scores compared to placebo while no statistically significant difference was found between patients that received topical diclofenac and placebo." | 9.24 | Diclofenac for pain associated with intravitreal injections: a prospective, randomized, placebo-controlled study. ( Georgakopoulos, CD; Makri, OE; Pagoulatos, DD; Pharmakakis, N; Tsapardoni, FN, 2017) |
| "To determine the effectiveness of diclofenac potassium combined with 2% lidocaine gel in reducing the pain of intrauterine device (IUD) insertion." | 9.22 | Diclofenac plus lidocaine gel for pain relief during intrauterine device insertion. A randomized, double-blinded, placebo-controlled study. ( Elsetohy, KA; Fouda, UM; Salah Eldin, NM; Shaban, MM; Sobh, SM; Tolba, HA, 2016) |
| "The results of our study showed that lidocaine puffs provided the best pain relief than the other analgesics used." | 9.20 | Effect of paracetamol, dexketoprofen trometamol, lidocaine spray, pethidine & diclofenac sodium application for pain relief during fractional curettage: A randomized controlled trial. ( Acmaz, G; Aksoy, H; Başer, M; Bayraktar, E; Müderris, İİ; Yilmaz, MO, 2015) |
| "These results show that the recommended daily dose of diclofenac potassium, in three 50 mg doses across the day and evening, offers effective menstrual pain relief across 24 h, compared with placebo, in women with severe primary dysmenorrhea." | 9.19 | The 24-h progression of menstrual pain in women with primary dysmenorrhea when given diclofenac potassium: a randomized, double-blinded, placebo-controlled crossover study. ( Avidon, I; Baker, FC; Iacovides, S, 2014) |
| "The aim of the study is to determine whether dermal scarification is equally effective for treating acute renal colic compared to diclofenac sodium intramuscular therapy." | 9.19 | Dermal scarification versus intramuscular diclofenac sodium injection for the treatment of renal colic: a prospective randomized clinical trial. ( Dimitriadis, G; Dimopoulos, P; Gkagkalidis, K; Ioannidis, A; Ioannidis, S; Kampantais, S; Laskaridis, L; Patsialas, C; Toutziaris, C; Vakalopoulos, I, 2014) |
| "Post-marketing study of combined therapy of OA of different localizations using diclofenac, aescin and original glucosamine sulfate in Russia and Ukraine demonstrated decrease of the pain severity, assessed by numeric rating scale, after 8 weeks of the treatment." | 9.17 | [Impact of combined therapy using glucosamine sulfate and anti-inflammatory agent on pain severity in patients with osteoarthritis: prospective, non-controlled postmarketing study]. ( Belen'kiĭ, DA; Borisenko, OV, 2013) |
| "Diclofenac suppository, a non-steroidal anti-inflammatory drug (NSAID), is used widely in rheumatoid arthritis (RA) patients with severe arthritic pain." | 9.17 | A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. ( Arimori, K; Chosa, E; Fujita, K; Kawai, K; Nishio, T; Ogata, K; Setoguchi, N; Takamura, N; Tokunaga, J; Yamamoto, R, 2013) |
| "The aim of this study was to assess the efficacy of desmopressin nasal spray compared with diclofenac given intramuscularly in patients with acute renal colic caused by urolithiasis." | 9.15 | A comparative assessment of the clinical efficacy of intranasal desmopressin spray and diclofenac in the treatment of renal colic. ( Behera, NC; Kumar, S; Mandal, AK; Prasad, S; Sarkar, D; Singh, SK, 2011) |
| "We assessed the analgesic efficacy of levobupivacaine when administered as an adjuvant to diclofenac sodium in prostate biopsy pain management and effects of prostate biopsy on sexual function." | 9.14 | 'Multimodal' approach to management of prostate biopsy pain and effects on sexual function: efficacy of levobupivacaine adjuvant to diclofenac sodium - a prospective randomized trial. ( Aktoz, T; Atakan, IH; Inci, O; Kaplan, M; Memis, D; Turan, U, 2010) |
| "To investigate the extent and time course of pain intensity upon treatment with a topical diclofenac patch compared with placebo in acute traumatic sport injury based on a validated and established end point." | 9.14 | Extent and time course of pain intensity upon treatment with a topical diclofenac sodium patch versus placebo in acute traumatic injury based on a validated end point: post hoc analysis of a randomized placebo-controlled trial. ( Kirch, W; Mueller, EA; Reiter, S, 2010) |
| "This randomized, controlled, double-blind clinical study in parallel groups evaluated the safety and efficacy of an oral combination diclofenac-cholestyramine, nucleotides (uridine and cytidine) and vitamin B12 versus the oral combination of nucleotides and vitamin B12 in the treatment of acute, non-traumatic pain." | 9.14 | Treatment of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxycobalamin. ( Bendavit, GG; Cohen, JC; Geller, M; Higashi, R; Mibielli, MA; Nunes, CP; Oliveira, L; Scussel, AB, 2010) |
| "To compare the efficacy and safety of the COX-2 inhibitor lumiracoxib 400 mg once daily (qd) and naproxen 500 mg twice daily (bid) in patients with acute musculoskeletal pain caused by uncomplicated soft tissue injury." | 9.13 | A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain. ( Adekunle, F; Andrews, C; Ellis, G; Kinch, H; Kyle, C; Zachariah, J, 2008) |
| "Randomized clinical trials evaluating ultramicronised diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified." | 9.12 | Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. ( Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M, 2021) |
| "To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis." | 9.12 | Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. ( Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C, 2006) |
| "A randomized, controlled, cross-over trial compared single doses of 50 mg diclofenac potassium sachets and tablets with placebo in 328 patients with migraine pain, treating 888 attacks." | 9.12 | Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. ( Diener, HC; Edson, K; Gács, G; Lyczak, P; Montagna, P; Mulder, LJ; Schumann, G; Siegel, J; Zöller, B, 2006) |
| "To compare the efficacy and side effects of transdermal diclofenac patch with eutectic mixture of local anesthetic (EMLA) cream in attenuating venous cannulation pain." | 9.12 | Transdermal diclofenac patch vs eutectic mixture of local anesthetics for venous cannulation pain. ( Agarwal, A; Gautam, S; Gupta, D; Singh, U, 2007) |
| "To compare the time to presentation of the analgetic and anti-inflammatory effects of granulated and tablet nimesulide and sodium diclofenac since the start of therapy for gouty arthritis (GA)." | 9.12 | [Comparison of the time to analgetic and anti-inflammatory effect in the treatment of gouty arthritis with nimesulide and sodium diclofenac]. ( Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonova, VA, 2007) |
| "It was concluded that diclofenac sodium and paracetamol are effective and well tolerated as a short term treatment alternatives for acute ankle injuries." | 9.12 | The efficacy of paracetamol in the treatment of ankle sprains in comparison with diclofenac sodium. ( Agus, H; Kayali, C; Surer, L; Turgut, A, 2007) |
| "A previously published study comparing the efficacy of comfrey extract to a commercial diclofenac (CAS 78213-16-8) preparation in the treatment of unilateral ankle sprains is critically re-evaluated." | 9.12 | Comfrey extract ointment in comparison to diclofenac gel in the treatment of acute unilateral ankle sprains (distortions). ( Bulitta, M; D'Anchise, R; Giannetti, B, 2007) |
| "To evaluate rectal diclofenac in the relief of perineal pain after trauma during childbirth." | 9.11 | Rectal analgesia for the relief of perineal pain after childbirth: a randomised controlled trial of diclofenac suppositories. ( Crowther, CA; Dodd, JM; Hedayati, H; Hotham, N; Pearce, E, 2004) |
| "Diclofenac is a non-steroidal anti-inflammatory drug used for a variety of painful and inflammatory conditions." | 9.11 | Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema. ( Kienzler, JL; Knops, A; Magnette, JL; Ménart, C; Nollevaux, F; Sallin, D, 2004) |
| "In a randomized, double-blind, controlled trial, 120 ASA 1 or 2 patients were allocated to receive diclofenac or normal saline as pretreatment to assess their effect on incidence and severity of pain during propofol injection." | 9.11 | Effect of diclofenac pretreatment on pain during propofol injection. ( Agarwal, D; Mohta, M; Sandhu, K; Sethi, AK, 2004) |
| "This double-blind randomized control study was conducted to evaluate whether a nonsteroidal anti-inflammatory drug (NSAID) could act as an effective pain control method during first trimester suction abortion, and whether co-treatment of NSAID with misoprostol will decrease the efficacy of the cervical ripening effect of misoprostol." | 9.10 | A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. ( Chan, CP; Ho, PC; Li, CF; Wong, CY, 2003) |
| "This was a randomized, double-blind, placebo-controlled study designed to compare the antihyperalgesic efficacy of topical (65 mg) and oral (93 mg) diclofenac via estimates of mechanical pain thresholds obtained at the site of induced inflammation with von Frey hairs." | 9.10 | Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain. ( Burian, M; Geisslinger, G; Seegel, M; Tegeder, I, 2003) |
| "There was minimal change in the degree of pain in the lidocaine-only and control groups during and after the treatment period." | 9.09 | Intrathecal methylprednisolone for intractable postherpetic neuralgia. ( Asai, M; Hashimoto, H; Kimura, F; Kotani, N; Kushikata, T; Matsuki, A; Muraoka, M; Yodono, M, 2000) |
| " The efficacy of misoprostol and ranitidine in the prevention of gastroduodenal damage in patients taking diclofenac for their cancer pain has been compared in this study." | 9.08 | Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. ( Bortolussi, R; Bortoluzzi, F; Cannizzaro, R; Fornasarig, M; Fracasso, A; Grazioli, I; Poletti, M; Sozzi, M; Testa, V; Valentini, M, 1995) |
| "Sixty female out-patients suffering from moderate to severe primary dysmenorrhea, aged 14-40 years (mean 27 years), entered this randomized, double-blind, 3-period, within-patient study, evaluating the efficacy and tolerability of diclofenac dispersible 46." | 9.08 | Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double-blind, within-patient, placebo-controlled study. ( Bakshi, R; Fedele, L; Marchini, M; Pistai, R; Tozzi, L, 1995) |
| "The efficacy and tolerability of aceclofenac, a new non-steroidal anti-inflammatory drug (NSAID) was compared to that of ketoprofen in a multicentre, double-blind, prospective, randomized study of 3-months duration in patients with rheumatoid arthritis." | 9.08 | Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. ( Ansoleaga, JJ; Gijón-Baños, J; Martín-Mola, E, 1995) |
| "Topical application, 4 times daily for 2 weeks, of the diclofenac-hyaluronan gel to 59 osteoarthritis patients induced a significantly greater (p = 0." | 9.08 | A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. ( Roth, SH, 1995) |
| "To compare the efficacy and tolerability of single doses of diclofenac dispersible and naproxen granular in patients with acute, painful, minor sports injuries." | 9.08 | Diclofenac dispersible provides superior analgesia with faster onset of action compared to naproxen granular in patients with acute, painful, minor sports injuries. ( Colombo, G; Giombini, A; Pamich, T; Peruzzi, E; Pisati, R, 1997) |
| "Efficacy of diclofenac in pain relief after hip alloplasty was investigated in 35 patients aged 61-73 (mean 66)." | 9.08 | [Diclofenac for treatment of postoperative pain after hip arthroplasty in older patients]. ( Bohatyrewicz, A; Litke, J; Mikulski, K, 1997) |
| "A prospective double-blind randomized trial was conducted on 184 cancer patients with moderate to severe chronic pain to evaluate the analgesic efficacy and tolerability of diclofenac alone (50 mg q." | 9.08 | Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. ( Celani, MG; De Angelis, V; Del Favero, A; Fumi, G; Lupatelli, M; Minotti, V; Monza, G; Pisati, R; Righetti, E; Rossetti, R; Tonato, M, 1998) |
| "Two hundred and sixty patients with lumbago or sciatic pain participated in a multicenter observer-blind randomized trial to compare the efficacy and tolerability of dipyrone 2." | 9.07 | Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer-blind multicenter study. ( Babej-Dölle, R; Eckmeyer, J; Freytag, S; Schinzel, S; Schmeider, G; Stankov, G; Zerle, G, 1994) |
| "The putative central analgesic activity of diclofenac was investigated in a human experimental pain model using intraneural electrical stimulation in the median nerve." | 9.07 | Diclofenac evaluated in a human experimental model of central pain. ( Björkman, R; Elam, M, 1993) |
| "The effect of diclofenac on pain after arthroscopy of the knee joint was investigated in 64 patients." | 9.07 | Diclofenac for pain relief after arthroscopy: a comparison of early and delayed treatment. ( Björkman, R; Brodd, B; Sandin, R; Stam, H; Sternlo, JE, 1993) |
| " as additive treatment to parenteral patient-controlled administration therapy (PCAT) with morphine in cancer pain has been investigated in a double-blind study." | 9.07 | Morphine-sparing effect of diclofenac in cancer pain. ( Björkman, R; Hedner, J; Ullman, A, 1993) |
| "At Helsinki University Central Hospital in Finland, clinical researchers divided 169 women into two groups (group 1: diagnostic laparoscopies; group 2: laparoscopic sterilizations) as part of a study to evaluate the effect of intravenous diclofenac on postoperative pain, nausea, and recovery after outpatient gynecological laparoscopy." | 9.07 | Effect of intravenous diclofenac on pain and recovery profile after day-case laparoscopy. ( Hovorka, J; Kallela, H; Korttila, K, 1993) |
| "In a multicentric, interindividual, double-blind study, the analgesic action, duration of effect, tolerability and side effects of the new combination preparation, Combaren (diclofenac-Na 50 mg+codeine phosphate 50 mg), were compared with those of diclofenac-Na 50 mg (Voltaren 50) in 184 patients with severe tumor-related pain." | 9.07 | [Drug therapy in severe tumor pain. Comparative study of a new combination preparation versus diclofenac-Na]. ( Strobel, E, 1992) |
| "A double-blind, crossover study was undertaken in general practice to compare the efficacy and tolerability of a new controlled-release indomethacin with sustained-release diclofenac sodium in patients with osteoarthritis." | 9.06 | Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of osteoarthritis: a comparative controlled clinical trial in general practice. ( Gostick, N; James, IG; Khong, TK; Miller, AJ; Roy, P; Shepherd, PR, 1990) |
| "The efficacy and tolerability of a new, controlled-release indomethacin (75 mg) tablet was compared to that of a sustained-release diclofenac sodium (100 mg) tablet in 84 patients with rheumatoid arthritis." | 9.06 | Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of rheumatoid arthritis: a comparative controlled clinical trial. ( Crowley, B; Hamill, JJ; Lyndon, S; McKellican, JF; Miller, AJ; Williams, P, 1990) |
| "Twenty-four patients with localized myofascial pain were treated with injections, 11 with 2 ml lidocaine 1% and 13 with 2 ml diclofenac (Voltaren) (50 mg) given in the trigger-point." | 9.06 | Diclofenac versus lidocaine as injection therapy in myofascial pain. ( Frost, A, 1986) |
| "The efficacy and tolerability of 100 mg suppositories of diclofenac sodium (Voltaren) and indomethacin were investigated in relieving symptoms of rheumatoid arthritis." | 9.05 | Comparison of diclofenac and indomethacin suppositories in rheumatoid arthritis. ( Valindas, E; Wafin, F; Wuolijoki, E, 1984) |
| "The efficacy of diclofenac sodium was investigated in the painful symptoms of primary dysmenorrhea and in reducing menstrual bleeding." | 9.05 | Treatment of primary dysmenorrhea with diclofenac sodium. ( Pulkkinen, MO; Riihiluoma, P; Wuolijoki, E, 1981) |
| "Diclofenac is commonly used for acute pain in children, but is not licensed for this indication in all age groups." | 8.85 | Diclofenac for acute pain in children. ( Pritchard, D; Savage, I; Standing, JF; Waddington, M, 2009) |
| "Topical diclofenac is widely used in the treatment of pain and inflammation." | 8.84 | Topical diclofenac and its role in pain and inflammation: an evidence-based review. ( Altman, R; Bellamy, N; Brühlmann, P; Da Silva, J; Huskisson, E; Taylor, RS; Zacher, J, 2008) |
| " It has proved as effective as diclofenac, naproxen and piroxicam in patients with osteoarthritis, diclofenac, ketorolac, tenoxicam and indomethacin in patients with rheumatoid arthritis and tenoxicam, naproxen and indomethacin in patients with ankylosing spondylitis." | 8.82 | Aceclofenac in the management of inflammatory pain. ( Legrand, E, 2004) |
| "Trials of 2 to 6 months' duration have shown aceclofenac to be an effective agent in the management of pain and rheumatic disease." | 8.81 | Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. ( Dooley, M; Dunn, CJ; Spencer, CM, 2001) |
| "The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of inflammation, its effect on cartilage remodeling and on the results of clinical studies comparing aceclofenac with other NSAIDs in these disorders." | 8.81 | [What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. ( Henrotin, Y; Paul, I; Reginster, JY, 2001) |
| "A meta-analysis was done with the final data from three trials that provided the first results relating to efficacy and safety of the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA) of the knee." | 8.78 | Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. ( Porzio, F, 1993) |
| " Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis." | 8.76 | Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980) |
| "Joint pain decreased after 2 weeks of therapy in all patients during treatment with Voltaren Emulgel 2% (diclofenac diethylamine 2%) in both groups." | 8.02 | [Evaluation of topical therapy of patients with osteoarthritis of small joints of the hands with Voltaren® Emulgel® 2% (diclofenac diethylamine 2%)]. ( Gromova, MA; Tsurko, VV, 2021) |
| "Using diclofenac mouthwash, 9/10 patients experienced pain score reduction from day 0 (mean score 6." | 7.96 | Diclofenac Mouthwash as a potential therapy for reducing pain and discomfort in chemo-radiotherapy-induced oral mucositis. ( Alam, P; Brennan, PA; Donnelly, O; Fedele, S; Gomez, RS; Lewthwaite, R; McGuigan, S; Sakthithasan, P, 2020) |
| " The goal of this study was to determine the impact of administration of the non-selective NSAID diclofenac in the inflammatory phase of bone repair in mice with or without lipopolysaccharide-induced systemic inflammation." | 7.91 | Defective bone repair in diclofenac treated C57Bl6 mice with and without lipopolysaccharide induced systemic inflammation. ( Abou-Rjeili, M; Akoury, E; Al-Saran, Y; Awlia, A; Chan, D; Henderson, JE; Lemarié, CA; Martineau, PA; Ouellet, S; Ramirez-Garcia-Luna, JL; Wong, TH, 2019) |
| "In this work, we propose a surgical suture that can sustainably release diclofenac (DF) for the local pain relief of surgical wounds." | 7.85 | Surgical suture braided with a diclofenac-loaded strand of poly(lactic-co-glycolic acid) for local, sustained pain mitigation. ( Choy, YB; Heo, CY; Huh, BK; Kim, BH; Kim, KR; Kim, SN; Lee, SH; Park, CG, 2017) |
| "To determine the frequency of perineal pain after childbirth after a single dose of diclofenac rectal suppository." | 7.83 | Diclofenac rectal suppository: an effective modality for perineal pain. ( Baloch, R; Memon, NY; Naz, S; Sattar, A, 2016) |
| "Topical diclofenac, with and without dimethyl sulfoxide (DMSO), modestly improves pain and function scores (by 4%-8%) for as long as 12 weeks in patients with osteoarthritis (OA) of the knee." | 7.81 | Clinical inquiry: does topical diclofenac relieve osteoarthritis pain? ( Hodge, B; Skolnik, D, 2015) |
| " In the present study, we compared the effects of crocin, safranal and diclofenac on local inflammation and its induced pain in rats." | 7.79 | Comparison of the effects of crocin, safranal and diclofenac on local inflammation and inflammatory pain responses induced by carrageenan in rats. ( Eghdami, K; Erfanparast, A; Farshid, AA; Samadi, F; Tamaddonfard, E, 2013) |
| "A pan-European study involving 23407 patients with pain due to various inflammatory or degenerative rheumatic diseases was undertaken in Austria, Belgium, Germany and Greece, to evaluate overall pain relief and satisfaction with aceclofenac therapy." | 7.71 | Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the manage ( Aslanidis, S; De Bast, J; Leeb, B; Lemmel, EM, 2002) |
| "This study determines the effects of dexamethasone versus co-administered dexamethasone and diclofenac, on carrageenan-evoked spinal c-Fos expression and peripheral oedema in the freely moving rat." | 7.69 | Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and associated spinal c-Fos expression in the rat. ( Besson, JM; Buritova, J; Chapman, V; Honoré, P, 1996) |
| "The effects of combined single oral treatments with non-steroidal anti-inflammatory drugs (NSAIDs) and the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan (DM) on arthritic pain were examined in a rat model of adjuvant-induced arthritis." | 7.69 | Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats. ( Caruso, FS; Frenk, H; Lu, J; Mao, J; Mayer, DJ; Price, DD, 1996) |
| "Adhesive capsulitis or frozen shoulder is a common condition characterized by shoulder pain and stiffness in which conservative methods of treatment such as glucocorticosteroids, anti-inflammatory drugs, and physiotherapy play a significant part." | 6.73 | Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder. ( Haghighi, MH; Hemmati, AA; Saeidian, SR, 2007) |
| "At day 3, pain was reduced by -20." | 6.71 | Analgesic efficacy of a lecithin-vehiculated diclofenac epolamine gel in shoulder periarthritis and lateral epicondylitis: a placebo-controlled, multicenter, randomized, double-blind clinical trial. ( Cacchio, A; Forgács, A; Monteforte, P; Rovetta, G; Spacca, G, 2005) |
| "Population pharmacokinetics of a fast release diclofenac were assessed with special focus on pharmacodynamic implications." | 6.69 | Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model. ( Brune, K; Drover, D; Geisslinger, G; Kettenmann, B; Kobal, G; Lötsch, J; Renner, B, 2000) |
| "Diclofenac patch was superior to placebo patch in relieving pain." | 6.69 | Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. ( Devers, A; Friedman, E; Galer, BS; Perander, J; Rowbotham, M, 2000) |
| "Ibuprofen was also better tolerated than diclofenac sodium (100 mg/day), the latter being associated with gastrointestinal side effects in a significant proportion of patients." | 6.68 | Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. ( Baumgartner, H; Blum, W; Bruhin, A; Gallachi, G; Goldinger, G; Saxer, M; Schwarz, HA; Trost, H, 1996) |
| " After achieving adequate analgesia with regular dosing of oral methadone (T1), patient-controlled analgesia with methadone was administered for 3 days (T2)." | 6.68 | Opioid-sparing effect of diclofenac in cancer pain. ( Barresi, L; Caligara, M; Dardanoni, G; Mercadante, S; Sapio, M; Serretta, R, 1997) |
| "Codeine 60 mg was significantly superior to placebo in all pain measures." | 6.66 | Experimental pain induced by electrical and thermal stimulation of the skin in healthy man: sensitivity to 75 and 150 mg diclofenac sodium in comparison with 60 mg codeine and placebo. ( Gaupmann, G; Mittelbach, G; Schneider, S; Stacher, G; Steinringer, H; Winklehner, S, 1986) |
| "Diclofenac HPβCD was generally well tolerated in clinical trials, with injection-site reactions among the most commonly reported adverse events." | 6.52 | Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain. ( Blair, HA; Plosker, GL, 2015) |
| "Many types of acute pain have been managed with traditional oral non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (coxibs)." | 6.46 | Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury. ( Argoff, CE; McCarberg, BH, 2010) |
| " The incidence of adverse events in patients taking single or multiple doses of diclofenac potassium is similar to that of ibuprofen and placebo." | 6.44 | Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. ( Moore, N, 2007) |
| " The chronic use of diclofenac sodium can lead to adverse gastrointestinal problems." | 6.43 | The use of topical diclofenac for pain in osteoarthritis of the knee: a review. ( Banning, M, 2006) |
| "Aceclofenac is a phenylacetic acid derivative with anti-inflammatory and analgesic properties similar to those of diclofenac." | 6.39 | Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. ( Brogden, RN; Wiseman, LR, 1996) |
| " This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action." | 6.38 | Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease. ( Franchimont, P; Reginster, JY, 1993) |
| "Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) advocated for use in painful and inflammatory rheumatic and certain non-rheumatic conditions." | 6.16 | Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. ( Sorkin, EM; Todd, PA, 1988) |
| "Dry needling on latent and active MTrPs combined with stretching and oral diclofenac combined with stretching can effectively relieve pain, improve function, and restore knee ROM affected by KOA." | 5.69 | Dry needling on latent and active myofascial trigger points versus oral diclofenac in patients with knee osteoarthritis: a randomized controlled trial. ( Dong, YL; Huang, QM; Ma, YT; Wang, B; Xie, WP; Zheng, YJ, 2023) |
| "Non-inferiority of SFPP to diclofenac gel was demonstrated in the efficacy for pain on rising from a chair." | 5.51 | Efficacy and safety of S-flurbiprofen plaster in knee osteoarthritis patients: A 2-week randomized controlled Phase III clinical trial compared to diclofenac gel. ( Fuady, A; Matsumoto, H; Tomatsu, K; Yasuda, S, 2022) |
| "To evaluate the efficacy and safety of intra-articular injection of diclofenac etalhyaluronate (DF-HA) in patients with osteoarthritis (OA) of the hip, ankle, shoulder, or elbow." | 5.51 | Diclofenac-hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial. ( Ikegami, H; Kano, K; Kubo, T; Kumai, T; Nishii, M; Seo, T, 2022) |
| "These findings suggest that acupuncture plus intramuscular injection of diclofenac is safe and provides fast and substantial pain relief for patients with renal colic compared with sham acupuncture in the emergency setting." | 5.51 | Effect of Adjunctive Acupuncture on Pain Relief Among Emergency Department Patients With Acute Renal Colic Due to Urolithiasis: A Randomized Clinical Trial. ( Cao, Y; Jia, LC; Li, HW; Liu, BL; Liu, CZ; Pei, XL; Qu, ZC; Shi, GX; Tu, JF; Wang, LQ; Yan, SY; Yang, JW; Yao, WH, 2022) |
| "There is a strong correlation between treatment resistant depression and increase in inflammatory cytokines in plasma and cerebrospinal fluid." | 5.48 | Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain. ( Abagyan, R; Cohen, IV; Lee, KC; Makunts, T, 2018) |
| " Both 27 and 48 demonstrated robust activity in the acute rat monoiodoacetate-induced osteoarthritis model of pain, and subchronic dosing of 48 showed a shift to a lower EC50 over 7 days." | 5.43 | Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain. ( Daanen, JF; DeGoey, DA; El-Kouhen, OF; Fricano, MM; Frost, JM; Ghoreishi-Haack, N; Gum, RJ; Hsieh, GC; Kort, ME; Lundgaard, GL; Matulenko, MA; Neelands, T; Pai, M; Shi, L; Zhan, C; Zhang, XF, 2016) |
| "Aceclofenac (ACE) is a systematically designed drug, developed to circumvent the concerns associated with diclofenac." | 5.43 | Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: a new therapeutic approach for pain and inflammation. ( Goyal, H; Katare, OP; Raza, K; Sharma, G; Thakur, K, 2016) |
| "The mechanical hyperalgesia was assessed by the Randall Selitto paw pressure test, which determines the paw withdrawal thresholds." | 5.43 | Association of terpinolene and diclofenac presents antinociceptive and anti-inflammatory synergistic effects in a model of chronic inflammation. ( Almeida, FR; Cunha, FV; Lopes, EM; Macedo, EM; Oliveira, FA; Piauilino, CA; Santos, WC; Sousa, BP; Sousa, DP, 2016) |
| "To compare the efficacy and safety of ketoprofen plasters and diclofenac plasters after 3 weeks of administration in patients with osteoarthritis-related knee pain." | 5.41 | Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial. ( Cha, JE; Ershova, O; Hyun, BJ; Kastanayan, A; Krechikova, D; Nikulenkova, N; Polyakova, S; Shvarts, Y; Vinogradova, I; Yakushin, S, 2021) |
| "To compare the effectiveness of suppository diclofenac (100mg), cervical lidocaine 25mg -prilocaine 25mg cream (5% EMLA) and placebo in pain relief for hysterosalpingography." | 5.41 | Pain Relief for Hysterosalpingography: A Randomized Controlled, Double Blinded Trial Comparing Suppository Diclofenac, Prilocaine/Lignocaine (EMLA) Cream And Placebo. ( Agboghoroma, OC; Babandi, RM; Durojaiye, KW; Essiet, EA; Jimoh, KO, 2021) |
| " Indomethacin was superior to celecoxib for pain score at rest at 8-12 h and celecoxib + parecoxib, diclofenac, and ketorolac for pain score on movement at 48 h." | 5.41 | Comparison of different nonsteroidal anti-inflammatory drugs for cesarean section: a systematic review and network meta-analysis. ( Blake, L; Carvalho, B; Carver, AL; Desai, N; Murdoch, I; O'Carroll, JE; Onwochei, DN; Sultan, P, 2023) |
| "The application of topical diclofenac has been suggested as a possible treatment for Achilles tendinopathy." | 5.41 | Topical diclofenac vs placebo for the treatment of chronic Achilles tendinopathy: A randomized controlled clinical trial. ( Bovard, J; Bussin, E; Cairns, B; Fredericson, M; Gerschman, T; Scott, A, 2021) |
| "6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED 50 = 37 micromol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED 50 = 72 micromol/kg, rat)." | 5.35 | Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. ( Adair, RM; Altenbach, RJ; Bettencourt, BM; Brioni, JD; Cowart, MD; Drizin, I; Esbenshade, TA; Fix-Stenzel, SR; Honore, P; Hsieh, GC; Liu, H; Marsh, KC; McPherson, MJ; Milicic, I; Miller, TR; Sullivan, JP; Wetter, JM; Wishart, N; Witte, DG, 2008) |
| "Both diclofenac and tramadol are equally effective in controlling pain in AP with similar safety profile." | 5.34 | Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study. ( Dhaka, N; Gupta, V; Kochhar, R; Kumar, NS; Muktesh, G; Samanta, J; Samra, T; Sarma, P; Sinha, SK; Yadav, TD, 2020) |
| " An open, randomized, prospective, longitudinal, comparative, and experimental clinical study was conducted to evaluate the efficacy of subcostal nerve block with lidocaine, comparing it in combination with tramadol or diclofenac for pain control during ESWL." | 5.27 | Comparison of three analgesic drug regimens with twelfth subcostal nerve block for pain control during extracorporeal shock wave lithotripsy. ( Del Rosario-Santiago, M; Garduño-Arteaga, LM; Jaspersen-Gastelum, J; Maldonado-Avila, M; Rios-Davila, V; Vela-Mollinedo, RA; Virgen-Gutierrez, F, 2018) |
| "Immediately post-IVI, patients in Group 2 reported significantly lower VAS pain scores compared to placebo while no statistically significant difference was found between patients that received topical diclofenac and placebo." | 5.24 | Diclofenac for pain associated with intravitreal injections: a prospective, randomized, placebo-controlled study. ( Georgakopoulos, CD; Makri, OE; Pagoulatos, DD; Pharmakakis, N; Tsapardoni, FN, 2017) |
| "This review was designated to evaluate the efficacy of parenteral ketorolac in treating acute migraine headache." | 5.22 | Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis. ( Abu Bakar, MA; Baharuddin, KA; Norhayati, MN; Nurathirah, MN; Yazid, MB, 2022) |
| "A phase II, 4 week, randomized, double-blind, parallel-group, two-arm, vehicle-controlled study compared pain relief with diclofenac sodium 2% topical solution versus control (vehicle only) in patients aged 40 to 85 years with radiographically confirmed primary OA of the knee." | 5.22 | Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, 4 week study. ( Holt, RJ; Kent, JD; Wadsworth, LT, 2016) |
| "To determine the effectiveness of diclofenac potassium combined with 2% lidocaine gel in reducing the pain of intrauterine device (IUD) insertion." | 5.22 | Diclofenac plus lidocaine gel for pain relief during intrauterine device insertion. A randomized, double-blinded, placebo-controlled study. ( Elsetohy, KA; Fouda, UM; Salah Eldin, NM; Shaban, MM; Sobh, SM; Tolba, HA, 2016) |
| "The combination of ibuprofen/paracetamol, taken immediately after initial endodontic therapy and root canal preparation in teeth with irreversible pulpitis, reduced post-endodontic pain (ClinicalTrials." | 5.22 | Double-blind Randomized Placebo-controlled Clinical Trial of Efficiency of Nonsteroidal Anti-inflammatory Drugs in the Control of Post-endodontic Pain. ( Abubakr, NH; Elzaki, WM; Ibrahim, YE; Ziada, HM, 2016) |
| "Patients with knee OA (n = 35) were compared on QST responses to a demographically-matched pain-free control group (n = 39), after which patients completed a month-long treatment study of diclofenac sodium topical gel (1 %), applied up to 4 times daily." | 5.22 | Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis. ( Cornelius, M; Dolman, AJ; Edwards, RR; Finan, PH; Lazaridou, A; Martel, MO; Wasan, AD, 2016) |
| "The results of our study showed that lidocaine puffs provided the best pain relief than the other analgesics used." | 5.20 | Effect of paracetamol, dexketoprofen trometamol, lidocaine spray, pethidine & diclofenac sodium application for pain relief during fractional curettage: A randomized controlled trial. ( Acmaz, G; Aksoy, H; Başer, M; Bayraktar, E; Müderris, İİ; Yilmaz, MO, 2015) |
| "These results show that the recommended daily dose of diclofenac potassium, in three 50 mg doses across the day and evening, offers effective menstrual pain relief across 24 h, compared with placebo, in women with severe primary dysmenorrhea." | 5.19 | The 24-h progression of menstrual pain in women with primary dysmenorrhea when given diclofenac potassium: a randomized, double-blinded, placebo-controlled crossover study. ( Avidon, I; Baker, FC; Iacovides, S, 2014) |
| "The aim of the study is to determine whether dermal scarification is equally effective for treating acute renal colic compared to diclofenac sodium intramuscular therapy." | 5.19 | Dermal scarification versus intramuscular diclofenac sodium injection for the treatment of renal colic: a prospective randomized clinical trial. ( Dimitriadis, G; Dimopoulos, P; Gkagkalidis, K; Ioannidis, A; Ioannidis, S; Kampantais, S; Laskaridis, L; Patsialas, C; Toutziaris, C; Vakalopoulos, I, 2014) |
| "To investigate whether sublingual misoprostol administered one hour before intrauterine device (IUD) insertion reduces failed insertions, insertion-related complications and pain in parous women delivered only by elective caesarean section (CS)." | 5.17 | Sublingual misoprostol prior to insertion of a T380A intrauterine device in women with no previous vaginal delivery. ( Ibrahim, ZM; Sayed Ahmed, WA, 2013) |
| "Diclofenac 4% spray gel rapidly relieves pain and improves mobility in patients with acute, uncomplicated ankle sprain and is well tolerated." | 5.17 | A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel in the treatment of acute uncomplicated ankle sprain. ( Giannetti, B; Menke, G; Novellini, R; Predel, HG; Seigfried, B, 2013) |
| "To compare the clinical efficacy between locally applied diclofenac diethylamine gel, EMLA cream and systemically given diclofenac sodium for the pain relief during extracorporeal shock wave lithotripsy (SWL) using Dornier Delta Compact Lithotripter." | 5.17 | Comparative study between three analgesic agents for the pain management during extracorporeal shock wave lithotripsy. ( Liu, J; Zang, YJ, 2013) |
| "Post-marketing study of combined therapy of OA of different localizations using diclofenac, aescin and original glucosamine sulfate in Russia and Ukraine demonstrated decrease of the pain severity, assessed by numeric rating scale, after 8 weeks of the treatment." | 5.17 | [Impact of combined therapy using glucosamine sulfate and anti-inflammatory agent on pain severity in patients with osteoarthritis: prospective, non-controlled postmarketing study]. ( Belen'kiĭ, DA; Borisenko, OV, 2013) |
| "Diclofenac suppository, a non-steroidal anti-inflammatory drug (NSAID), is used widely in rheumatoid arthritis (RA) patients with severe arthritic pain." | 5.17 | A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. ( Arimori, K; Chosa, E; Fujita, K; Kawai, K; Nishio, T; Ogata, K; Setoguchi, N; Takamura, N; Tokunaga, J; Yamamoto, R, 2013) |
| "Hyaluronic acid alone and in combination with sodium clodronate or diclofenac sodium produced a significant improvement in mean VAS pain score at 3 and 6-month follow-up." | 5.17 | Preliminary study of highly cross-linked hyaluronic acid-based combination therapy for management of knee osteoarthritis-related pain. ( Iannitti, T; Palmieri, B; Rottigni, V, 2013) |
| "To investigate if the 180-mg diclofenac epolamine and heparin sodium 5600 IU medicated plaster (DHEP-heparin) is more effective for pain reduction in mild-to-moderate contusions than the reference diclofenac epolamine 180 mg plaster (DHEP)." | 5.16 | Efficacy and tolerability of DHEP-heparin plaster in reducing pain in mild-to-moderate muscle contusions: a double-blind, randomized trial. ( Gugliotta, B; Hoffmann, P; Kopačka, P; Rovati, S, 2012) |
| "The aim of this study was to assess the efficacy of desmopressin nasal spray compared with diclofenac given intramuscularly in patients with acute renal colic caused by urolithiasis." | 5.15 | A comparative assessment of the clinical efficacy of intranasal desmopressin spray and diclofenac in the treatment of renal colic. ( Behera, NC; Kumar, S; Mandal, AK; Prasad, S; Sarkar, D; Singh, SK, 2011) |
| "To assess the spontaneous passage rate for patients being treated with alfuzosin 10mg daily after presenting with an acute ureteral stone compared with a control group, and to assess the respective pain control status." | 5.15 | Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial. ( Chau, LH; Fan, CW; Fung, BT; Li, JC; Li, MK; Tai, DC, 2011) |
| "The objective of this study was to evaluate the benefit of a seven-day buprenorphine transdermal patch for patients with chronic musculoskeletal pain previously receiving long-term treatment with ibuprofen or diclofenac alone." | 5.15 | [Application of a seven-day buprenorphine transdermal patch in multimorbid patients on long-term ibuprofen or diclofenac]. ( Böhme, K; Heckes, B; Thomitzek, K, 2011) |
| "In this prospective and randomized study, we aimed to compare the efficacy of a eutectic mixture of local anesthetics (EMLA) cream, diclofenac sodium (DS) and EMLA in combination with DS (EMLA+DS) for pain management during extracorporeal shock wave lithotripsy (ESWL)." | 5.14 | Comparison of three analgesic treatment protocols for pain management during extracorporeal shock wave lithotripsy. ( Eryildirim, B; Faydaci, G; Kuyumcuoğlu, U; Tarhan, F; Uruç, F, 2009) |
| "We assessed the analgesic efficacy of levobupivacaine when administered as an adjuvant to diclofenac sodium in prostate biopsy pain management and effects of prostate biopsy on sexual function." | 5.14 | 'Multimodal' approach to management of prostate biopsy pain and effects on sexual function: efficacy of levobupivacaine adjuvant to diclofenac sodium - a prospective randomized trial. ( Aktoz, T; Atakan, IH; Inci, O; Kaplan, M; Memis, D; Turan, U, 2010) |
| "To investigate the extent and time course of pain intensity upon treatment with a topical diclofenac patch compared with placebo in acute traumatic sport injury based on a validated and established end point." | 5.14 | Extent and time course of pain intensity upon treatment with a topical diclofenac sodium patch versus placebo in acute traumatic injury based on a validated end point: post hoc analysis of a randomized placebo-controlled trial. ( Kirch, W; Mueller, EA; Reiter, S, 2010) |
| "The severity of SWL-related pain was significantly better tolerated with dexketoprofen trometamol." | 5.14 | Comparison of the analgesic effects of dexketoprofen and diclofenac during shockwave lithotripsy: a randomized, double-blind clinical trial. ( Akduman, B; Erol, B; Hanci, V; Mungan, A; Tokgoz, H; Turksoy, O; Yurtlu, S, 2010) |
| "This randomized, controlled, double-blind clinical study in parallel groups evaluated the safety and efficacy of an oral combination diclofenac-cholestyramine, nucleotides (uridine and cytidine) and vitamin B12 versus the oral combination of nucleotides and vitamin B12 in the treatment of acute, non-traumatic pain." | 5.14 | Treatment of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxycobalamin. ( Bendavit, GG; Cohen, JC; Geller, M; Higashi, R; Mibielli, MA; Nunes, CP; Oliveira, L; Scussel, AB, 2010) |
| "to prospectively evaluate degree of pain during transrectal ultrasound-guided prostate biopsy after receiving analgesics treatment of oral morphine sulphate compared to suppository sodium diclofenac." | 5.13 | Comparison of efficacy between oral morphine sulphate and diclofenac suppository for analgesia during transrectal ultrasound-guided prostate biopsy. ( Haswir, H; Umbas, R, 2008) |
| "To compare the efficacy and safety of the COX-2 inhibitor lumiracoxib 400 mg once daily (qd) and naproxen 500 mg twice daily (bid) in patients with acute musculoskeletal pain caused by uncomplicated soft tissue injury." | 5.13 | A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain. ( Adekunle, F; Andrews, C; Ellis, G; Kinch, H; Kyle, C; Zachariah, J, 2008) |
| "Randomized clinical trials evaluating ultramicronised diclofenac, diclofenac, celecoxib, etodolac and placebo in patients with osteoarthritis were identified." | 5.12 | Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis. ( Auletta, LL; de Almeida Macedo, E; de Campos, GC; Kummer, AM; Millan Fachi, M; Papaleo Rosim, M, 2021) |
| " The meta-analysis indicated that celecoxib reduced pain more effectively than diclofenac sodium in patients with KOA, as evaluated by the VAS score." | 5.12 | Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis. ( Hou, S; Huang, H; Liang, G; Liang, H; Liu, J; Luo, M; Pan, J; Yang, W; Zeng, L; Zhao, J, 2021) |
| "Topical diclofenac and ketoprofen are the most rigorously studied topical NSAIDs in the treatment of knee OA and have demonstrated the most significant reduction in pain and improvement of function." | 5.12 | Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis. ( Brown, SM; Christophersen, C; Mulcahey, MK; Wolff, DG, 2021) |
| "To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib, compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with osteoarthritis." | 5.12 | Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. ( Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C, 2006) |
| "A randomized, controlled, cross-over trial compared single doses of 50 mg diclofenac potassium sachets and tablets with placebo in 328 patients with migraine pain, treating 888 attacks." | 5.12 | Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. ( Diener, HC; Edson, K; Gács, G; Lyczak, P; Montagna, P; Mulder, LJ; Schumann, G; Siegel, J; Zöller, B, 2006) |
| "To compare the ketoprofen TDS patch with diclofenac gel in the treatment of traumatic acute pain in benign sport-related soft-tissue injuries." | 5.12 | Topical ketoprofen TDS patch versus diclofenac gel: efficacy and tolerability in benign sport related soft-tissue injuries. ( Cobián, C; Esparza, F; García-Cota, JJ; Jiménez, JF; Maestro, A; Sánchez, C, 2007) |
| "To compare the efficacy and side effects of transdermal diclofenac patch with eutectic mixture of local anesthetic (EMLA) cream in attenuating venous cannulation pain." | 5.12 | Transdermal diclofenac patch vs eutectic mixture of local anesthetics for venous cannulation pain. ( Agarwal, A; Gautam, S; Gupta, D; Singh, U, 2007) |
| "The mean pain scores for the three groups were: diclofenac and paracervical block 5." | 5.12 | A randomized comparison of different methods of analgesia in abortion using manual vacuum aspiration. ( López, JC; Ruiz, E; Vega-Malek, JC; Vergara, V; Vigil-De Gracia, P, 2007) |
| "To compare the time to presentation of the analgetic and anti-inflammatory effects of granulated and tablet nimesulide and sodium diclofenac since the start of therapy for gouty arthritis (GA)." | 5.12 | [Comparison of the time to analgetic and anti-inflammatory effect in the treatment of gouty arthritis with nimesulide and sodium diclofenac]. ( Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonova, VA, 2007) |
| "It was concluded that diclofenac sodium and paracetamol are effective and well tolerated as a short term treatment alternatives for acute ankle injuries." | 5.12 | The efficacy of paracetamol in the treatment of ankle sprains in comparison with diclofenac sodium. ( Agus, H; Kayali, C; Surer, L; Turgut, A, 2007) |
| "A previously published study comparing the efficacy of comfrey extract to a commercial diclofenac (CAS 78213-16-8) preparation in the treatment of unilateral ankle sprains is critically re-evaluated." | 5.12 | Comfrey extract ointment in comparison to diclofenac gel in the treatment of acute unilateral ankle sprains (distortions). ( Bulitta, M; D'Anchise, R; Giannetti, B, 2007) |
| "Patients given diclofenac had significantly lower pain scores than those given placebo (2." | 5.11 | Diclofenac suppository analgesia for transrectal ultrasound guided biopsies of the prostate: a double-blind, randomized controlled trial. ( Donaldson, PJ; Habib, MR; Haq, A; Parry, JR; Patel, HR, 2004) |
| "To evaluate rectal diclofenac in the relief of perineal pain after trauma during childbirth." | 5.11 | Rectal analgesia for the relief of perineal pain after childbirth: a randomised controlled trial of diclofenac suppositories. ( Crowther, CA; Dodd, JM; Hedayati, H; Hotham, N; Pearce, E, 2004) |
| "Diclofenac is a non-steroidal anti-inflammatory drug used for a variety of painful and inflammatory conditions." | 5.11 | Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema. ( Kienzler, JL; Knops, A; Magnette, JL; Ménart, C; Nollevaux, F; Sallin, D, 2004) |
| " In well designed clinical trials of 1-52 weeks' duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100-400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily." | 5.11 | Lumiracoxib. ( Curran, MP; Lyseng-Williamson, KA, 2004) |
| "To analyse the efficacy of acupuncture as a complementary therapy to the pharmacological treatment of osteoarthritis of the knee, with respect to pain relief, reduction of stiffness, and increased physical function during treatment; modifications in the consumption of diclofenac during treatment; and changes in the patient's quality of life." | 5.11 | Acupuncture as a complementary therapy to the pharmacological treatment of osteoarthritis of the knee: randomised controlled trial. ( Aguilar, I; Borge, MA; Gaspar, O; Jurado, R; León, JM; Méndez, C; Panadero, MD; Perea-Milla, E; Sánchez-Rodríguez, F; Vas, J; Vega, E, 2004) |
| "STUDY OF HEALTHY VOLUNTEERS: This double blind study (bioadhesive plaster of diclofenac epolamine versus placebo), showed that the application of diclofenac epolamine for 24 hours induced a selective hypoanalgesic effect on the muscle, proportional to the degree of hypersensitivity to the pain observed in baseline conditions." | 5.11 | [Proof of the pharmacodynamic activity of Flector Plaster in healthy volunteers and patients suffering from osteo-arthritis of the knee]. ( Solignac, M, 2004) |
| " In the first few weeks of treatment, the mean changes in some variables (VAS, which assessed walking pain, standing pain and stiffness, as well as Lequesne's functional index) of the DJW group were significantly lower than those of the diclofenac group." | 5.11 | Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892]. ( Kunanusorn, P; Lhieochaiphunt, S; Pojchamarnwiputh, S; Pruksakorn, S; Rojanasthien, N; Sananpanich, K; Teekachunhatean, S, 2004) |
| "In a randomized, double-blind, controlled trial, 120 ASA 1 or 2 patients were allocated to receive diclofenac or normal saline as pretreatment to assess their effect on incidence and severity of pain during propofol injection." | 5.11 | Effect of diclofenac pretreatment on pain during propofol injection. ( Agarwal, D; Mohta, M; Sandhu, K; Sethi, AK, 2004) |
| "The aim of this study was to investigate the analgesic efficacy of Neodolpasse, a fixed-dose combination of orphenadrine and diclofenac, compared with those of its single active ingredients in a human pain model." | 5.11 | Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentials fro ( Eggenreich, U; Gschanes, A; Reitmeir, P; Schaffler, K, 2005) |
| "The topical diclofenac group had a significantly greater mean change in score (final minus baseline) compared to the vehicle control group for pain (-5." | 5.11 | Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. ( Baer, PA; Shainhouse, Z; Thomas, LM, 2005) |
| "There was no statistical difference in the mean reduction in pain score between any of the combinations at any point, although combination therapy was the first to reach a clinically significant reduction in pain score (<13 mm), and diclofenac-paracetamol combinations consistently produced a greater reduction in mean pain score than either nonsteroidal antiinflammatory drugs or paracetamol alone." | 5.11 | Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury. ( Lam, PK; Man, SY; Rainer, TH; Woo, WW, 2005) |
| "Intrarectal diclofenac suppository administration is a simple, safe, and effective procedure to reduce pain and improve patients' tolerance of transrectal ultrasound-guided prostate biopsy." | 5.11 | Diclofenac suppository administration in conjunction with lidocaine gel during transrectal ultrasound-guided prostate biopsy: prospective, randomized, placebo-controlled study. ( Aslan, G; Celebi, I; Goktay, Y; Gulcu, A; Irer, B, 2005) |
| "This double-blind randomized control study was conducted to evaluate whether a nonsteroidal anti-inflammatory drug (NSAID) could act as an effective pain control method during first trimester suction abortion, and whether co-treatment of NSAID with misoprostol will decrease the efficacy of the cervical ripening effect of misoprostol." | 5.10 | A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy. ( Chan, CP; Ho, PC; Li, CF; Wong, CY, 2003) |
| "This was a randomized, double-blind, placebo-controlled study designed to compare the antihyperalgesic efficacy of topical (65 mg) and oral (93 mg) diclofenac via estimates of mechanical pain thresholds obtained at the site of induced inflammation with von Frey hairs." | 5.10 | Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain. ( Burian, M; Geisslinger, G; Seegel, M; Tegeder, I, 2003) |
| "Patients who fitted the study criteria were given either 25 mg oral dexketoprofen trometamol or 50 mg sodium diclofenac immediately after triage; baseline and 15 minute pain scores were then recorded for one hour." | 5.10 | Randomised controlled trial of the onset of analgesic efficacy of dexketoprofen and diclofenac in lower limb injury. ( Herington, J; Kapadia, Y; Leman, P, 2003) |
| "Tamsulosin used as a spasmolytic drug during renal colic due to juxtavesical calculi increased the stone expulsion rate and decreased expulsion time, the need for hospitalization and endoscopic procedures, and provided particularly good control of colic pain." | 5.10 | Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. ( Dellabella, M; Milanese, G; Muzzonigro, G, 2003) |
| "Visual analog scale (VAS), verbal pain score (VPS), sedation score, frequency of opioid side effects, and morphine consumption were recorded every 4 hours." | 5.10 | Comparison of the morphine-sparing effects of diclofenac sodium and ketorolac tromethamine after major orthopedic surgery. ( Alexander, R; El-Moalem, HE; Gan, TJ, 2002) |
| "This study was undertaken to determine whether a special postoperative pain administration of tramadol and diclofenac provides any benefits in patients who underwent microsurgical lumbar discectomy." | 5.09 | Postoperative pain therapy after lumbar disc surgery. ( Filippi, R; Jage, J; Laun, J; Perneczky, A, 1999) |
| "There was minimal change in the degree of pain in the lidocaine-only and control groups during and after the treatment period." | 5.09 | Intrathecal methylprednisolone for intractable postherpetic neuralgia. ( Asai, M; Hashimoto, H; Kimura, F; Kotani, N; Kushikata, T; Matsuki, A; Muraoka, M; Yodono, M, 2000) |
| " The efficacy of misoprostol and ranitidine in the prevention of gastroduodenal damage in patients taking diclofenac for their cancer pain has been compared in this study." | 5.08 | Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. ( Bortolussi, R; Bortoluzzi, F; Cannizzaro, R; Fornasarig, M; Fracasso, A; Grazioli, I; Poletti, M; Sozzi, M; Testa, V; Valentini, M, 1995) |
| "Sixty female out-patients suffering from moderate to severe primary dysmenorrhea, aged 14-40 years (mean 27 years), entered this randomized, double-blind, 3-period, within-patient study, evaluating the efficacy and tolerability of diclofenac dispersible 46." | 5.08 | Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double-blind, within-patient, placebo-controlled study. ( Bakshi, R; Fedele, L; Marchini, M; Pistai, R; Tozzi, L, 1995) |
| "The efficacy and tolerability of aceclofenac, a new non-steroidal anti-inflammatory drug (NSAID) was compared to that of ketoprofen in a multicentre, double-blind, prospective, randomized study of 3-months duration in patients with rheumatoid arthritis." | 5.08 | Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. ( Ansoleaga, JJ; Gijón-Baños, J; Martín-Mola, E, 1995) |
| "Topical application, 4 times daily for 2 weeks, of the diclofenac-hyaluronan gel to 59 osteoarthritis patients induced a significantly greater (p = 0." | 5.08 | A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. ( Roth, SH, 1995) |
| "The clinical efficacy of the two topical analgesics, ketoprofen hydroalcoholic gel (Fastum gel) and diclofenac emulgel, for osteoarthritis of the knee was studied." | 5.08 | Topical analgesics for knee arthrosis: a parallel study of ketoprofen gel and diclofenac emulgel. ( Boonsanong, W; Penkitti, P; Soparat, K; Waikakul, S, 1997) |
| "To compare the efficacy and tolerability of single doses of diclofenac dispersible and naproxen granular in patients with acute, painful, minor sports injuries." | 5.08 | Diclofenac dispersible provides superior analgesia with faster onset of action compared to naproxen granular in patients with acute, painful, minor sports injuries. ( Colombo, G; Giombini, A; Pamich, T; Peruzzi, E; Pisati, R, 1997) |
| "Efficacy of diclofenac in pain relief after hip alloplasty was investigated in 35 patients aged 61-73 (mean 66)." | 5.08 | [Diclofenac for treatment of postoperative pain after hip arthroplasty in older patients]. ( Bohatyrewicz, A; Litke, J; Mikulski, K, 1997) |
| "A prospective double-blind randomized trial was conducted on 184 cancer patients with moderate to severe chronic pain to evaluate the analgesic efficacy and tolerability of diclofenac alone (50 mg q." | 5.08 | Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. ( Celani, MG; De Angelis, V; Del Favero, A; Fumi, G; Lupatelli, M; Minotti, V; Monza, G; Pisati, R; Righetti, E; Rossetti, R; Tonato, M, 1998) |
| "The gastric tolerability of nimesulide, a new nonsteroidal anti-inflammatory drug (NSAID), was compared with diclofenac, an established NSAID for the treatment of osteoarthritis (OA)." | 5.07 | Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients. ( Almeida, H; Cunha, MJ; Macciocchi, A; Porto, A, 1994) |
| "Two hundred and sixty patients with lumbago or sciatic pain participated in a multicenter observer-blind randomized trial to compare the efficacy and tolerability of dipyrone 2." | 5.07 | Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer-blind multicenter study. ( Babej-Dölle, R; Eckmeyer, J; Freytag, S; Schinzel, S; Schmeider, G; Stankov, G; Zerle, G, 1994) |
| "The putative central analgesic activity of diclofenac was investigated in a human experimental pain model using intraneural electrical stimulation in the median nerve." | 5.07 | Diclofenac evaluated in a human experimental model of central pain. ( Björkman, R; Elam, M, 1993) |
| "The effect of diclofenac on pain after arthroscopy of the knee joint was investigated in 64 patients." | 5.07 | Diclofenac for pain relief after arthroscopy: a comparison of early and delayed treatment. ( Björkman, R; Brodd, B; Sandin, R; Stam, H; Sternlo, JE, 1993) |
| " as additive treatment to parenteral patient-controlled administration therapy (PCAT) with morphine in cancer pain has been investigated in a double-blind study." | 5.07 | Morphine-sparing effect of diclofenac in cancer pain. ( Björkman, R; Hedner, J; Ullman, A, 1993) |
| "At Helsinki University Central Hospital in Finland, clinical researchers divided 169 women into two groups (group 1: diagnostic laparoscopies; group 2: laparoscopic sterilizations) as part of a study to evaluate the effect of intravenous diclofenac on postoperative pain, nausea, and recovery after outpatient gynecological laparoscopy." | 5.07 | Effect of intravenous diclofenac on pain and recovery profile after day-case laparoscopy. ( Hovorka, J; Kallela, H; Korttila, K, 1993) |
| " Ninety-six patients with rheumatoid arthritis took single daily doses of controlled release naproxen (N), diclofenac S." | 5.07 | Four commonly prescribed non-steroidal anti-inflammatory drugs for rheumatoid arthritis. ( Huskisson, EC, 1991) |
| "In a multicentric, interindividual, double-blind study, the analgesic action, duration of effect, tolerability and side effects of the new combination preparation, Combaren (diclofenac-Na 50 mg+codeine phosphate 50 mg), were compared with those of diclofenac-Na 50 mg (Voltaren 50) in 184 patients with severe tumor-related pain." | 5.07 | [Drug therapy in severe tumor pain. Comparative study of a new combination preparation versus diclofenac-Na]. ( Strobel, E, 1992) |
| "A double-blind, crossover study was undertaken in general practice to compare the efficacy and tolerability of a new controlled-release indomethacin with sustained-release diclofenac sodium in patients with osteoarthritis." | 5.06 | Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of osteoarthritis: a comparative controlled clinical trial in general practice. ( Gostick, N; James, IG; Khong, TK; Miller, AJ; Roy, P; Shepherd, PR, 1990) |
| "The efficacy and tolerability of a new, controlled-release indomethacin (75 mg) tablet was compared to that of a sustained-release diclofenac sodium (100 mg) tablet in 84 patients with rheumatoid arthritis." | 5.06 | Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of rheumatoid arthritis: a comparative controlled clinical trial. ( Crowley, B; Hamill, JJ; Lyndon, S; McKellican, JF; Miller, AJ; Williams, P, 1990) |
| " Eight hundred and forty-six patients with pain in one or two joints of the hip, knee, ankle or wrist participated in a randomised double-blind trial to compare the efficacy, tolerability and effect on quality of life of diclofenac sodium slow release (DSR) 100 mg daily and a combination of dextropropoxyphene 180 mg and paracetamol 1." | 5.06 | Joint pain and quality of life; results of a randomised trial. ( Bulpitt, CJ; Darekar, B; Fletcher, A; Parr, G, 1989) |
| " In clinical conditions marked by acute or chronic pain and inflammation, such as oral surgery, dysmenorrhea, low back pain, renal colic, and biliary colic, as well as in post-traumatic and postoperative conditions, diclofenac sodium, a nonsteroidal anti-inflammatory drug with potent prostaglandin synthetase inhibition, has been shown to be an effective analgesic agent." | 5.06 | Use of diclofenac in analgesia. ( Kantor, TG, 1986) |
| "Twenty-four patients with localized myofascial pain were treated with injections, 11 with 2 ml lidocaine 1% and 13 with 2 ml diclofenac (Voltaren) (50 mg) given in the trigger-point." | 5.06 | Diclofenac versus lidocaine as injection therapy in myofascial pain. ( Frost, A, 1986) |
| "The efficacy and tolerability of 100 mg suppositories of diclofenac sodium (Voltaren) and indomethacin were investigated in relieving symptoms of rheumatoid arthritis." | 5.05 | Comparison of diclofenac and indomethacin suppositories in rheumatoid arthritis. ( Valindas, E; Wafin, F; Wuolijoki, E, 1984) |
| "The efficacy of diclofenac sodium was investigated in the painful symptoms of primary dysmenorrhea and in reducing menstrual bleeding." | 5.05 | Treatment of primary dysmenorrhea with diclofenac sodium. ( Pulkkinen, MO; Riihiluoma, P; Wuolijoki, E, 1981) |
| "The nonsteroidal anti-inflammatory drug (NSAID) diclofenac epolamine (DHEP) formulated as a topical patch has demonstrated efficacy and safety in the localized treatment of acute pain from minor strains, sprains and contusions, and for epicondylitis and knee osteoarthritis." | 5.01 | Rationale and evidence for the incorporation of heparin into the diclofenac epolamine medicated plaster. ( Jones, C; Nencioni, A; Rainsford, KD; Roberts, MS, 2019) |
| " It was suggested that the new diclofenac/HPβCD formulation gives a rapid and effective response to acute pain and, furthermore, has pharmacokinetic and efficacy/safety profiles comparable to other medicinal products not containing cyclodextrins." | 4.93 | Efficacy and Safety Profile of Diclofenac/Cyclodextrin and Progesterone/Cyclodextrin Formulations: A Review of the Literature Data. ( Bonagura, AC; Cenami, R; Cimmaruta, D; Fiorentino, S; Fossati, T; Rossi, F; Scavone, C; Torella, M, 2016) |
| " All treatments except acetaminophen showed clinically significant improvement from baseline pain." | 4.91 | Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. ( Bannuru, RR; Kent, DM; McAlindon, TE; Schmid, CH; Vaysbrot, EE; Wong, JB, 2015) |
| "The non-opioid analgesic diclofenac is used worldwide for musculoskeletal and perioperative pain therapy." | 4.90 | [Diclofenac up2date - Part 1: Pharmacology and comparison with other drugs]. ( Bolbrinker, J; Bushuven, S; Heise, D, 2014) |
| "Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of inflammation and pain." | 4.88 | Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels. ( Gwanyanya, A; Macianskiene, R; Mubagwa, K, 2012) |
| "Diclofenac is a proven, commonly prescribed nonsteroidal anti-inflammatory drug (NSAID) that has analgesic, anti-inflammatory, and antipyretic properties, and has been shown to be effective in treating a variety of acute and chronic pain and inflammatory conditions." | 4.86 | Diclofenac: an update on its mechanism of action and safety profile. ( Gan, TJ, 2010) |
| "Diclofenac is commonly used for acute pain in children, but is not licensed for this indication in all age groups." | 4.85 | Diclofenac for acute pain in children. ( Pritchard, D; Savage, I; Standing, JF; Waddington, M, 2009) |
| "Topical formulations of non-steroidal anti-inflammatory drugs (NSAIDs), in particular diclofenac (DI), have become popular for treating various acute and chronic painful inflammatory conditions." | 4.84 | Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. ( Ehrlich, GE; Kean, WF; Rainsford, KD, 2008) |
| "Topical diclofenac is widely used in the treatment of pain and inflammation." | 4.84 | Topical diclofenac and its role in pain and inflammation: an evidence-based review. ( Altman, R; Bellamy, N; Brühlmann, P; Da Silva, J; Huskisson, E; Taylor, RS; Zacher, J, 2008) |
| " It has proved as effective as diclofenac, naproxen and piroxicam in patients with osteoarthritis, diclofenac, ketorolac, tenoxicam and indomethacin in patients with rheumatoid arthritis and tenoxicam, naproxen and indomethacin in patients with ankylosing spondylitis." | 4.82 | Aceclofenac in the management of inflammatory pain. ( Legrand, E, 2004) |
| "Trials of 2 to 6 months' duration have shown aceclofenac to be an effective agent in the management of pain and rheumatic disease." | 4.81 | Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. ( Dooley, M; Dunn, CJ; Spencer, CM, 2001) |
| "The aim of this article is to critically review the potential role of aceclofenac in the treatment of inflammatory pain and chronic osteoarticular disorder, based on its activity on the mediators of inflammation, its effect on cartilage remodeling and on the results of clinical studies comparing aceclofenac with other NSAIDs in these disorders." | 4.81 | [What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?]. ( Henrotin, Y; Paul, I; Reginster, JY, 2001) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "Injections of diclofenac induced antinociception in visceral pain models (writhing test, colorectal distension test), but not in two models of somatosensory pain (tail-flick and hot-plate test)." | 4.79 | Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. ( Björkman, R, 1995) |
| "Hyaluronan (HA) in combination with diclofenac is currently undergoing clinical trials as a topical preparation in the management of osteoarthritic pain, basal-cell carcinoma and actinic keratosis." | 4.79 | Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. ( Moore, AR; Willoughby, DA, 1995) |
| "A meta-analysis was done with the final data from three trials that provided the first results relating to efficacy and safety of the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA) of the knee." | 4.78 | Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. ( Porzio, F, 1993) |
| " Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis." | 4.76 | Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980) |
| "Diclofenac sodium is an anti-inflammatory drug commonly used to cure pain in various treatments." | 4.31 | Development of zinc ferrite nanoparticles with enhanced photocatalytic performance for remediation of environmentally toxic pharmaceutical waste diclofenac sodium from wastewater. ( Bilal, M; Hussain, N; Imran, M; Javaid, A; Jesionowski, T; Latif, S; Liaqat, A, 2023) |
| "Joint pain decreased after 2 weeks of therapy in all patients during treatment with Voltaren Emulgel 2% (diclofenac diethylamine 2%) in both groups." | 4.02 | [Evaluation of topical therapy of patients with osteoarthritis of small joints of the hands with Voltaren® Emulgel® 2% (diclofenac diethylamine 2%)]. ( Gromova, MA; Tsurko, VV, 2021) |
| " The acetylcholinesterase inhibitor (ACHEI); neostigmine, is known clinically for its analgesic effect in the perioperative phases proving high efficacy; besides possessing anti-inflammatory properties controlling immune cells and cytokine level." | 4.02 | The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation. ( Abdel-Bary, A; El-Tahan, RA; Gowayed, MA, 2021) |
| "Using diclofenac mouthwash, 9/10 patients experienced pain score reduction from day 0 (mean score 6." | 3.96 | Diclofenac Mouthwash as a potential therapy for reducing pain and discomfort in chemo-radiotherapy-induced oral mucositis. ( Alam, P; Brennan, PA; Donnelly, O; Fedele, S; Gomez, RS; Lewthwaite, R; McGuigan, S; Sakthithasan, P, 2020) |
| " platensis on different types of pain and inflammation in comparison to diclofenac sodium." | 3.96 | Effects of Spirulina platensis on pain and inflammation in long Evans rats. ( Akhter, S; Ali, T; Nipa, NS; Rafiq, K, 2020) |
| " The goal of this study was to determine the impact of administration of the non-selective NSAID diclofenac in the inflammatory phase of bone repair in mice with or without lipopolysaccharide-induced systemic inflammation." | 3.91 | Defective bone repair in diclofenac treated C57Bl6 mice with and without lipopolysaccharide induced systemic inflammation. ( Abou-Rjeili, M; Akoury, E; Al-Saran, Y; Awlia, A; Chan, D; Henderson, JE; Lemarié, CA; Martineau, PA; Ouellet, S; Ramirez-Garcia-Luna, JL; Wong, TH, 2019) |
| "In this work, we propose a surgical suture that can sustainably release diclofenac (DF) for the local pain relief of surgical wounds." | 3.85 | Surgical suture braided with a diclofenac-loaded strand of poly(lactic-co-glycolic acid) for local, sustained pain mitigation. ( Choy, YB; Heo, CY; Huh, BK; Kim, BH; Kim, KR; Kim, SN; Lee, SH; Park, CG, 2017) |
| "To determine the frequency of perineal pain after childbirth after a single dose of diclofenac rectal suppository." | 3.83 | Diclofenac rectal suppository: an effective modality for perineal pain. ( Baloch, R; Memon, NY; Naz, S; Sattar, A, 2016) |
| "Topical diclofenac, with and without dimethyl sulfoxide (DMSO), modestly improves pain and function scores (by 4%-8%) for as long as 12 weeks in patients with osteoarthritis (OA) of the knee." | 3.81 | Clinical inquiry: does topical diclofenac relieve osteoarthritis pain? ( Hodge, B; Skolnik, D, 2015) |
| "This study showed that TS has anti-visceral pain properties comparable with those of rofecoxib (a cyclooxygenase-2 inhibitor) and diclofenac, which suggests promise for the treatment of intractable visceral pain in humans." | 3.81 | Toona sinensis leaf extract has antinociceptive effect comparable with non-steroidal anti-inflammatory agents in mouse writhing test. ( Chan, TF; Hsu, HK; Hwang, SL; Lee, KS; Lieu, AS; Lin, CL; Su, YF; Yang, YC, 2015) |
| "This study investigated the effects of Phα1β, pregabalin and diclofenac using an animal model of fibromyalgia (FM)." | 3.80 | The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model. ( Castro, CJ; da Costa Lopes, AM; da Silva, CA; da Silva, JF; de Souza, AH; Ferreira, J; Gomez, MV; Klein, CP; Pereira, EM, 2014) |
| " Both pretreatment and post-treatment with the opioid antagonist naloxone into the DH significantly reduced the antinociceptive effect of NSAIDs in both pain models." | 3.80 | Antinociceptive tolerance to NSAIDs microinjected into dorsal hippocampus. ( Gurtskaia, G; Nebieridze, M; Nozadze, I; Tsagareli, MG; Tsiklauri, N, 2014) |
| " In the present study, we compared the effects of crocin, safranal and diclofenac on local inflammation and its induced pain in rats." | 3.79 | Comparison of the effects of crocin, safranal and diclofenac on local inflammation and inflammatory pain responses induced by carrageenan in rats. ( Eghdami, K; Erfanparast, A; Farshid, AA; Samadi, F; Tamaddonfard, E, 2013) |
| "05) and dosedependent anti-inflammatory activity in carrageenan induced paw oedema models of inflammation and the result was comparable with the standard drug diclofenac." | 3.79 | Evaluation of antinociceptive and anti-inflammatory activity of hydromethanol extract of Cocos nucifera L. ( Gupta, M; Haldar, PK; Mazumder, UK; Naskar, S; Pramanik, G; Saha, P, 2013) |
| "The anti-edematous and anti-allodynic effects of JZL184 were compared to those of PF-3845, an inhibitor of fatty acid amide hydrolase (FAAH), and diclofenac, a non-selective cyclooxygenase inhibitor." | 3.79 | The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. ( Chen, Y; Cravatt, BF; Ghosh, S; Gujjar, R; Lichtman, AH; Mahadevan, A; Wise, LE, 2013) |
| " Carrageenan induced paw edema model was used for anti-inflammatory and acetic acid induced model used for analgesic activity." | 3.78 | Anti-inflammatory and analgesic potential of a novel steroidal derivative from Bryophyllum pinnatum. ( Afzal, M; Afzal, O; Alam, J; Anwar, F; Gupta, G; Gupta, R; Hakeem, KR; Kazmi, I; Pravez, M; Rahman, M, 2012) |
| "The aim of the present study was to investigate the preemptive analgesic effects of intraperitoneally administrated midazolam and diclofenac, before acute and inflammatory induced pain in rat model." | 3.77 | Preemptive analgesic effects of midazolam and diclofenac in rat model. ( Hasani, A; Jakupi, M; Soljakova, M; Ustalar-Ozgen, S, 2011) |
| " The five most commonly reported adverse events were abdominal pain by 23." | 3.77 | Overall safety of Arthrotec. ( Geis, GS, 1992) |
| " First, validate PEAP with Complete Freund's Adjuvant (CFA)-induced inflammation for the assessment of the affective component of pain using the reference analgesics celecoxib, diclofenac and duloxetine; fluoxetine and scopolamine were tested as negative controls." | 3.76 | Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. ( Baker, SJ; Boyce-Rustay, JM; Decker, MW; Honore, P; Kohnken, R; Simler, GH; Wensink, EJ; Zhong, C, 2010) |
| " The blueberry extract produced a significant decrease in constrictions induced by acetic acid and caused graded inhibition of the second phase of formalin-induced pain." | 3.76 | Preliminary studies on the antinociceptive activity of Vaccinium ashei berry in experimental animal models. ( Barros, DM; de Castro, MR; de Souza, MM; Dickel, OE; Guterres, L; Henriques, AT; Ramirez, MR, 2010) |
| "The aim of this study was to investigate the type of common (occurring in >1% of patients) adverse reactions caused by diclofenac when given to children for acute pain." | 3.75 | Prospective observational study of adverse drug reactions to diclofenac in children. ( Howard, RF; Keady, S; Ooi, K; Savage, I; Standing, JF; Wong, IC, 2009) |
| " EtCD at the dose of 300 mg/kg produced significant decrease in paw volume and pain when compared with reference drug diclofenac and morphine, respectively." | 3.75 | Antioxidant, anti-inflammatory and analgesic potential of the Citrus decumana L. peel extract. ( Arora, B; Arora, R; Bali, M; Bansal, S; Gill, NS; Muthuraman, A; Sharma, PD; Sood, S, 2009) |
| " In the acute phase, violent colic pain is treated with diclophenac or morphine." | 3.74 | [Summary of the practice guideline 'Urolithiasis' (first revision) from the Dutch College of General Practitioners]. ( Boukes, FS; Goudswaard, AN; van Koningsbruggen, PJ; van Lieshout, J, 2008) |
| "To evaluate the efficacy of intramuscular injection of 75 mg diclofenac sodium and periprostatic nerve block (PPNB) with 1% lignocaine in controlling pain during transrectal ultrasound (TRUS)-guided prostate biopsy." | 3.74 | Control of pain during transrectal ultrasound-guided prostate biopsy: a prospective study comparing two methods. ( Bhomi, KK; Consigliere, DT; Lim, HH; Tiong, HY, 2007) |
| " The antiinflammatory property of the aqueous leaf extract was investigated in rats, using fresh egg albumin-induced pedal (paw) edema, while the analgesic effect of the plant extract was evaluated by the "hot-plate" and "acetic acid" test models of pain in mice." | 3.73 | Antiinflammatory and analgesic effects of Psidium guajava Linn. (Myrtaceae) leaf aqueous extract in rats and mice. ( Ojewole, JA, 2006) |
| "5, 5 and 10 mg kg (-1)) was investigated and compared with diclofenac sodium (5 mg kg (-1)) using the formalin-, histamine-, and carrageenan-induced paw oedema and cotton pellet granuloma tests." | 3.71 | Anti-inflammatory and antinociceptive properties of dantrolene sodium in rats and mice. ( Büyükokuroğlu, ME, 2002) |
| "The peripheral antinociceptive effect of the selective COX-2 inhibitor celecoxib in the formalin-induced inflammatory pain was compared with that of resveratrol (COX-1 inhibitor) and diclofenac (non-selective COX inhibitor)." | 3.71 | Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. ( Alonso-López, R; Asomoza-Espinosa, R; Castañeda-Hernández, G; Granados-Soto, V; Ortiz, MI; Torres-López, JE, 2002) |
| " The effect of the extracts against acute inflammation was studied by acetic acid increased vascular permeability and xylene-induced ear edema in mice." | 3.71 | Antinociceptive, anti-inflammatory and acute toxicity effects of Zhumeria majdae extracts in mice and rats. ( Fadishei, M; Hosseinzadeh, H; Mahmoudi, M; Ramezani, M, 2002) |
| "A pan-European study involving 23407 patients with pain due to various inflammatory or degenerative rheumatic diseases was undertaken in Austria, Belgium, Germany and Greece, to evaluate overall pain relief and satisfaction with aceclofenac therapy." | 3.71 | Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the manage ( Aslanidis, S; De Bast, J; Leeb, B; Lemmel, EM, 2002) |
| "Narcotics and topical diclofenac were used to control pain in a patient who developed a corneal ulcer after abusing topical anesthetics." | 3.70 | Topical diclofenac sodium in the management of anesthetic abuse keratopathy. ( Dornic, DI; Lass, JH; Thomas, JM, 1998) |
| "The present study shows that meloxicam dose-dependently exhibited systemic antinociceptive action when assessed against neurogenic and inflammatory pain caused by acetic acid, formalin and capsaicin models." | 3.70 | Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in mice. ( De Freitas, GA; Santos, AR; Vedana, EM, 1998) |
| " Both etodolac and bromelain inhibited the inflammatory pain in concanavalin A-treated paws of rats in a dose-dependent manner, but indomethacin did not." | 3.69 | Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation. ( Dainaka, J; Hashii, H; Inoue, K; Kimura, K; Motonaga, A; Nishimura, T; Ueda, F; Yamate, K, 1994) |
| "The antinociceptive activity of intramuscular 6-methoxy-2-naphthylacetic acid (6-MNA), the active metabolite of nabumetone, was examined in a rat model of unilateral hindpaw inflammation/hyperalgesia and compared with that of three other non-steroidal anti-inflammatory drugs (NSAIDs)--diclofenac, naproxen and piroxicam." | 3.69 | Antinociceptive effects of non-steroidal anti-inflammatory drugs in a rat model of unilateral hindpaw inflammation. ( Clarke, GD; MacPherson, IS; Petrone, G; Spangler, RS, 1994) |
| "Due to pain from infected 12 per cent TBSA flame injuries a 71-year-old female was treated with a non-steroidal antiinflammatory drug (diclofenac), thereby inhibiting the synthesis of prostaglandins, and developed transient impairment of renal function." | 3.69 | Impairment of renal function after treatment of a burn patient with diclofenac, a non-steroidal antiinflammatory drug. ( Ericsson, F; Jonsson, CE, 1995) |
| "This study determines the effects of dexamethasone versus co-administered dexamethasone and diclofenac, on carrageenan-evoked spinal c-Fos expression and peripheral oedema in the freely moving rat." | 3.69 | Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and associated spinal c-Fos expression in the rat. ( Besson, JM; Buritova, J; Chapman, V; Honoré, P, 1996) |
| "The effects of combined single oral treatments with non-steroidal anti-inflammatory drugs (NSAIDs) and the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan (DM) on arthritic pain were examined in a rat model of adjuvant-induced arthritis." | 3.69 | Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats. ( Caruso, FS; Frenk, H; Lu, J; Mao, J; Mayer, DJ; Price, DD, 1996) |
| " The anti-inflammatory potency of NS-398 in rat carrageenin-induced edema was as potent as that of indomethacin and 8 times more potent than diclofenac." | 3.68 | NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. ( Arai, I; Futaki, N; Hamasaka, Y; Higuchi, S; Iizuka, H; Otomo, S; Yoshikawa, K, 1993) |
| "In this trial, 20 patients suffering from bone metastasis pain received diclofenac, a non-steroid anti-inflammatory agent, by continuous IV infusion." | 3.67 | [Efficacy of diclofenac continuous perfusion in hyperalgic bone metastases. Apropos of 20 cases treated at Gustave Roussy Institute]. ( Ammarguellat, H; Benahmed, M; Court, B; Kple Faget, P; Pichard, E; Wibault, P, 1988) |
| "The pre-treatment pain severity of the groups was similar (p = 0." | 3.30 | The efficacy of intradermal sterile water application in severe renal colic: a randomised clinical trial. ( Ak, R; Aykanat, MC; Cimilli Öztürk, T; Kılıç, M; Ustaalioğlu, İ, 2023) |
| " No difference in adverse events was observed between the two groups." | 2.87 | Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. ( Wang, J, 2018) |
| "Diclofenac alone was not better than double-placebo." | 2.84 | Side effects can enhance treatment response through expectancy effects: an experimental analgesic randomized controlled trial. ( Berna, C; Edwards, RR; Jensen, KB; Kaptchuk, TJ; Kirsch, I; Lee, YC; Sadler, P; Zion, SR, 2017) |
| " Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic." | 2.82 | Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years. ( Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC, 2022) |
| " The incidence of adverse events of abnormal peripheral sensation was lower than in previous tanezumab trials." | 2.79 | Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. ( Balanescu, AR; Brown, MT; Davignon, I; Feist, E; Smith, MD; West, CR; Wolfram, G, 2014) |
| "Aceclofenac was better tolerated in terms of incidence and severity of GI AEs and GPA requirement and was as efficacious as diclofenac." | 2.78 | Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. ( Chandurkar, N; Pareek, A, 2013) |
| " Both the study medications were well tolerated with no incidence of serious adverse events." | 2.76 | Zaltoprofen, a noninferior alternative to diclofenac for the treatment of primary knee osteoarthritis -- a comparative evaluation of efficacy and safety in a 4-week, multicentric, randomized, double-blind, double-dummy trial. ( Ambade, RE; Chandurkar, NB; Gupta, AK; Jesalpura, BH; Pareek, A; Sirsikar, AD; Swamy, AP, 2011) |
| " The most common adverse events were treatment site related (n=16, 7." | 2.76 | Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury. ( Carr, W; Kuehl, K; Magelli, M; Rovati, S; Yanchick, J, 2011) |
| "Electroacupuncture can treat effectively hip osteoarthritis, relieve joint pain and improve joint function." | 2.75 | [Comparative observation on hip osteoarthritis treated with electroacupuncture and medication]. ( Fan, TY; Sheng, XP, 2010) |
| "Adhesive capsulitis or frozen shoulder is a common condition characterized by shoulder pain and stiffness in which conservative methods of treatment such as glucocorticosteroids, anti-inflammatory drugs, and physiotherapy play a significant part." | 2.73 | Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder. ( Haghighi, MH; Hemmati, AA; Saeidian, SR, 2007) |
| "Aceclofenac is a phenylacetic acid derivative with analgesic and anti-inflammatory properties and an improved gastrointestinal tolerance compared with other NSAIDs, such as diclofenac." | 2.73 | Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. ( Kang, JS; Lee, MH; Park, JH; Park, YS; Rhim, SY; Shaw, LM, 2008) |
| "Diclofenac-K was superior to placebo (P < 0." | 2.71 | A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms. ( Frank, WO; Gold, MS; Grebe, W; Ionescu, E; Liu, JM, 2003) |
| " Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting." | 2.71 | Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. ( Beier, J; Geusens, P; Gitton, X; Hasler, P; Moore, A; Patel, SK; Poór, G; Schnitzer, TJ; Senftleber, I; Sloan, VS, 2004) |
| "Forty healthy volunteers instilled Dicloabak in the randomised eye and thiomersal-preserved diclofenac in the other eye, according to a strictly identical dosing regimen, for 28 days." | 2.71 | [Ocular tolerance of a new formulation of nonpreserved diclofenac]. ( Chiambaretta, F; Creuzot-Garcher, C; Dubray, C; Pilon, F; Pouliquen, P; Rebika, H; Rigal, D, 2004) |
| "At day 3, pain was reduced by -20." | 2.71 | Analgesic efficacy of a lecithin-vehiculated diclofenac epolamine gel in shoulder periarthritis and lateral epicondylitis: a placebo-controlled, multicenter, randomized, double-blind clinical trial. ( Cacchio, A; Forgács, A; Monteforte, P; Rovetta, G; Spacca, G, 2005) |
| "Diclofenac gel was effective and safe for relief of symptoms of OA of the knee over 3 weeks of dosing." | 2.71 | Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. ( Albrecht, HH; Elkik, F; Gold, MS; Liu, JM; Niethard, FU; Solomon, GS; Unkauf, M, 2005) |
| "Population pharmacokinetics of a fast release diclofenac were assessed with special focus on pharmacodynamic implications." | 2.69 | Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model. ( Brune, K; Drover, D; Geisslinger, G; Kettenmann, B; Kobal, G; Lötsch, J; Renner, B, 2000) |
| "Diclofenac patch was superior to placebo patch in relieving pain." | 2.69 | Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. ( Devers, A; Friedman, E; Galer, BS; Perander, J; Rowbotham, M, 2000) |
| "Ibuprofen was also better tolerated than diclofenac sodium (100 mg/day), the latter being associated with gastrointestinal side effects in a significant proportion of patients." | 2.68 | Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. ( Baumgartner, H; Blum, W; Bruhin, A; Gallachi, G; Goldinger, G; Saxer, M; Schwarz, HA; Trost, H, 1996) |
| " After achieving adequate analgesia with regular dosing of oral methadone (T1), patient-controlled analgesia with methadone was administered for 3 days (T2)." | 2.68 | Opioid-sparing effect of diclofenac in cancer pain. ( Barresi, L; Caligara, M; Dardanoni, G; Mercadante, S; Sapio, M; Serretta, R, 1997) |
| "Diclofenac is a non-steroidal anti-inflammatory drug available in an ophthalmic preparation." | 2.68 | The effectiveness of topical diclofenac in relieving discomfort following traumatic corneal abrasions. ( Andrews, RM; Dayan, M; Fitt, AW; Griffiths, PG; Jayamanne, DG; Mitchell, KW, 1997) |
| "Ankylosing spondylitis is a systemic rheumatic disorder characterized by inflammation of the spine, sacroiliac, and large peripheral joints." | 2.66 | Efficacy of diclofenac in ankylosing spondylitis. ( Calabro, JJ, 1986) |
| "Diclofenac was preferred to naproxen, aspirin and indomethacin, while piroxicam and placebo were preferred only to aspirin." | 2.66 | Double-blind preference and compliance multicentre study in osteoarthritis: once-a-day treatment. ( Bassi, GP; Borghi, C; Camarri, E; Cocco, F; Francucci, BM; Giannini, R; Giordano, N; Marcolongo, R; Mordini, M; Neri, D, 1985) |
| "Codeine 60 mg was significantly superior to placebo in all pain measures." | 2.66 | Experimental pain induced by electrical and thermal stimulation of the skin in healthy man: sensitivity to 75 and 150 mg diclofenac sodium in comparison with 60 mg codeine and placebo. ( Gaupmann, G; Mittelbach, G; Schneider, S; Stacher, G; Steinringer, H; Winklehner, S, 1986) |
| "Diclofenac HPβCD was generally well tolerated in clinical trials, with injection-site reactions among the most commonly reported adverse events." | 2.52 | Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain. ( Blair, HA; Plosker, GL, 2015) |
| "Commonly used approaches that are effective to minimise pain or discomfort include intravenous sedoanalgesia, inhalational agents and periprostatic infiltration of local anaesthetic." | 2.50 | Current methods of analgesia for transrectal ultrasonography (TRUS)-guided prostate biopsy -- a systematic review. ( Lee, C; Woo, HH, 2014) |
| " The combination of diclofenac sodium and metamizole sodium is acceptable, although, at a lower dosage of metamizole, the duration of analgesia is shortened." | 2.46 | Evidence-based intravenous pain treatment with analgesic infusion regimens. ( Cihal, P; Kamyar, MR; Lemmens-Gruber, R; Nemec, K; Timin, E, 2010) |
| "Many types of acute pain have been managed with traditional oral non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (coxibs)." | 2.46 | Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury. ( Argoff, CE; McCarberg, BH, 2010) |
| " The bioavailability in terms of systemic exposure from the patch compared with oral intake (75 mg/day) is in the order of 1%." | 2.45 | Diclofenac epolamine (Flector) patch: evidence for topical activity. ( Petersen, B; Rovati, S, 2009) |
| " The incidence of adverse events in patients taking single or multiple doses of diclofenac potassium is similar to that of ibuprofen and placebo." | 2.44 | Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. ( Moore, N, 2007) |
| "Pain is a common symptom experienced by people with osteoarthritis and rheumatoid arthritis and impacts upon mobility and quality of life." | 2.44 | Pain relief in osteoarthritis and rheumatoid arthritis: TENS. ( While, A; Ying, KN, 2007) |
| " Following oral administration, the less lipophilic celecoxib has a lower bioavailability (20-40%) than the other two coxibs (74-100%)." | 2.44 | Clinical use and pharmacological properties of selective COX-2 inhibitors. ( Klotz, U; Shi, S, 2008) |
| " The chronic use of diclofenac sodium can lead to adverse gastrointestinal problems." | 2.43 | The use of topical diclofenac for pain in osteoarthritis of the knee: a review. ( Banning, M, 2006) |
| " The usual oral dosage of aceclofenac is 100 mg twice daily in adults." | 2.40 | [Pharma-clinics. The drug of the month. Aceclofenac (Biofenac)]. ( Scheen, AJ, 1999) |
| "Aceclofenac is a phenylacetic acid derivative with anti-inflammatory and analgesic properties similar to those of diclofenac." | 2.39 | Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. ( Brogden, RN; Wiseman, LR, 1996) |
| " This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action." | 2.38 | Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease. ( Franchimont, P; Reginster, JY, 1993) |
| "BACKGROUND Peyronie's disease is a chronic inflammatory disease involving the tunica albuginea of the penile corpora cavernosa." | 1.72 | Complete Plaque Regression in Patients with Peyronie's Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases. ( De Giorgio, G; Paulis, G, 2022) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used medications for pain, even though they increase the risk for adverse cardiovascular events." | 1.72 | Reduced risk of NSAID-Induced adverse events with concomitant use of misoprostol (MICRO study). ( Cheung, AK; Munger, MA; Nelson, SD; Sauer, BC; Teng, CC, 2022) |
| "Conservative medical approaches encompass oral, topical, and physical treatment." | 1.72 | Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series. ( De Giorgio, G; Paulis, G, 2022) |
| "Pain is a major problem that burdens the health and economy of societies worldwide." | 1.72 | Preclinical comparison of antinociceptive effects between ibuprofen, diclofenac, naproxen, and acetaminophen on acid-stimulated body stretching and acid-depressed feeding behaviors in rats. ( Al-Mousa, AA; Alsalem, MI; Altarifi, AA; Neubert, JK; Nuseir, KQ; Qaoud, AK; Younis, BA, 2022) |
| "There is a strong correlation between treatment resistant depression and increase in inflammatory cytokines in plasma and cerebrospinal fluid." | 1.48 | Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain. ( Abagyan, R; Cohen, IV; Lee, KC; Makunts, T, 2018) |
| "Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence." | 1.46 | Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. ( Abagyan, R; Atayee, R; Cohen, IV; Makunts, T, 2017) |
| " In the pyridine series, compound 7a was found to be a highly potent and selective EP4 antagonist, with suitable rat and dog pharmacokinetic profiles." | 1.43 | Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile. ( Blanco, MJ; Chambers, M; Chandrasekhar, S; Fisher, MJ; Harvey, A; Lin, C; Mudra, D; Oskins, J; Vetman, T; Wang, XS; Warshawsky, AM; Yu, XP, 2016) |
| " Both 27 and 48 demonstrated robust activity in the acute rat monoiodoacetate-induced osteoarthritis model of pain, and subchronic dosing of 48 showed a shift to a lower EC50 over 7 days." | 1.43 | Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain. ( Daanen, JF; DeGoey, DA; El-Kouhen, OF; Fricano, MM; Frost, JM; Ghoreishi-Haack, N; Gum, RJ; Hsieh, GC; Kort, ME; Lundgaard, GL; Matulenko, MA; Neelands, T; Pai, M; Shi, L; Zhan, C; Zhang, XF, 2016) |
| "Aceclofenac (ACE) is a systematically designed drug, developed to circumvent the concerns associated with diclofenac." | 1.43 | Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: a new therapeutic approach for pain and inflammation. ( Goyal, H; Katare, OP; Raza, K; Sharma, G; Thakur, K, 2016) |
| "The mechanical hyperalgesia was assessed by the Randall Selitto paw pressure test, which determines the paw withdrawal thresholds." | 1.43 | Association of terpinolene and diclofenac presents antinociceptive and anti-inflammatory synergistic effects in a model of chronic inflammation. ( Almeida, FR; Cunha, FV; Lopes, EM; Macedo, EM; Oliveira, FA; Piauilino, CA; Santos, WC; Sousa, BP; Sousa, DP, 2016) |
| " Worldwide health authorities, including the European Medicines Agency, Health Canada, and the US Food and Drug Administration, have advised that NSAIDs be prescribed at the lowest effective dosage and for the shortest duration." | 1.43 | Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac. ( Miles, L; Mladsi, D; Odom, D; Ronquest, N; Saag, K, 2016) |
| "Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, antinociceptive, and antipyretic activities." | 1.42 | Evaluation of antinociceptive activity of nanoliposome-encapsulated and free-form diclofenac in rats and mice. ( Chiong, HS; Goh, JZ; Hakim, MN; Tang, SN; Yong, YK; Zuraini, A, 2015) |
| "Diclofenac treatment produced dose-related reversal of CRANE at 0." | 1.42 | Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats. ( Bannon, AW; Joshi, SK; Zhu, CZ, 2015) |
| "Cancer-induced bone pain is described as dull, aching ongoing pain." | 1.42 | Behavioral and neurochemical analysis of ongoing bone cancer pain in rats. ( King, T; Navratilova, E; Okun, A; Porreca, F; Remeniuk, B; Sukhtankar, D; Xie, JY, 2015) |
| "Valdecoxib has highest similarity to analogs 8, 19, 21, 22, 23, 26, 27, and 28." | 1.40 | Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization. ( Bartzatt, R, 2014) |
| "A major concern in the treatment of acute pain/inflammation is the potential for drug-drug interactions resulting from P-gp induction by therapeutic agents co-administered with opioids." | 1.40 | P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac. ( Davis, TP; DeMarco, KM; Laracuente, ML; Ronaldson, PT; Sanchez-Covarrubias, L; Slosky, LM; Thompson, BJ; Zhang, Y, 2014) |
| " To determine the possibility of a pharmacokinetic interaction, the oral bioavailability of diclofenac (10 mg/kg) was studied in presence and the absence of curcumin (31 mg/kg)." | 1.40 | Synergistic effect of the interaction between curcumin and diclofenac on the formalin test in rats. ( Castañeda-Hernández, G; Chávez Piña, AE; De Paz-Campos, MA; Ortiz, MI; Zazueta-Beltrán, L, 2014) |
| "Cancer pain is one of the most severe types of chronic pain, and the most common cancer pain is bone cancer pain." | 1.38 | Targeting A-type K(+) channels in primary sensory neurons for bone cancer pain in a rat model. ( Duan, KZ; Mei, YA; Xu, Q; Zhang, XM; Zhang, YQ; Zhao, ZQ, 2012) |
| "Two patients experienced oral numbness and intractable tongue pain, and 1 patient required endotracheal intubation because of upper respiratory tract obstruction." | 1.37 | Toxicities of raw Alocasia odora. ( Chun, BJ; Lee, BK; Moon, JM, 2011) |
| "Inflammation was induced in one hind paw of rats by intraplantar injection of carrageenan (250 μg)." | 1.36 | Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity? ( Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM, 2010) |
| "6 h, oral bioavailability of 37% and 90%) with anti-inflammatory activity (ED 50 = 37 micromol/kg, mouse) and efficacy in pain models (thermal hyperalgesia, ED 50 = 72 micromol/kg, rat)." | 1.35 | Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. ( Adair, RM; Altenbach, RJ; Bettencourt, BM; Brioni, JD; Cowart, MD; Drizin, I; Esbenshade, TA; Fix-Stenzel, SR; Honore, P; Hsieh, GC; Liu, H; Marsh, KC; McPherson, MJ; Milicic, I; Miller, TR; Sullivan, JP; Wetter, JM; Wishart, N; Witte, DG, 2008) |
| " The purpose of this work was to examine in the rat if such interaction involves pharmacokinetic mechanisms or is solely limited to the pharmacodynamic level." | 1.35 | Pharmacokinetics and pharmacodynamics of diclofenac in the presence and absence of glibenclamide in the rat. ( Castañeda-Hernández, G; León-Reyes, MR; Ortiz, MI, 2008) |
| "Thermal hyperalgesia was also decreased by intraplantar treatment with morphine (10 microg) or diclofenac (100 microg)." | 1.35 | Effects of analgesics on the plantar incision-induced drop of the noxious heat threshold measured with an increasing-temperature water bath in the rat. ( Bölcskei, K; Füredi, R; Petho, G; Szolcsányi, J, 2009) |
| " Therefore, in view of the vast clinical uses and interactions of NSAIDs with commonly used therapeutic agents, the interaction of the NSAID diclofenac and glibenclamide was investigated about pharmacokinetic profile and antinociceptive effect in rats." | 1.35 | Pharmacokinetic of diclofenac in the presence and absence of glibenclamide in the rat. ( Castañeda-Hernández, G; León-Reyes, MR; Ortiz, MI, 2009) |
| "Pain was inferred from impairment of gait and stance." | 1.34 | Spontaneous nociceptive behaviour in female mice with Freund's complete adjuvant- and carrageenan-induced monoarthritis. ( Arborelius, L; Berge, OG; Brodin, E; Heilborn, U, 2007) |
| "Carrageenan induced significant mechanical allodynia, thermal hyperalgesia and paw oedema at 6 h post-carrageenan, while paw incision surgery induced significant mechanical allodynia and thermal hyperalgesia at 6 and 24 h post-surgery." | 1.34 | Oral administration of Ginkgo biloba extract, EGb-761 inhibits thermal hyperalgesia in rodent models of inflammatory and post-surgical pain. ( Biddlestone, L; Corbett, AD; Dolan, S, 2007) |
| "Naloxone pretreatment had no effect on the antinociceptive effects of intradermal diclofenac, ketorolac, lysine acetyl salicylate, and sodium salicylate." | 1.34 | The local antinociceptive actions of nonsteroidal antiinflammatory drugs in the mouse radiant heat tail-flick test. ( Deveci, MS; Dogrul, A; Gul, H; Gülmez, SE; Ossipov, MH; Porreca, F; Tulunay, FC, 2007) |
| "Thermal hyperalgesia was induced by mild heat injury (51 degrees C water for 20 s) which led to a 7-8 degrees C decrease of the noxious heat threshold." | 1.34 | Heat injury-induced drop of the noxious heat threshold measured with an increasing-temperature water bath: a novel rat thermal hyperalgesia model. ( Bölcskei, K; Horváth, D; Petho, G; Szolcsányi, J, 2007) |
| " Etoricoxib is partly metabolised by the cytochrome P450 isoenzyme CYP 3A4 and increases the bioavailability of ethinylestradiol." | 1.34 | Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain. ( , 2007) |
| "Diclofenac iontophoresis was performed by varying either the current density (0." | 1.32 | The antinociceptive effect of iontophoretic direct application of diclofenac to arthritic knee-joints of rats. ( Borges Junior, NG; da Fonseca, JC; Motta, AF; Tonussi, CR, 2003) |
| "Chronic pain resulting from metastatic bone cancer remains poorly understood and resistant to treatment." | 1.32 | Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. ( Bevan, S; Courade, JP; Dawson, J; Fox, A; Glatt, M; Gonzalez, I; Medhurst, S; Urban, L, 2004) |
| "Patients with renal colic are usually treated in emergency care units or by their family doctors and require immediate diagnosis and treatment." | 1.32 | [Rational therapy of urolithiasis in every-day practice]. ( Gschwend, JE; Hautmann, RE; Rinnab, L; Straub, M, 2004) |
| " We evaluated the antinociceptive effects of chronic administration of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), anandamide (an endogenous cannabinoid), arachadonic acid, ethanolamine, and methanandamide on several NSAIDs via p." | 1.31 | Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. ( Anikwue, R; Huffman, JW; Martin, ZL; Welch, SP, 2002) |
| "Allodynia and hyperalgesia appeared on day 5 post-inoculation." | 1.31 | Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain. ( Andoh, T; Kuraishi, Y; Nemoto, H; Nitta, M; Nojima, H; Shiraki, K; Takahata, H; Takasaki, I, 2000) |
| " The aim of the present study was to evaluate the comparative efficacy of intramuscularly injected nimesulide with that of diclofenac and to elucidate the pharmacokinetic profile of this formulation." | 1.30 | Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide. ( Gupta, SK; Mathur, P; Sengupta, S; Velpandian, T, 1998) |
| "Diclofenac was the NSAID of choice for 69." | 1.30 | Analgesia in soft-tissue injury: current practice in Auckland is not supported by the available evidence. ( Jones, PG, 1999) |
| "Meclofenamic acid is an analgesic endowed with anti-inflammatory properties." | 1.28 | Clinical experiences in the treatment of pain in rheumatology. ( Pellegrini, P, 1991) |
Research
Studies (429)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (6.99) | 18.7374 |
| 1990's | 85 (19.81) | 18.2507 |
| 2000's | 143 (33.33) | 29.6817 |
| 2010's | 124 (28.90) | 24.3611 |
| 2020's | 47 (10.96) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Alagarsamy, V | 2 |
| Raja Solomon, V | 1 |
| Dhanabal, K | 1 |
| Cowart, MD | 1 |
| Altenbach, RJ | 1 |
| Liu, H | 1 |
| Hsieh, GC | 2 |
| Drizin, I | 1 |
| Milicic, I | 1 |
| Miller, TR | 1 |
| Witte, DG | 1 |
| Wishart, N | 1 |
| Fix-Stenzel, SR | 1 |
| McPherson, MJ | 1 |
| Adair, RM | 1 |
| Wetter, JM | 1 |
| Bettencourt, BM | 1 |
| Marsh, KC | 1 |
| Sullivan, JP | 1 |
| Honore, P | 3 |
| Esbenshade, TA | 1 |
| Brioni, JD | 1 |
| Sujith, KV | 1 |
| Rao, JN | 1 |
| Shetty, P | 1 |
| Kalluraya, B | 1 |
| Hollinshead, SP | 1 |
| Astles, PC | 1 |
| Chambers, MG | 1 |
| Johnson, MP | 1 |
| Palmer, J | 1 |
| Tidwell, MW | 1 |
| Singh, A | 2 |
| Kaur, M | 1 |
| Sharma, S | 1 |
| Bhatti, R | 1 |
| Singh, P | 2 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Blanco, MJ | 1 |
| Vetman, T | 1 |
| Chandrasekhar, S | 1 |
| Fisher, MJ | 1 |
| Harvey, A | 1 |
| Chambers, M | 1 |
| Lin, C | 1 |
| Mudra, D | 1 |
| Oskins, J | 1 |
| Wang, XS | 1 |
| Yu, XP | 1 |
| Warshawsky, AM | 1 |
| Frost, JM | 1 |
| DeGoey, DA | 1 |
| Shi, L | 1 |
| Gum, RJ | 1 |
| Fricano, MM | 1 |
| Lundgaard, GL | 1 |
| El-Kouhen, OF | 1 |
| Neelands, T | 1 |
| Matulenko, MA | 1 |
| Daanen, JF | 1 |
| Pai, M | 1 |
| Ghoreishi-Haack, N | 1 |
| Zhan, C | 1 |
| Zhang, XF | 1 |
| Kort, ME | 1 |
| Bua, S | 1 |
| Lucarini, L | 1 |
| Micheli, L | 1 |
| Menicatti, M | 1 |
| Bartolucci, G | 1 |
| Selleri, S | 1 |
| Di Cesare Mannelli, L | 1 |
| Ghelardini, C | 1 |
| Masini, E | 1 |
| Carta, F | 1 |
| Gratteri, P | 1 |
| Nocentini, A | 1 |
| Supuran, CT | 1 |
| Yakushin, S | 1 |
| Polyakova, S | 1 |
| Shvarts, Y | 1 |
| Kastanayan, A | 1 |
| Krechikova, D | 1 |
| Ershova, O | 1 |
| Nikulenkova, N | 1 |
| Vinogradova, I | 1 |
| Hyun, BJ | 1 |
| Cha, JE | 1 |
| de Campos, GC | 1 |
| de Almeida Macedo, E | 1 |
| Kummer, AM | 1 |
| Papaleo Rosim, M | 1 |
| Millan Fachi, M | 1 |
| Auletta, LL | 1 |
| Mohan, T | 1 |
| Ajdnik, U | 1 |
| Nagaraj, C | 1 |
| Lackner, F | 1 |
| Dobaj Štiglic, A | 1 |
| Palani, T | 1 |
| Amornkitbamrung, L | 1 |
| Gradišnik, L | 2 |
| Maver, U | 2 |
| Kargl, R | 1 |
| Stana Kleinschek, K | 1 |
| Babandi, RM | 1 |
| Agboghoroma, OC | 1 |
| Durojaiye, KW | 1 |
| Jimoh, KO | 1 |
| Essiet, EA | 1 |
| Nurathirah, MN | 1 |
| Yazid, MB | 1 |
| Norhayati, MN | 1 |
| Baharuddin, KA | 1 |
| Abu Bakar, MA | 1 |
| Tomatsu, K | 1 |
| Yasuda, S | 1 |
| Fuady, A | 1 |
| Matsumoto, H | 1 |
| Paulis, G | 2 |
| De Giorgio, G | 2 |
| Kubo, T | 1 |
| Kumai, T | 1 |
| Ikegami, H | 1 |
| Kano, K | 1 |
| Nishii, M | 1 |
| Seo, T | 1 |
| Ribeiro, H | 1 |
| Rodrigues, I | 1 |
| Napoleão, L | 1 |
| Lira, L | 1 |
| Marques, D | 1 |
| Veríssimo, M | 1 |
| Andrade, JP | 1 |
| Dourado, M | 1 |
| Lee, N | 1 |
| Mårtensson, LB | 1 |
| Hashemi, SMH | 1 |
| Enayatifard, R | 1 |
| Akbari, J | 1 |
| Saeedi, M | 1 |
| Seyedabadi, M | 1 |
| Morteza-Semnani, K | 1 |
| Babaei, A | 1 |
| Asare-Addo, K | 1 |
| Nokhodchi, A | 1 |
| Munger, MA | 1 |
| Nelson, SD | 1 |
| Teng, CC | 1 |
| Cheung, AK | 1 |
| Sauer, BC | 1 |
| Chobpenthai, T | 1 |
| Arunwatthanangkul, P | 1 |
| Mahikul, W | 1 |
| Tu, JF | 1 |
| Cao, Y | 2 |
| Wang, LQ | 1 |
| Shi, GX | 1 |
| Jia, LC | 1 |
| Liu, BL | 1 |
| Yao, WH | 1 |
| Pei, XL | 1 |
| Li, HW | 1 |
| Yan, SY | 1 |
| Yang, JW | 1 |
| Qu, ZC | 1 |
| Liu, CZ | 1 |
| Li, T | 1 |
| Guo, M | 1 |
| Zhang, W | 2 |
| Ziesenitz, VC | 1 |
| Welzel, T | 1 |
| van Dyk, M | 1 |
| Saur, P | 1 |
| Gorenflo, M | 1 |
| van den Anker, JN | 1 |
| Altarifi, AA | 1 |
| Younis, BA | 1 |
| Nuseir, KQ | 1 |
| Al-Mousa, AA | 1 |
| Qaoud, AK | 1 |
| Alsalem, MI | 1 |
| Neubert, JK | 1 |
| Latif, S | 1 |
| Liaqat, A | 1 |
| Imran, M | 1 |
| Javaid, A | 1 |
| Hussain, N | 1 |
| Jesionowski, T | 1 |
| Bilal, M | 1 |
| Tsurko, VV | 1 |
| Gromova, MA | 1 |
| Arai, T | 1 |
| Suzuki-Narita, M | 1 |
| Takeuchi, J | 1 |
| Tajiri, I | 1 |
| Inage, K | 1 |
| Kawarai, Y | 1 |
| Eguchi, Y | 1 |
| Shiga, Y | 1 |
| Hozumi, T | 1 |
| Kim, G | 1 |
| Tsuchiya, R | 1 |
| Otagiri, T | 1 |
| Mukaihata, T | 1 |
| Hishiya, T | 1 |
| Toshi, N | 1 |
| Okuyama, K | 1 |
| Tokeshi, S | 1 |
| Furuya, T | 1 |
| Maki, S | 1 |
| Matsuura, Y | 1 |
| Suzuki, T | 1 |
| Nakamura, J | 1 |
| Hagiwara, S | 1 |
| Ohtori, S | 1 |
| Orita, S | 1 |
| Yin, F | 1 |
| Ma, J | 1 |
| Xiao, H | 1 |
| Ao, R | 1 |
| Zhang, F | 1 |
| Li, W | 1 |
| Wang, W | 1 |
| Zeng, P | 1 |
| Lu, T | 1 |
| Revel, FB | 1 |
| Araga, M | 1 |
| Patel, S | 1 |
| Moreira, S | 1 |
| Zhang, J | 1 |
| Ma, YT | 1 |
| Dong, YL | 1 |
| Wang, B | 1 |
| Xie, WP | 1 |
| Huang, QM | 1 |
| Zheng, YJ | 1 |
| Murdoch, I | 1 |
| Carver, AL | 1 |
| Sultan, P | 1 |
| O'Carroll, JE | 1 |
| Blake, L | 1 |
| Carvalho, B | 1 |
| Onwochei, DN | 1 |
| Desai, N | 1 |
| Karami, Z | 1 |
| Zanjani, MS | 1 |
| Andalib, S | 1 |
| Babaie, H | 1 |
| Aminoroaia, P | 1 |
| Hamdi, BA | 1 |
| Amin, ZA | 1 |
| Shareef, AMY | 1 |
| Al-Bustany, HA | 1 |
| Aykanat, MC | 1 |
| Kılıç, M | 1 |
| Cimilli Öztürk, T | 1 |
| Ustaalioğlu, İ | 1 |
| Ak, R | 1 |
| Kumar, NS | 1 |
| Muktesh, G | 1 |
| Samra, T | 1 |
| Sarma, P | 1 |
| Samanta, J | 1 |
| Sinha, SK | 1 |
| Dhaka, N | 1 |
| Yadav, TD | 1 |
| Gupta, V | 1 |
| Kochhar, R | 1 |
| Brennan, PA | 1 |
| Lewthwaite, R | 1 |
| Sakthithasan, P | 1 |
| McGuigan, S | 1 |
| Donnelly, O | 1 |
| Alam, P | 1 |
| Gomez, RS | 1 |
| Fedele, S | 1 |
| Gromova, OA | 1 |
| Torshin, IY | 1 |
| Putilina, MV | 1 |
| Stakhovskaia, LV | 1 |
| Rudakov, KV | 1 |
| Moussa, M | 2 |
| Papatsoris, AG | 2 |
| Chakra, MA | 2 |
| Golcuk, Y | 1 |
| Demir, A | 1 |
| Yıldırım, B | 1 |
| Acar, E | 1 |
| Ailincai, D | 1 |
| Mititelu-Tartau, L | 1 |
| Marin, L | 1 |
| Aras, B | 2 |
| Uruç, F | 3 |
| Huang, H | 1 |
| Luo, M | 1 |
| Liang, H | 1 |
| Pan, J | 1 |
| Yang, W | 1 |
| Zeng, L | 1 |
| Liang, G | 1 |
| Hou, S | 1 |
| Zhao, J | 1 |
| Liu, J | 2 |
| Zarro, M | 1 |
| Tamberrino, K | 1 |
| Bane, EM | 1 |
| Bihlet, AR | 1 |
| Byrjalsen, I | 1 |
| Simon, LS | 1 |
| Carrara, D | 1 |
| Delpy, L | 1 |
| Derne, C | 1 |
| Ivelik, HI | 1 |
| Kopečná, M | 1 |
| Kováčik, A | 1 |
| Novák, P | 1 |
| Boncheva Bettex, M | 1 |
| Vávrová, K | 1 |
| Wolff, DG | 1 |
| Christophersen, C | 1 |
| Brown, SM | 1 |
| Mulcahey, MK | 1 |
| Bussin, E | 1 |
| Cairns, B | 1 |
| Gerschman, T | 1 |
| Fredericson, M | 1 |
| Bovard, J | 1 |
| Scott, A | 1 |
| Nipa, NS | 1 |
| Ali, T | 1 |
| Akhter, S | 1 |
| Rafiq, K | 1 |
| Gowayed, MA | 1 |
| Abdel-Bary, A | 1 |
| El-Tahan, RA | 1 |
| Mishra, NR | 1 |
| Kumar, R | 1 |
| Tripathy, SK | 1 |
| Lai, PM | 1 |
| Collaku, A | 1 |
| Reed, K | 1 |
| Cohen, IV | 2 |
| Makunts, T | 2 |
| Atayee, R | 1 |
| Abagyan, R | 2 |
| Makri, OE | 1 |
| Tsapardoni, FN | 1 |
| Pagoulatos, DD | 1 |
| Pharmakakis, N | 1 |
| Georgakopoulos, CD | 1 |
| Huh, BK | 1 |
| Kim, BH | 1 |
| Kim, SN | 1 |
| Park, CG | 1 |
| Lee, SH | 1 |
| Kim, KR | 1 |
| Heo, CY | 1 |
| Choy, YB | 1 |
| Maver, T | 1 |
| Kurečič, M | 1 |
| Hribernik, S | 1 |
| Smrke, DM | 1 |
| Kleinschek, KS | 1 |
| Wang, J | 1 |
| Breivik, H | 2 |
| Maldonado-Avila, M | 1 |
| Garduño-Arteaga, LM | 1 |
| Vela-Mollinedo, RA | 1 |
| Jaspersen-Gastelum, J | 1 |
| Virgen-Gutierrez, F | 1 |
| Del Rosario-Santiago, M | 1 |
| Rios-Davila, V | 1 |
| Tsiklauri, N | 2 |
| Pirkulashvili, N | 1 |
| Nozadze, I | 2 |
| Nebieridze, M | 2 |
| Gurtskaia, G | 2 |
| Abzianidze, E | 1 |
| Tsagareli, MG | 2 |
| Lee, KC | 1 |
| Kreutzkamp, B | 1 |
| Ogawa, S | 1 |
| Natsume, T | 1 |
| Takamatsu, H | 1 |
| Ramirez-Garcia-Luna, JL | 1 |
| Wong, TH | 1 |
| Chan, D | 1 |
| Al-Saran, Y | 1 |
| Awlia, A | 1 |
| Abou-Rjeili, M | 1 |
| Ouellet, S | 1 |
| Akoury, E | 1 |
| Lemarié, CA | 1 |
| Henderson, JE | 1 |
| Martineau, PA | 1 |
| Şahin, M | 1 |
| Eşer, İ | 1 |
| Rainsford, KD | 2 |
| Roberts, MS | 1 |
| Nencioni, A | 1 |
| Jones, C | 1 |
| Andreev, YA | 1 |
| Osmakov, DI | 1 |
| Koshelev, SG | 1 |
| Maleeva, EE | 1 |
| Logashina, YA | 1 |
| Palikov, VA | 1 |
| Palikova, YA | 1 |
| Dyachenko, IA | 1 |
| Kozlov, SA | 1 |
| Karateev, AE | 1 |
| Pogozheva, EY | 1 |
| Filatova, EA | 1 |
| Amirjanova, VN | 1 |
| Lila, AM | 1 |
| Antipova, OV | 1 |
| Babaeva, AR | 1 |
| Volkorezova, AV | 1 |
| Davydova, AF | 1 |
| Davtyan, VG | 1 |
| Zonova, EV | 1 |
| Ivanova, ON | 1 |
| Kalinina, NN | 1 |
| Kiseleva, NI | 1 |
| Knyazeva, LA | 1 |
| Kulikov, AI | 1 |
| Nesmeyanova, OB | 1 |
| Mazurov, VI | 1 |
| Masneva, LV | 1 |
| Menshikova, LV | 1 |
| Obuhova, IV | 1 |
| Otteva, EN | 1 |
| Salnikova, TS | 1 |
| Shсhendrygin, IN | 1 |
| Yakupova, SP | 1 |
| Wade, AG | 1 |
| Crawford, GM | 1 |
| Young, D | 1 |
| Corson, S | 1 |
| Brown, C | 1 |
| Pareek, A | 2 |
| Chandurkar, N | 1 |
| Gu, LJ | 1 |
| Qiu, XD | 1 |
| Zhao, Y | 1 |
| Qin, WK | 1 |
| Dong, FH | 1 |
| Ibrahim, ZM | 1 |
| Sayed Ahmed, WA | 1 |
| Balanescu, AR | 1 |
| Feist, E | 1 |
| Wolfram, G | 1 |
| Davignon, I | 1 |
| Smith, MD | 1 |
| Brown, MT | 1 |
| West, CR | 1 |
| Predel, HG | 2 |
| Giannetti, B | 3 |
| Seigfried, B | 1 |
| Novellini, R | 1 |
| Menke, G | 1 |
| de Knegt, NC | 1 |
| Evenhuis, HM | 1 |
| Lobbezoo, F | 1 |
| Schuengel, C | 1 |
| Scherder, EJ | 1 |
| Bartzatt, R | 1 |
| Sifferlin, A | 1 |
| Lee, C | 2 |
| Woo, HH | 1 |
| Zang, YJ | 1 |
| Borisenko, OV | 1 |
| Belen'kiĭ, DA | 1 |
| Iacovides, S | 1 |
| Baker, FC | 1 |
| Avidon, I | 1 |
| Inal, S | 1 |
| Kabay, S | 1 |
| Cayci, MK | 1 |
| Kuru, HI | 1 |
| Altikat, S | 1 |
| Akkas, G | 1 |
| Deger, A | 1 |
| Tamaddonfard, E | 1 |
| Farshid, AA | 1 |
| Eghdami, K | 1 |
| Samadi, F | 1 |
| Erfanparast, A | 1 |
| de Souza, AH | 1 |
| da Costa Lopes, AM | 1 |
| Castro, CJ | 1 |
| Pereira, EM | 1 |
| Klein, CP | 1 |
| da Silva, CA | 1 |
| da Silva, JF | 1 |
| Ferreira, J | 1 |
| Gomez, MV | 1 |
| Sanchez-Covarrubias, L | 1 |
| Slosky, LM | 1 |
| Thompson, BJ | 1 |
| Zhang, Y | 1 |
| Laracuente, ML | 1 |
| DeMarco, KM | 1 |
| Ronaldson, PT | 1 |
| Davis, TP | 2 |
| Maulvi, FA | 1 |
| Thakkar, VT | 1 |
| Soni, TG | 1 |
| Gandhi, TR | 1 |
| Kara, D | 1 |
| Yapucu Güneş, Ü | 1 |
| Ioannidis, S | 1 |
| Kampantais, S | 1 |
| Ioannidis, A | 1 |
| Gkagkalidis, K | 1 |
| Vakalopoulos, I | 1 |
| Toutziaris, C | 1 |
| Patsialas, C | 1 |
| Laskaridis, L | 1 |
| Dimopoulos, P | 1 |
| Dimitriadis, G | 1 |
| Bushuven, S | 1 |
| Heise, D | 1 |
| Bolbrinker, J | 1 |
| Dhokchawle, BV | 1 |
| Bhandari, AB | 1 |
| De Paz-Campos, MA | 1 |
| Ortiz, MI | 6 |
| Chávez Piña, AE | 1 |
| Zazueta-Beltrán, L | 1 |
| Castañeda-Hernández, G | 7 |
| Bannuru, RR | 1 |
| Schmid, CH | 1 |
| Kent, DM | 1 |
| Vaysbrot, EE | 1 |
| Wong, JB | 1 |
| McAlindon, TE | 1 |
| Hodge, B | 1 |
| Skolnik, D | 1 |
| Goh, JZ | 1 |
| Tang, SN | 1 |
| Chiong, HS | 1 |
| Yong, YK | 1 |
| Zuraini, A | 1 |
| Hakim, MN | 1 |
| Zhu, CZ | 1 |
| Bannon, AW | 1 |
| Joshi, SK | 1 |
| Datar, PA | 1 |
| Limaye, SA | 1 |
| Su, YF | 1 |
| Yang, YC | 1 |
| Hsu, HK | 1 |
| Hwang, SL | 1 |
| Lee, KS | 1 |
| Lieu, AS | 1 |
| Chan, TF | 1 |
| Lin, CL | 1 |
| Colak, S | 1 |
| Kutlucan, L | 1 |
| Erdogan, MO | 1 |
| Afacan, MA | 1 |
| Saritas, A | 1 |
| Kandis, H | 1 |
| Remeniuk, B | 1 |
| Sukhtankar, D | 1 |
| Okun, A | 1 |
| Navratilova, E | 1 |
| Xie, JY | 1 |
| King, T | 1 |
| Porreca, F | 2 |
| Ilango, K | 1 |
| Valentina, P | 1 |
| Kumar, G | 1 |
| Dixit, D | 1 |
| Nilewar, S | 1 |
| Kathiravan, MK | 1 |
| Blair, HA | 1 |
| Plosker, GL | 1 |
| Standing, JF | 3 |
| Savage, I | 3 |
| Pritchard, D | 2 |
| Waddington, M | 2 |
| Paull, DR | 1 |
| Small, AH | 1 |
| Labeur, L | 1 |
| Colditz, IG | 1 |
| Sarganas, G | 1 |
| Buttery, AK | 1 |
| Zhuang, W | 1 |
| Wolf, IK | 1 |
| Grams, D | 1 |
| Rosario, AS | 1 |
| Scheidt-Nave, C | 1 |
| Knopf, H | 1 |
| Wadsworth, LT | 1 |
| Kent, JD | 1 |
| Holt, RJ | 1 |
| Acmaz, G | 1 |
| Bayraktar, E | 1 |
| Aksoy, H | 1 |
| Başer, M | 1 |
| Yilmaz, MO | 1 |
| Müderris, İİ | 1 |
| Han, YM | 1 |
| Woo, SU | 1 |
| Choi, MS | 1 |
| Park, YN | 1 |
| Kim, SH | 1 |
| Yim, H | 1 |
| Yoo, HH | 1 |
| Fouda, UM | 1 |
| Salah Eldin, NM | 1 |
| Elsetohy, KA | 1 |
| Tolba, HA | 1 |
| Shaban, MM | 1 |
| Sobh, SM | 1 |
| Scavone, C | 1 |
| Bonagura, AC | 1 |
| Fiorentino, S | 1 |
| Cimmaruta, D | 1 |
| Cenami, R | 1 |
| Torella, M | 1 |
| Fossati, T | 1 |
| Rossi, F | 1 |
| Sharma, G | 1 |
| Goyal, H | 1 |
| Thakur, K | 1 |
| Raza, K | 1 |
| Katare, OP | 1 |
| Elzaki, WM | 1 |
| Abubakr, NH | 1 |
| Ziada, HM | 1 |
| Ibrahim, YE | 1 |
| Macedo, EM | 1 |
| Santos, WC | 1 |
| Sousa, BP | 1 |
| Lopes, EM | 1 |
| Piauilino, CA | 1 |
| Cunha, FV | 1 |
| Sousa, DP | 1 |
| Oliveira, FA | 1 |
| Almeida, FR | 1 |
| Edwards, RR | 2 |
| Dolman, AJ | 1 |
| Martel, MO | 1 |
| Finan, PH | 1 |
| Lazaridou, A | 1 |
| Cornelius, M | 1 |
| Wasan, AD | 1 |
| Schattner, A | 1 |
| Naz, S | 1 |
| Memon, NY | 1 |
| Sattar, A | 1 |
| Baloch, R | 1 |
| Sen, H | 1 |
| Erturhan, S | 1 |
| Sadioglu, E | 1 |
| Bayrak, O | 1 |
| Seckiner, İ | 1 |
| Mladsi, D | 1 |
| Ronquest, N | 1 |
| Odom, D | 1 |
| Miles, L | 1 |
| Saag, K | 1 |
| Goh, CF | 1 |
| Craig, DQ | 1 |
| Hadgraft, J | 1 |
| Lane, ME | 1 |
| Iannitti, T | 2 |
| McDermott, MF | 1 |
| Laurino, C | 1 |
| Malagoli, A | 1 |
| Palmieri, B | 2 |
| Raison, N | 1 |
| Ahmed, K | 1 |
| Brunckhorst, O | 1 |
| Dasgupta, P | 1 |
| Krügel, U | 1 |
| Straub, I | 1 |
| Beckmann, H | 1 |
| Schaefer, M | 1 |
| Berna, C | 1 |
| Kirsch, I | 1 |
| Zion, SR | 1 |
| Lee, YC | 1 |
| Jensen, KB | 1 |
| Sadler, P | 1 |
| Kaptchuk, TJ | 1 |
| Hosni, HM | 1 |
| Abdulla, MM | 1 |
| León-Reyes, MR | 2 |
| Kean, WF | 2 |
| Ehrlich, GE | 1 |
| Haswir, H | 1 |
| Umbas, R | 1 |
| Kampitak, T | 1 |
| van Lieshout, J | 1 |
| van Koningsbruggen, PJ | 1 |
| Boukes, FS | 1 |
| Goudswaard, AN | 1 |
| Petersen, B | 1 |
| Rovati, S | 5 |
| Pourmorad, F | 1 |
| Ebrahimzadeh, MA | 1 |
| Mahmoudi, M | 2 |
| Yasini, S | 1 |
| Naidu, PS | 1 |
| Booker, L | 1 |
| Cravatt, BF | 2 |
| Lichtman, AH | 2 |
| Kyle, C | 1 |
| Zachariah, J | 1 |
| Kinch, H | 1 |
| Ellis, G | 1 |
| Andrews, C | 1 |
| Adekunle, F | 1 |
| Füredi, R | 1 |
| Bölcskei, K | 3 |
| Szolcsányi, J | 3 |
| Petho, G | 3 |
| Woodson, SA | 1 |
| Faaij, RA | 1 |
| Ziere, G | 1 |
| Zietse, R | 1 |
| Van der Cammen, TJ | 1 |
| Harris, D | 1 |
| Pease, N | 1 |
| Eryildirim, B | 1 |
| Kuyumcuoğlu, U | 1 |
| Tarhan, F | 1 |
| Faydaci, G | 1 |
| Niazi, J | 1 |
| Bansal, Y | 1 |
| Goel, RK | 1 |
| Dolan, S | 2 |
| Gunn, MD | 1 |
| Biddlestone, L | 2 |
| Nolan, AM | 1 |
| Ooi, K | 1 |
| Keady, S | 1 |
| Howard, RF | 1 |
| Wong, IC | 1 |
| Boyce-Rustay, JM | 1 |
| Zhong, C | 1 |
| Kohnken, R | 1 |
| Baker, SJ | 1 |
| Simler, GH | 1 |
| Wensink, EJ | 1 |
| Decker, MW | 1 |
| Schuelert, N | 1 |
| McDougall, JJ | 1 |
| Sood, S | 1 |
| Arora, B | 1 |
| Bansal, S | 1 |
| Muthuraman, A | 1 |
| Gill, NS | 1 |
| Arora, R | 1 |
| Bali, M | 1 |
| Sharma, PD | 1 |
| Moen, MD | 1 |
| Rahimi, M | 1 |
| Makarem, J | 1 |
| Goharrizi, AG | 1 |
| Barthel, HR | 1 |
| Peniston, JH | 1 |
| Clark, MB | 1 |
| Gold, MS | 3 |
| Altman, RD | 1 |
| Aktoz, T | 1 |
| Kaplan, M | 1 |
| Turan, U | 1 |
| Memis, D | 1 |
| Atakan, IH | 1 |
| Inci, O | 1 |
| Mueller, EA | 1 |
| Kirch, W | 1 |
| Reiter, S | 1 |
| Ramirez, MR | 1 |
| Guterres, L | 1 |
| Dickel, OE | 1 |
| de Castro, MR | 1 |
| Henriques, AT | 1 |
| de Souza, MM | 1 |
| Barros, DM | 1 |
| Hiros, M | 1 |
| Selimovic, M | 1 |
| Spahovic, H | 1 |
| Sadovic, S | 1 |
| Spuzic-Celic, E | 1 |
| Ahmad, NS | 1 |
| Waheed, A | 1 |
| Farman, M | 1 |
| Qayyum, A | 1 |
| Tokgoz, H | 1 |
| Yurtlu, S | 1 |
| Hanci, V | 1 |
| Turksoy, O | 1 |
| Erol, B | 2 |
| Akduman, B | 1 |
| Mungan, A | 1 |
| Gan, TJ | 2 |
| Joshi, RS | 1 |
| Mandhane, PG | 1 |
| Diwakar, SD | 1 |
| Dabhade, SK | 1 |
| Gill, CH | 1 |
| Nemec, K | 1 |
| Cihal, P | 1 |
| Timin, E | 1 |
| Kamyar, MR | 1 |
| Lemmens-Gruber, R | 1 |
| Kapoor, S | 1 |
| Yanchick, J | 2 |
| Magelli, M | 3 |
| Bodie, J | 1 |
| Sjogren, J | 1 |
| Gassani, BC | 1 |
| Rezende, RM | 1 |
| Paiva-Lima, P | 1 |
| Ferreira-Alves, DL | 1 |
| dos Reis, WG | 1 |
| Bakhle, YS | 1 |
| de Francischi, JN | 1 |
| Kuehl, KS | 1 |
| McCarberg, BH | 1 |
| Argoff, CE | 1 |
| Resorlu, B | 1 |
| Bozkurt, OF | 1 |
| Senocak, C | 1 |
| Unsal, A | 1 |
| Böttcher, A | 1 |
| Guder, E | 1 |
| Just, T | 1 |
| Moon, JM | 1 |
| Lee, BK | 1 |
| Chun, BJ | 1 |
| Ağaç, E | 1 |
| Güneş, UY | 1 |
| Kumar, S | 1 |
| Behera, NC | 1 |
| Sarkar, D | 1 |
| Prasad, S | 1 |
| Mandal, AK | 1 |
| Singh, SK | 1 |
| Sheng, XP | 1 |
| Fan, TY | 1 |
| Taha, HM | 1 |
| Rehmani, RS | 1 |
| Gupta, AK | 1 |
| Chandurkar, NB | 1 |
| Sirsikar, AD | 1 |
| Ambade, RE | 1 |
| Jesalpura, BH | 1 |
| Swamy, AP | 1 |
| Kuehl, K | 1 |
| Carr, W | 1 |
| Chau, LH | 1 |
| Tai, DC | 1 |
| Fung, BT | 1 |
| Li, JC | 1 |
| Fan, CW | 1 |
| Li, MK | 1 |
| Böhme, K | 1 |
| Heckes, B | 1 |
| Thomitzek, K | 1 |
| Schnitzer, TJ | 2 |
| Dattani, ID | 1 |
| Seriolo, B | 1 |
| Schneider, H | 1 |
| Moore, A | 2 |
| Tseng, L | 1 |
| Sallstig, P | 1 |
| Rebuli, R | 1 |
| Maxwell, T | 1 |
| Hasani, A | 1 |
| Soljakova, M | 1 |
| Jakupi, M | 1 |
| Ustalar-Ozgen, S | 1 |
| Brewer, AR | 1 |
| Pierchala, LA | 1 |
| Yanchick, JK | 1 |
| Moisseiev, E | 1 |
| Varssano, D | 1 |
| Lende, AB | 1 |
| Kshirsagar, AD | 1 |
| Deshpande, AD | 1 |
| Muley, MM | 1 |
| Patil, RR | 1 |
| Bafna, PA | 1 |
| Naik, SR | 1 |
| Mibielli, MA | 1 |
| Nunes, CP | 1 |
| Cohen, JC | 1 |
| Scussel, AB | 1 |
| Higashi, R | 1 |
| Bendavit, GG | 1 |
| Oliveira, L | 1 |
| Geller, M | 1 |
| Duan, KZ | 1 |
| Xu, Q | 1 |
| Zhang, XM | 1 |
| Zhao, ZQ | 1 |
| Mei, YA | 1 |
| Zhang, YQ | 1 |
| Das, S | 1 |
| Haldar, PK | 2 |
| Pramanik, G | 2 |
| Panda, SP | 1 |
| Bera, S | 1 |
| Kumar, A | 2 |
| Lohan, P | 1 |
| Aneja, DK | 1 |
| Gupta, GK | 1 |
| Kaushik, D | 1 |
| Prakash, O | 1 |
| Afzal, M | 1 |
| Gupta, G | 1 |
| Kazmi, I | 1 |
| Rahman, M | 1 |
| Afzal, O | 1 |
| Alam, J | 1 |
| Hakeem, KR | 1 |
| Pravez, M | 1 |
| Gupta, R | 1 |
| Anwar, F | 1 |
| Hamelsky, S | 1 |
| Gold, M | 1 |
| Naskar, S | 1 |
| Mazumder, UK | 1 |
| Saha, P | 1 |
| Gupta, M | 1 |
| Ghosh, S | 1 |
| Wise, LE | 1 |
| Chen, Y | 1 |
| Gujjar, R | 1 |
| Mahadevan, A | 1 |
| Hoffmann, P | 1 |
| Kopačka, P | 1 |
| Gugliotta, B | 1 |
| Gwanyanya, A | 1 |
| Macianskiene, R | 1 |
| Mubagwa, K | 1 |
| Vélez de Mendizábal, N | 1 |
| Vásquez-Bahena, D | 1 |
| Jiménez-Andrade, JM | 1 |
| Trocóniz, IF | 1 |
| Setoguchi, N | 1 |
| Takamura, N | 1 |
| Fujita, K | 1 |
| Ogata, K | 1 |
| Tokunaga, J | 1 |
| Nishio, T | 1 |
| Chosa, E | 1 |
| Arimori, K | 1 |
| Kawai, K | 1 |
| Yamamoto, R | 1 |
| Rottigni, V | 1 |
| Büyükokuroğlu, ME | 1 |
| Labenz, J | 1 |
| Blum, AL | 2 |
| Bolten, WW | 1 |
| Dragosics, B | 1 |
| Rösch, W | 1 |
| Stolte, M | 2 |
| Koelz, HR | 1 |
| Gottesdiener, K | 1 |
| Schnitzer, T | 1 |
| Fisher, C | 1 |
| Bockow, B | 1 |
| Markenson, J | 1 |
| Ko, A | 1 |
| DeTora, L | 1 |
| Curtis, S | 1 |
| Geissler, L | 1 |
| Gertz, BJ | 1 |
| Kohase, H | 1 |
| Miyamoto, T | 1 |
| Umino, M | 1 |
| Anikwue, R | 1 |
| Huffman, JW | 1 |
| Martin, ZL | 1 |
| Welch, SP | 1 |
| Okuyama, M | 1 |
| Shibata, T | 1 |
| Morita, T | 1 |
| Kitada, M | 1 |
| Tukahara, Y | 1 |
| Fukushima, Y | 1 |
| Ikeda, K | 1 |
| Fuzita, J | 1 |
| Shimano, T | 1 |
| Weaver, CS | 1 |
| Terrell, KM | 1 |
| Li, CF | 1 |
| Wong, CY | 1 |
| Chan, CP | 1 |
| Ho, PC | 1 |
| Colak, T | 1 |
| Ipek, T | 1 |
| Kanik, A | 1 |
| Ogetman, Z | 1 |
| Aydin, S | 1 |
| Almási, R | 1 |
| Grebe, W | 1 |
| Ionescu, E | 1 |
| Liu, JM | 2 |
| Frank, WO | 1 |
| Lázaro, C | 1 |
| Caseras, X | 1 |
| Torrubia, R | 1 |
| Baños, JE | 1 |
| Burian, M | 2 |
| Tegeder, I | 2 |
| Seegel, M | 1 |
| Geisslinger, G | 4 |
| Motta, AF | 1 |
| Borges Junior, NG | 1 |
| da Fonseca, JC | 1 |
| Tonussi, CR | 1 |
| Tallarida, RJ | 1 |
| Cowan, A | 1 |
| Raffa, RB | 1 |
| Michalsen, A | 1 |
| Klotz, S | 1 |
| Lüdtke, R | 1 |
| Moebus, S | 1 |
| Spahn, G | 1 |
| Dobos, GJ | 1 |
| Leman, P | 1 |
| Kapadia, Y | 1 |
| Herington, J | 1 |
| Patil, CS | 1 |
| Jain, NK | 1 |
| Kulkarni, SK | 1 |
| Dellabella, M | 1 |
| Milanese, G | 1 |
| Muzzonigro, G | 1 |
| Murugananthan, G | 1 |
| Venkateshperumal, R | 1 |
| Fox, A | 1 |
| Medhurst, S | 1 |
| Courade, JP | 1 |
| Glatt, M | 1 |
| Dawson, J | 1 |
| Urban, L | 1 |
| Bevan, S | 1 |
| Gonzalez, I | 1 |
| Haq, A | 1 |
| Patel, HR | 1 |
| Habib, MR | 1 |
| Donaldson, PJ | 1 |
| Parry, JR | 1 |
| Legrand, E | 1 |
| Amir, M | 1 |
| Shikha, K | 1 |
| Ukhal', MI | 1 |
| Melenevskiĭ, DA | 1 |
| Sørensen, OG | 1 |
| Hansen, TB | 1 |
| Akhtar, NM | 1 |
| Naseer, R | 1 |
| Farooqi, AZ | 1 |
| Aziz, W | 1 |
| Nazir, M | 1 |
| Mysler, E | 1 |
| Beier, J | 1 |
| Geusens, P | 1 |
| Hasler, P | 1 |
| Patel, SK | 1 |
| Senftleber, I | 1 |
| Gitton, X | 1 |
| Sloan, VS | 2 |
| Poór, G | 1 |
| Bezer, M | 1 |
| Gökkuş, K | 1 |
| Kocaoğlu, B | 1 |
| Güven, O | 1 |
| Dodd, JM | 1 |
| Hedayati, H | 1 |
| Pearce, E | 1 |
| Hotham, N | 1 |
| Crowther, CA | 1 |
| Adler, S | 1 |
| Schostak, M | 1 |
| Haas, H | 1 |
| Walz, J | 1 |
| Magnette, JL | 1 |
| Kienzler, JL | 1 |
| Sallin, D | 1 |
| Ménart, C | 1 |
| Nollevaux, F | 1 |
| Knops, A | 1 |
| Lyseng-Williamson, KA | 1 |
| Curran, MP | 1 |
| Vas, J | 1 |
| Méndez, C | 1 |
| Perea-Milla, E | 1 |
| Vega, E | 1 |
| Panadero, MD | 1 |
| León, JM | 1 |
| Borge, MA | 1 |
| Gaspar, O | 1 |
| Sánchez-Rodríguez, F | 1 |
| Aguilar, I | 1 |
| Jurado, R | 1 |
| Rinnab, L | 1 |
| Gschwend, JE | 1 |
| Hautmann, RE | 1 |
| Straub, M | 1 |
| Chiambaretta, F | 1 |
| Creuzot-Garcher, C | 1 |
| Pilon, F | 1 |
| Pouliquen, P | 1 |
| Rebika, H | 1 |
| Dubray, C | 1 |
| Rigal, D | 1 |
| Solignac, M | 2 |
| Jones, NG | 1 |
| Slater, R | 1 |
| Cadiou, H | 1 |
| McNaughton, P | 1 |
| McMahon, SB | 1 |
| Khan, MS | 1 |
| Akhter, M | 1 |
| Teekachunhatean, S | 1 |
| Kunanusorn, P | 1 |
| Rojanasthien, N | 1 |
| Sananpanich, K | 1 |
| Pojchamarnwiputh, S | 1 |
| Lhieochaiphunt, S | 1 |
| Pruksakorn, S | 1 |
| Mohta, M | 1 |
| Agarwal, D | 1 |
| Sethi, AK | 1 |
| Sandhu, K | 1 |
| Christidis, N | 1 |
| Kopp, S | 1 |
| Ernberg, M | 1 |
| Bierma-Zeinstra, SM | 1 |
| Belo, JN | 1 |
| Thomas, S | 1 |
| Di Rienzo Businco, L | 1 |
| Di Rienzo Businco, A | 1 |
| D'Emilia, M | 1 |
| Lauriello, M | 1 |
| Coen Tirelli, G | 1 |
| Lozano-Cuenca, J | 1 |
| Granados-Soto, V | 5 |
| Schaffler, K | 1 |
| Reitmeir, P | 1 |
| Gschanes, A | 1 |
| Eggenreich, U | 1 |
| Baer, PA | 1 |
| Thomas, LM | 1 |
| Shainhouse, Z | 1 |
| Wright, GA | 1 |
| Fleischmann, R | 1 |
| Sheldon, E | 1 |
| Maldonado-Cocco, J | 1 |
| Dutta, D | 1 |
| Yu, S | 1 |
| Woo, WW | 1 |
| Man, SY | 1 |
| Lam, PK | 1 |
| Rainer, TH | 1 |
| Spacca, G | 1 |
| Cacchio, A | 1 |
| Forgács, A | 1 |
| Monteforte, P | 1 |
| Rovetta, G | 1 |
| Irer, B | 1 |
| Gulcu, A | 1 |
| Aslan, G | 1 |
| Goktay, Y | 1 |
| Celebi, I | 1 |
| Niethard, FU | 1 |
| Solomon, GS | 1 |
| Unkauf, M | 1 |
| Albrecht, HH | 1 |
| Elkik, F | 1 |
| Kim, JS | 1 |
| Hwang, JM | 1 |
| Singh, G | 1 |
| Fort, JG | 1 |
| Goldstein, JL | 1 |
| Levy, RA | 1 |
| Hanrahan, PS | 1 |
| Bello, AE | 1 |
| Andrade-Ortega, L | 1 |
| Wallemark, C | 1 |
| Agrawal, NM | 1 |
| Eisen, GM | 1 |
| Stenson, WF | 1 |
| Triadafilopoulos, G | 1 |
| Zochling, J | 1 |
| Bohl-Bühler, MH | 1 |
| Baraliakos, X | 1 |
| Feldtkeller, E | 1 |
| Braun, J | 1 |
| Agarwal, A | 2 |
| Dhiraaj, S | 1 |
| Singhal, V | 1 |
| Singh, U | 2 |
| Diener, HC | 1 |
| Montagna, P | 1 |
| Gács, G | 1 |
| Lyczak, P | 1 |
| Schumann, G | 1 |
| Zöller, B | 1 |
| Mulder, LJ | 1 |
| Siegel, J | 1 |
| Edson, K | 1 |
| Gøtzsche, PC | 1 |
| Ericsson, E | 1 |
| Wadsby, M | 1 |
| Hultcrantz, E | 1 |
| Ojewole, JA | 2 |
| Esparza, F | 1 |
| Cobián, C | 1 |
| Jiménez, JF | 1 |
| García-Cota, JJ | 1 |
| Sánchez, C | 1 |
| Maestro, A | 1 |
| Banning, M | 1 |
| Parker, AG | 1 |
| Peraza, GG | 1 |
| Sena, J | 1 |
| Silva, ES | 1 |
| Soares, MC | 1 |
| Vaz, MR | 1 |
| Furlong, EB | 1 |
| Muccillo-Baisch, AL | 1 |
| Moore, N | 1 |
| Heilborn, U | 1 |
| Berge, OG | 1 |
| Arborelius, L | 1 |
| Brodin, E | 1 |
| Gautam, S | 1 |
| Gupta, D | 1 |
| Mutalik, S | 1 |
| Naha, A | 1 |
| Usha, AN | 1 |
| Ranjith, AK | 1 |
| Musmade, P | 1 |
| Manoj, K | 1 |
| Anju, P | 1 |
| Prasanna, S | 1 |
| Corbett, AD | 1 |
| Dogrul, A | 1 |
| Gülmez, SE | 1 |
| Deveci, MS | 1 |
| Gul, H | 1 |
| Ossipov, MH | 1 |
| Tulunay, FC | 1 |
| Horváth, D | 1 |
| Saeidian, SR | 1 |
| Hemmati, AA | 1 |
| Haghighi, MH | 1 |
| Orssaud, C | 1 |
| Roche, O | 1 |
| El Dirani, H | 1 |
| Allali, J | 1 |
| Dufier, JL | 1 |
| López, JC | 1 |
| Vigil-De Gracia, P | 1 |
| Vega-Malek, JC | 1 |
| Ruiz, E | 1 |
| Vergara, V | 1 |
| Bannwarth, B | 1 |
| Bérenbaum, F | 1 |
| Kudaeva, FM | 1 |
| Eliseev, MS | 1 |
| Barskova, VG | 1 |
| Nasonova, VA | 1 |
| Azevedo, AO | 1 |
| Campos, JJ | 1 |
| Galdino, GS | 1 |
| Braga, FC | 1 |
| Duarte, ID | 1 |
| Perez, AC | 1 |
| Ying, KN | 1 |
| While, A | 1 |
| Duh, D | 1 |
| Vandevijver, A | 1 |
| Shi, S | 1 |
| Klotz, U | 1 |
| Bhomi, KK | 1 |
| Lim, HH | 1 |
| Consigliere, DT | 1 |
| Tiong, HY | 1 |
| Kayali, C | 1 |
| Agus, H | 1 |
| Surer, L | 1 |
| Turgut, A | 1 |
| D'Anchise, R | 1 |
| Bulitta, M | 1 |
| Zacher, J | 1 |
| Altman, R | 1 |
| Bellamy, N | 2 |
| Brühlmann, P | 1 |
| Da Silva, J | 1 |
| Huskisson, E | 1 |
| Taylor, RS | 1 |
| Brooks, TA | 1 |
| Nametz, N | 1 |
| Charles, R | 1 |
| Rhim, SY | 1 |
| Park, JH | 1 |
| Park, YS | 1 |
| Lee, MH | 1 |
| Shaw, LM | 1 |
| Kang, JS | 1 |
| Baroni, L | 2 |
| Borghi, C | 2 |
| Trombetta, N | 2 |
| Marcolongo, R | 3 |
| Giordano, N | 2 |
| Mattara, L | 1 |
| Leardini, G | 1 |
| Lavezzari, M | 1 |
| Gruni, G | 1 |
| Mandelli, V | 1 |
| Wafin, F | 1 |
| Valindas, E | 1 |
| Wuolijoki, E | 2 |
| Grossi, E | 2 |
| Brogden, RN | 2 |
| Heel, RC | 1 |
| Pakes, GE | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Riihiluoma, P | 1 |
| Pulkkinen, MO | 1 |
| Muriel-Villoria, C | 1 |
| Zungri-Telo, E | 1 |
| Díaz-Curiel, M | 1 |
| Fernández-Guerrero, M | 1 |
| Moreno, J | 1 |
| Puerta, J | 1 |
| Ortiz, P | 1 |
| Haddad, FS | 1 |
| Williams, RL | 1 |
| Valentini, M | 1 |
| Cannizzaro, R | 1 |
| Poletti, M | 1 |
| Bortolussi, R | 1 |
| Fracasso, A | 1 |
| Testa, V | 1 |
| Sozzi, M | 1 |
| Fornasarig, M | 1 |
| Bortoluzzi, F | 1 |
| Grazioli, I | 1 |
| Porto, A | 1 |
| Almeida, H | 1 |
| Cunha, MJ | 1 |
| Macciocchi, A | 1 |
| Bakshi, R | 2 |
| Ezzet, N | 1 |
| Frey, L | 1 |
| Lasry, D | 1 |
| Salliere, D | 1 |
| Inoue, K | 1 |
| Motonaga, A | 1 |
| Dainaka, J | 1 |
| Nishimura, T | 1 |
| Hashii, H | 1 |
| Yamate, K | 1 |
| Ueda, F | 1 |
| Kimura, K | 1 |
| Björkman, R | 4 |
| Bombardier, C | 1 |
| Peloso, PM | 1 |
| Goldsmith, CH | 1 |
| Reginster, JY | 2 |
| Franchimont, P | 1 |
| Benoit, R | 1 |
| Blanchi, A | 1 |
| Roubin, C | 1 |
| Chapeau, MC | 1 |
| Ardia, A | 1 |
| Franchini, S | 1 |
| Baggio, A | 1 |
| Cornelli, U | 1 |
| Barr, S | 1 |
| Buchanan, WW | 1 |
| Chalmers, A | 1 |
| Ford, PM | 1 |
| Kraag, GR | 1 |
| Gerecz-Simon, E | 1 |
| Campbell, J | 1 |
| March, L | 1 |
| Irwig, L | 1 |
| Schwarz, J | 1 |
| Simpson, J | 1 |
| Chock, C | 1 |
| Brooks, P | 1 |
| Dawson, C | 1 |
| Vale, JA | 1 |
| Corry, DA | 1 |
| Cohen, NP | 1 |
| Gallagher, J | 1 |
| Nockler, IB | 1 |
| Whitfield, HN | 1 |
| Babej-Dölle, R | 1 |
| Freytag, S | 1 |
| Eckmeyer, J | 1 |
| Zerle, G | 1 |
| Schinzel, S | 1 |
| Schmeider, G | 1 |
| Stankov, G | 1 |
| Frey, W | 1 |
| Wassmer, P | 1 |
| Frey-Rindova, P | 1 |
| Braun, D | 1 |
| Schwarz, F | 1 |
| Arnold, M | 1 |
| Piguet, A | 1 |
| Villiger, B | 1 |
| Clarke, GD | 1 |
| MacPherson, IS | 1 |
| Petrone, G | 1 |
| Spangler, RS | 1 |
| Dolenska, S | 1 |
| Kahraman, S | 1 |
| Ercan, S | 1 |
| Aypar, U | 1 |
| Erdem, K | 1 |
| Porzio, F | 1 |
| Bacon, P | 1 |
| Elam, M | 1 |
| Sandin, R | 1 |
| Sternlo, JE | 1 |
| Stam, H | 1 |
| Brodd, B | 1 |
| Ullman, A | 1 |
| Hedner, J | 2 |
| Hovorka, J | 1 |
| Kallela, H | 1 |
| Korttila, K | 1 |
| Futaki, N | 1 |
| Yoshikawa, K | 1 |
| Hamasaka, Y | 1 |
| Arai, I | 1 |
| Higuchi, S | 1 |
| Iizuka, H | 1 |
| Otomo, S | 1 |
| Nunez, J | 1 |
| Lake, AP | 1 |
| Marchini, M | 1 |
| Tozzi, L | 1 |
| Pistai, R | 1 |
| Fedele, L | 1 |
| Jonsson, CE | 1 |
| Ericsson, F | 1 |
| Martín-Mola, E | 1 |
| Gijón-Baños, J | 1 |
| Ansoleaga, JJ | 1 |
| Buritova, J | 1 |
| Chapman, V | 1 |
| Besson, JM | 1 |
| Wiseman, LR | 1 |
| Roth, SH | 1 |
| Moore, AR | 1 |
| Willoughby, DA | 1 |
| Tankó, A | 1 |
| Tamás, G | 1 |
| Baumgartner, H | 1 |
| Schwarz, HA | 1 |
| Blum, W | 1 |
| Bruhin, A | 1 |
| Gallachi, G | 1 |
| Goldinger, G | 1 |
| Saxer, M | 1 |
| Trost, H | 1 |
| Winters, JC | 1 |
| Sobel, JS | 1 |
| Groenier, KH | 1 |
| Arendzen, JH | 1 |
| Meyboom-de Jong, B | 1 |
| Graham, MJ | 1 |
| Kent, JE | 1 |
| Molony, V | 1 |
| Somwanshi, M | 1 |
| Tripathi, A | 1 |
| Singh, B | 1 |
| Mercadante, S | 1 |
| Sapio, M | 1 |
| Caligara, M | 1 |
| Serretta, R | 1 |
| Dardanoni, G | 1 |
| Barresi, L | 1 |
| Jayamanne, DG | 1 |
| Fitt, AW | 1 |
| Dayan, M | 1 |
| Andrews, RM | 1 |
| Mitchell, KW | 1 |
| Griffiths, PG | 1 |
| Price, DD | 1 |
| Mao, J | 1 |
| Lu, J | 1 |
| Caruso, FS | 1 |
| Frenk, H | 1 |
| Mayer, DJ | 1 |
| Chen, X | 1 |
| Gallar, J | 1 |
| Belmonte, C | 1 |
| Gans, RO | 1 |
| Stehouwer, CD | 1 |
| Saxen, MA | 1 |
| Ambrosius, WT | 1 |
| Russell, AL | 1 |
| Eckert, GJ | 1 |
| Waikakul, S | 1 |
| Penkitti, P | 1 |
| Soparat, K | 1 |
| Boonsanong, W | 1 |
| Gehling, M | 1 |
| Colombo, G | 1 |
| Giombini, A | 1 |
| Pamich, T | 1 |
| Peruzzi, E | 1 |
| Pisati, R | 2 |
| Le Loët, X | 1 |
| Dreiser, RL | 1 |
| Le Gros, V | 1 |
| Febvre, N | 1 |
| Litke, J | 1 |
| Bohatyrewicz, A | 1 |
| Mikulski, K | 1 |
| Polati, E | 1 |
| Finco, G | 1 |
| Gottin, L | 1 |
| Bassi, C | 1 |
| Pederzoli, P | 1 |
| Ischia, S | 1 |
| Minotti, V | 2 |
| De Angelis, V | 1 |
| Righetti, E | 1 |
| Celani, MG | 1 |
| Rossetti, R | 1 |
| Lupatelli, M | 1 |
| Tonato, M | 2 |
| Monza, G | 1 |
| Fumi, G | 1 |
| Del Favero, A | 2 |
| Gupta, SK | 1 |
| Velpandian, T | 1 |
| Mathur, P | 1 |
| Sengupta, S | 1 |
| Dornic, DI | 1 |
| Thomas, JM | 1 |
| Lass, JH | 1 |
| Euchenhofer, C | 1 |
| Maihófner, C | 1 |
| Brune, K | 2 |
| Santos, AR | 1 |
| Vedana, EM | 1 |
| De Freitas, GA | 1 |
| Reyes, G | 2 |
| Medina, R | 2 |
| Castillo, EF | 1 |
| Herrera, JE | 1 |
| Tinajero, J | 1 |
| Chaves, F | 1 |
| Valdes, B | 1 |
| Scheen, AJ | 1 |
| Matambo, J | 1 |
| Moodley, J | 1 |
| Chigumadzi, P | 1 |
| Gordon, A | 1 |
| Bartlett, JD | 1 |
| Lin, M | 1 |
| Akpinar, F | 1 |
| Aydinlioğlu, A | 1 |
| Tosun, N | 1 |
| Fioravanti, A | 1 |
| Cicero, MR | 1 |
| Nerucci, F | 1 |
| Manopulo, R | 1 |
| Jones, PG | 1 |
| Zgradie, I | 1 |
| Lötsch, J | 1 |
| Kettenmann, B | 1 |
| Renner, B | 1 |
| Drover, D | 1 |
| Kobal, G | 1 |
| Edwards, SR | 1 |
| Mather, LE | 1 |
| Lin, Y | 1 |
| Power, I | 2 |
| Cousins, MJ | 1 |
| Galer, BS | 1 |
| Rowbotham, M | 1 |
| Perander, J | 1 |
| Devers, A | 1 |
| Friedman, E | 1 |
| Filippi, R | 1 |
| Laun, J | 1 |
| Jage, J | 1 |
| Perneczky, A | 1 |
| Takasaki, I | 1 |
| Andoh, T | 1 |
| Nitta, M | 1 |
| Takahata, H | 1 |
| Nemoto, H | 1 |
| Shiraki, K | 1 |
| Nojima, H | 1 |
| Kuraishi, Y | 1 |
| Castillo, C | 1 |
| Rodríguez, J | 1 |
| Mateos, E | 1 |
| Terán, F | 1 |
| Kotani, N | 1 |
| Kushikata, T | 1 |
| Hashimoto, H | 1 |
| Kimura, F | 1 |
| Muraoka, M | 1 |
| Yodono, M | 1 |
| Asai, M | 1 |
| Matsuki, A | 1 |
| Hoogewijs, J | 1 |
| Diltoer, MW | 1 |
| Hubloue, I | 1 |
| Spapen, HD | 1 |
| Camu, F | 1 |
| Corne, L | 1 |
| Huyghens, LP | 1 |
| Tive, L | 1 |
| Asomoza-Espinosa, R | 3 |
| Alonso-López, R | 3 |
| Mixcoatl-Zecuatl, T | 1 |
| Aguirre-Bañuelos, P | 1 |
| Torres-López, JE | 3 |
| Kakar, S | 1 |
| Jeffery, JA | 1 |
| Bentley, G | 1 |
| Mahé, I | 1 |
| Mouly, S | 1 |
| Mahé, E | 1 |
| Diemer, M | 1 |
| Knellwolf, AL | 1 |
| Simoneau, G | 1 |
| Caulin, C | 1 |
| Bergmann, JF | 1 |
| Dooley, M | 1 |
| Spencer, CM | 1 |
| Dunn, CJ | 1 |
| Paul, I | 1 |
| Henrotin, Y | 1 |
| Rufino, MO | 1 |
| Gomes-Lopes, LD | 1 |
| Ferreira, SH | 1 |
| Jurna, I | 1 |
| Rosas, R | 1 |
| Vidal-Cantú, GC | 1 |
| Miranda, HF | 1 |
| Sierralta, F | 1 |
| Pinardi, G | 1 |
| Hosseinzadeh, H | 1 |
| Ramezani, M | 1 |
| Fadishei, M | 1 |
| Alexander, R | 1 |
| El-Moalem, HE | 1 |
| Lemmel, EM | 1 |
| Leeb, B | 1 |
| De Bast, J | 1 |
| Aslanidis, S | 1 |
| Goch, JH | 1 |
| Adamska-Dyniewska, H | 1 |
| Vigneron, JR | 1 |
| Thys, R | 1 |
| Huskisson, EC | 1 |
| Corts Giner, JR | 1 |
| García Borrás, JJ | 1 |
| Strobel, E | 1 |
| Björkman, RL | 1 |
| Hedner, T | 1 |
| Hallman, KM | 1 |
| Henning, M | 1 |
| Geis, GS | 1 |
| Loew, D | 1 |
| Schuster, O | 1 |
| Schneider, B | 1 |
| Biehl, J | 1 |
| De Conno, F | 1 |
| Ripamonti, C | 1 |
| Bianchi, M | 1 |
| Ventafridda, V | 1 |
| Panerai, AE | 1 |
| Fainsinger, RL | 1 |
| Miller, MJ | 1 |
| Bruera, E | 1 |
| Berenfeld, A | 1 |
| Bessing, WD | 1 |
| Bisplinghoff, U | 1 |
| Bittner, G | 1 |
| Matthiesen, HO | 1 |
| Tilscher, H | 1 |
| Ramm, S | 1 |
| Ebeling, L | 1 |
| Schmitz, H | 1 |
| Wiesenberg-Boettcher, I | 1 |
| Pfeilschifter, J | 1 |
| Schweizer, A | 4 |
| Sallmann, A | 1 |
| Wenk, P | 1 |
| Pellegrini, P | 1 |
| Grau, M | 1 |
| Guasch, J | 1 |
| Montero, JL | 1 |
| Felipe, A | 1 |
| Carrasco, E | 1 |
| Juliá, S | 1 |
| Stiefel, F | 1 |
| Morant, R | 1 |
| Stadler, P | 1 |
| Armstrong, D | 1 |
| Margalith, D | 1 |
| Saraga, E | 1 |
| Lualdi, P | 1 |
| Mautone, G | 1 |
| Morán, M | 1 |
| Sanahuja, J | 1 |
| Corbera, G | 1 |
| Garau, J | 1 |
| Plá, R | 1 |
| Carmen Carré, M | 1 |
| McGalliard, J | 1 |
| Bell, AL | 1 |
| Gostick, N | 1 |
| James, IG | 1 |
| Khong, TK | 1 |
| Roy, P | 1 |
| Shepherd, PR | 1 |
| Miller, AJ | 2 |
| Crowley, B | 1 |
| Hamill, JJ | 1 |
| Lyndon, S | 1 |
| McKellican, JF | 1 |
| Williams, P | 1 |
| Patoia, L | 1 |
| Roila, F | 1 |
| Basurto, C | 1 |
| Pasqualucci, V | 1 |
| Maresca, V | 1 |
| Parr, G | 1 |
| Darekar, B | 1 |
| Fletcher, A | 1 |
| Bulpitt, CJ | 1 |
| Kromann-Andersen, B | 1 |
| Sommer, P | 1 |
| Finnerup, B | 1 |
| Lendorf, A | 1 |
| Lyngdorf, P | 1 |
| Mouritsen, AL | 1 |
| Møller, P | 1 |
| Rasmussen, F | 1 |
| Kantor, TG | 1 |
| Rossi, PC | 1 |
| Giudicelli, N | 1 |
| Parenti, G | 1 |
| Pacetti, E | 1 |
| Scholer, DW | 1 |
| Ku, EC | 1 |
| Boettcher, I | 1 |
| Khalifa, MS | 1 |
| Sharkawi, MA | 1 |
| Attal, N | 1 |
| Kayser, V | 1 |
| Eschalier, A | 1 |
| Benoist, JM | 1 |
| Guilbaud, G | 1 |
| Bremerich, A | 1 |
| Wiegel, W | 1 |
| Faigle, JW | 1 |
| Böttcher, I | 1 |
| Godbillon, J | 1 |
| Kriemler, HP | 1 |
| Schlumpf, E | 1 |
| Schneider, W | 1 |
| Stierlin, H | 1 |
| Winkler, T | 1 |
| Todd, PA | 1 |
| Sorkin, EM | 1 |
| Donnelly, AE | 1 |
| McCormick, K | 1 |
| Maughan, RJ | 1 |
| Whiting, PH | 1 |
| Clarkson, PM | 1 |
| Benahmed, M | 1 |
| Wibault, P | 1 |
| Court, B | 1 |
| Kple Faget, P | 1 |
| Ammarguellat, H | 1 |
| Pichard, E | 1 |
| Calabro, JJ | 1 |
| Garagiola, U | 1 |
| Marconi, A | 1 |
| Broggini, M | 1 |
| Frost, A | 1 |
| Bassi, GP | 1 |
| Giannini, R | 1 |
| Francucci, BM | 1 |
| Camarri, E | 1 |
| Mordini, M | 1 |
| Cocco, F | 1 |
| Neri, D | 1 |
| Stacher, G | 1 |
| Steinringer, H | 1 |
| Schneider, S | 1 |
| Mittelbach, G | 1 |
| Winklehner, S | 1 |
| Gaupmann, G | 1 |
| Brom, R | 1 |
| Caldwell, JR | 1 |
| Khan, MA | 1 |
| Machtey, I | 1 |
Clinical Trials (38)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Clinical Study on Pain Control of Cervical Dilation by Lidocaine Solution Injected Into a Single-use Micro-non-invasive Injection Cervical Dilator"[NCT05955768] | 74 participants (Anticipated) | Interventional | 2023-07-21 | Enrolling by invitation | |||
| A Clinical Study to Assess the Efficacy and Onset of Pain Relief of Topical MFC51123 Diclofenac-Menthol Gel Versus Controls in Ankle Sprain[NCT02100670] | Phase 3 | 385 participants (Actual) | Interventional | 2013-11-01 | Completed | ||
| Comparison of Topical 1% Diclofenac and Topical 2.5% Hydrocortisone for TMJ Arthralgia[NCT05816226] | Phase 3 | 90 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | ||
| Double-blind, Randomized, Placebo-controlled Study on the Effect of Multimodal Analgesia on Pain With Insertion of Levonorgestrel-releasing Intrauterine System[NCT02799641] | 61 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| A PHASE 3, RANDOMIZED, DOUBLE BLIND, CONTROLLED, MULTI CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP[NCT00864097] | Phase 3 | 607 participants (Actual) | Interventional | 2009-08-11 | Terminated (stopped due to See termination reason in detailed description.) | ||
| Anorectal Application of 5% Lidocaine Cream Reduces Pain Prior to Periprostatic Nerve Block During Transrectal Ultrasound Guided Biopsy: Randomized, Prospective Controlled Study[NCT04064047] | 284 participants (Actual) | Interventional | 2016-12-31 | Completed | |||
| Comparison of Dexketoprofen, Paracetamol and Ibuprofen in the Treatment of Primary Dysmenorrhea[NCT03697746] | 300 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | |||
| "Efficacy of the Combination of Z-track and Airlock Techniques During Intramuscular Injection of Haloperidol Decanoate in Adult Patients With Schizophrenic or Related Disorder : A Multicenter Randomized Controlled Trial"[NCT05995457] | 84 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| Pilot, Open Non-controled Trial to Assess the Feasibility of Implementing Objective Parameters as Primary Endpoints in a Clinical Trial With Patients Affected by Knee Osteoarthritis[NCT03421054] | 8 participants (Actual) | Interventional | 2018-03-19 | Completed | |||
| Double Blind, Placebo Controlled Trial to Evaluate the Effects of a Nutraceutical Containing High-Molecular-Weight Hyaluronic Acid (HA) and Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) in Patients Affected by Knee Osteoarthritis[NCT03612986] | 72 participants (Actual) | Interventional | 2018-08-22 | Completed | |||
| A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Clinical Study to Evaluate the Safety and Efficacy of PENNSAID Gel in the Symptomatic Treatment of Osteoarthritis of the Knee[NCT01119898] | Phase 2 | 260 participants (Actual) | Interventional | 2010-08-02 | Completed | ||
| [NCT01993589] | 144 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Diclofenac Plus Lidocaine Gel for Pain Relief During Intrauterine Device (IUD) Insertion. A Randomized Double Blinded Placebo-controlled Study[NCT02332057] | Phase 2 | 90 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Efficacy of Pain Control Following Root Canal Treatment Using Paracetamol Alone and in Combination With Three Different Non-Steroidal Anti-Inflammatory Analgesics[NCT02417337] | Phase 2 | 170 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Effect of Preoperative, Single-dose Diclofenac Potassium on Postoperative Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis: A Double Blind Randomized Controlled Trial[NCT03341260] | Phase 2/Phase 3 | 70 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Investigating Brain Abnormalities in People With Knee Osteoarthritis Using MRI: a Nociplastic Pain Mechanism Based Assessment[NCT05986513] | 66 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis[NCT01383954] | Phase 4 | 52 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Potential for Improved Analgesia From Combined Medication for Superficial Pain[NCT02194088] | Phase 3 | 100 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A 7-Day Multicenter Randomized Double-Blind, Double-Dummy Parallel Group Trial to Assess the Safety and Efficacy of 400 mg Lumiracoxib Once Daily Versus 500 mg Naproxen Twice Daily in Patients With Acute Musculoskeletal Pain Due to Uncomplicated Soft Tiss[NCT00170898] | Phase 4 | 419 participants | Interventional | 2004-11-30 | Completed | ||
| Efficacy of PENNSAID® for Pain Management in the Emergency Department[NCT01350622] | 0 participants (Actual) | Interventional | 2011-12-31 | Withdrawn (stopped due to Study never initiated) | |||
| Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis[NCT00171652] | Phase 3 | 360 participants | Interventional | 2005-05-31 | Completed | ||
| Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis[NCT00171665] | Phase 3 | 360 participants | Interventional | 2005-05-31 | Completed | ||
| A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control[NCT00154219] | Phase 3 | 1,200 participants | Interventional | 2004-11-30 | Completed | ||
| A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.[NCT00242489] | Phase 2 | 1,167 participants (Actual) | Interventional | 1998-06-30 | Completed | ||
| Single and Repeated Leech Therapy for the Treatment of Late Stage Knee Osteoarthritis. A Randomized, Placebo Controlled Comparative Trial[NCT00435773] | Phase 2 | 118 participants | Interventional | 2004-02-29 | Completed | ||
| [NCT00451061] | Phase 4 | 120 participants (Anticipated) | Interventional | 2007-04-30 | Not yet recruiting | ||
| Diclofenac Suppository As a Preemptive Analgesia in Ultrasound Guided Biopsy of Prostate: Randomized Controlled Trial[NCT01939743] | Phase 2 | 100 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| External Validation of a Clinical Scoring System to Predict Microscopic Colitis in Patients With Chronic Watery Diarrhoea[NCT06031064] | 200 participants (Anticipated) | Observational | 2022-05-15 | Recruiting | |||
| Efficacy of Tramadol Hcl in the Treatment of Renal Colic[NCT00310908] | Phase 4 | 100 participants (Anticipated) | Interventional | 2006-09-30 | Completed | ||
| Randomized, Double-Blind, Placebo-Controlled Trial, Parallel Design Used To Evaluate Pain, Endocrinologic Variations, Life Quality And Medication Use, After Electro-Acupuncture Treatment In Patients With Osteoarthritis Of The Knee[NCT02299713] | 160 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles[NCT02230371] | Phase 4 | 40 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| The Use of Cannabinoid Patch for Knee Osteoarthritis[NCT04412837] | Phase 2 | 0 participants (Actual) | Interventional | 2022-10-31 | Withdrawn (stopped due to Inadequate funding) | ||
| IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine[NCT02664116] | Phase 4 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| An Evaluation of the Paracervical Block for Pain Control in First Trimester Surgical Abortion[NCT01094366] | Phase 4 | 121 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Trial of Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles[NCT02046317] | Phase 4 | 12 participants (Actual) | Interventional | 2011-05-31 | Terminated (stopped due to No further enrolled patients, Primary researcher left the institution) | ||
| Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach[NCT01398943] | 60 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| Does Repetitive Peripheral Nerve Blocks Vs Single Peripheral Nerve Block Vs Standard Medical Treatment Provide a Better Pain Relief on Zoster Pain at the Acute Phase and Reduce the Risk of Post Herpetic Neuralgia?[NCT04133142] | 0 participants (Actual) | Interventional | 2020-05-15 | Withdrawn (stopped due to No enrollement and covid) | |||
| Double-blind, Prospective Comparison of Medications Used in Trigger Point Injections - Ketorolac, Lidocaine, or Dexamethasone[NCT03028012] | Phase 4 | 10 participants (Actual) | Interventional | 2017-05-02 | Terminated (stopped due to Poor enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel
AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing. (NCT02100670)
Timeframe: up to 72 hours
| Intervention | NRS Score (0 - 10 scale) * hrs (Mean) |
|---|---|
| 1% Diclofenac Sodium Plus (+) 3% Menthol | 276.97 |
| Placebo | 282.88 |
AUC1-3 Days of PI on Movement for Diclofenac Sodium + Methanol, Diclofenac, Methanol and Placebo
AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing. (NCT02100670)
Timeframe: up to 72 hours
| Intervention | NRS Score (0 - 10 scale) * hrs (Mean) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 276.97 |
| 1% Diclofenac Sodium | 261.11 |
| 3% Menthol | 272.65 |
| Placebo | 282.88 |
Time of Onset of Cooling Sensation (TOCS)
"Time of onset of cooling sensation measured by time when subjects reported to have a 'cooling effect as an enhancement of pain relief'. To assess this endpoint, participants were asked at 10, 30 minutes and at 1, 4, 6 hours post first dose Do you feel a cooling sensation at the injured ankle from the study gel?" (NCT02100670)
Timeframe: up to 6 hours
| Intervention | Hours (Median) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 0.17 |
| 1% Diclofenac Sodium | 0.17 |
| 3% Menthol | 0.17 |
| Placebo | 0.17 |
Time of Onset of Meaningful Pain Relief (TOMR)
"TOMR was measured by time when participants reported PRS ≥ 2, i.e. some or meaningful pain relief" (NCT02100670)
Timeframe: up to 10 days (end of study)
| Intervention | Hours (Median) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 92.50 |
| 1% Diclofenac Sodium | 76.83 |
| 3% Menthol | 72.00 |
| Placebo | 93.50 |
Time of Onset of Pain Relief (TOPR)
"TOPR was measured by time when participants reported PRS ≥ 1, i.e. a little or perceptible pain relief'." (NCT02100670)
Timeframe: Baseline to 10 days (end of study)
| Intervention | Hours (Median) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 1.03 |
| 1% Diclofenac Sodium | 4.00 |
| 3% Menthol | 1.00 |
| Placebo | 4.00 |
Time to Complete Recovery
Time to complete recovery measured as the day with complete relief of ankle pain (Participant-rated NRS scores were 0 for pain intensity at rest and pain) and swelling (Participants did not have any apparent swelling nor experience any pain or limitation of movement of the injured ankle as determined by the Principal Investigator or designee during the course of an ankle exam). (NCT02100670)
Timeframe: up to 240 hours
| Intervention | Hours (Median) |
|---|---|
| 1% Diclofenac Sodium+3% Menthol | 240.00 |
| 1% Diclofenac Sodium | 240.00 |
| 3% Menthol | 240.00 |
| Placebo | 240.00 |
Ankle Swelling
"Ankle swelling measured by figure of eight method of injured ankle." (NCT02100670)
Timeframe: Day 1 (baseline), 3, and 7
| Intervention | Millimeters (Mean) | ||
|---|---|---|---|
| At Day 1 | At Day 3 | At Day 7 | |
| 1% Diclofenac Sodium | 573.6 | 566.9 | 558.8 |
| 1% Diclofenac Sodium+3% Menthol | 573.9 | 566.2 | 558.3 |
| 3% Menthol | 577.1 | 567.0 | 558.4 |
| Placebo | 576.1 | 565.4 | 557.0 |
Pain Intensity Difference (PID) on Movement
"PID on movement, calculated as PI at a given time 't' (after walking 5 steps on a flat surface) subtracted by the PI at baseline.~Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain). PI was measured at baseline (prior to treatment) and at 10, 30 minutes (min.) and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing." (NCT02100670)
Timeframe: Baseline to 10 days
| Intervention | score on scale (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PI at Baseline (n=117, 112, 77, 75) | PID at 10 min. (n=117, 112, 77, 75) | PID at 30 min. (n=117, 112, 77, 75) | PID at 1 hour (n=117, 112, 77, 75) | PID at 4 hour (n=117, 112, 77, 75) | PID at 6 hour (n=117, 112, 77, 75) | PID at 12 hour (n= 117, 112, 77, 75) | PID at 18 hour (n=117, 112, 77, 75) | PID at 24 hour (n=117, 112, 77, 75) | PID at 36 hour (n=117, 112, 77, 75) | PID at 48 hour (n=117, 112, 77, 75) | PID at 60 hour (n=117, 112, 77, 75) | PID at 72 hour (n=117, 112, 77, 75) | PID at 84 hour (n=113, 107, 75, 75) | PID at 96 hour (n=112, 107, 75, 74) | PID at 108 hour (n=112, 107, 75, 74) | PID at 120 hour (n=111, 107, 74, 74) | PID at 132 hour (n=110, 107, 74, 74) | PID at 144 hour (n=110, 107, 74, 74) | PID at 156 hour (n=109, 107, 74, 74) | PID at 168 hour (n=105, 104, 73, 74) | PID at 180 hour (n=105, 104, 73, 72) | PID at 192 hour (n=101, 102, 71, 72) | PID at 204 hour (n=101, 100, 71, 72) | PID at 216 hour (n=95, 100, 69, 72) | PID at 228 hour (n=95, 100, 69, 72) | PID at 240 hour (n=32, 43, 22, 42) | |
| 1% Diclofenac Sodium | 7.4 | 0.19 | 0.36 | 0.50 | 0.48 | 0.67 | 0.99 | 1.32 | 1.58 | 1.65 | 2.01 | 2.26 | 2.42 | 2.68 | 2.78 | 3.01 | 3.17 | 3.53 | 3.78 | 4.05 | 4.11 | 4.45 | 4.59 | 4.94 | 5.21 | 5.62 | 5.44 |
| 1% Diclofenac Sodium+3% Menthol | 7.8 | 0.23 | 0.44 | 0.56 | 0.71 | 0.79 | 0.84 | 1.19 | 1.62 | 1.59 | 1.91 | 2.41 | 2.55 | 2.84 | 3.10 | 3.34 | 3.38 | 3.70 | 3.76 | 4.17 | 4.26 | 4.58 | 4.55 | 5.17 | 5.28 | 5.71 | 5.56 |
| 3% Menthol | 7.8 | 0.29 | 0.49 | 0.64 | 0.79 | 0.91 | 1.17 | 1.44 | 1.75 | 1.55 | 2.04 | 2.56 | 2.55 | 3.08 | 3.03 | 3.48 | 3.35 | 3.72 | 3.68 | 3.95 | 3.90 | 4.37 | 4.21 | 4.87 | 4.87 | 5.28 | 5.41 |
| Placebo | 7.7 | 0.32 | 0.55 | 0.64 | 0.69 | 0.87 | 0.95 | 1.16 | 1.53 | 1.32 | 1.92 | 2.05 | 2.28 | 2.68 | 2.78 | 3.18 | 3.14 | 3.47 | 3.59 | 3.88 | 3.95 | 4.08 | 4.22 | 4.56 | 4.78 | 5.01 | 5.60 |
Pain Relief Score (PRS)
Pain relief was measured at each time point using a 5-point Pain Relief Scale ranging from 0-4 while at rest (Where: 0- No pain relief; 1- A little or perceptible pain relief; 2- Meaningful pain relief; 3- A lot of relief; 4- Complete relief). Participants assessed the degree of ankle pain relief using the PRS scores at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after the first day of treatment. (NCT02100670)
Timeframe: Day 1 to Day 7
| Intervention | score on a scale (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 10 min. (n= 117, 111, 77, 74) | At 30 min. (n=117, 111, 77, 75) | At 1 hour (n=116, 112, 77, 75) | At 4 hour (n= 115, 110, 74, 71) | At 6 hour (n= 109, 105, 70, 69) | At 12 hour (n= 77, 89, 53, 58) | At 18 hour (n= 76, 78, 53, 57) | At 24 hour (n= 111, 105, 72, 72) | At 36 hour (n= 116, 112, 77, 74) | At 48 hour (n= 116, 112, 77, 75) | At 60 hour (n=115, 111, 77, 75) | At 72 hour (n= 114, 109, 75, 74) | At 84 hour (n= 113, 106, 75, 75) | At 96 hour (n= 112, 106, 75, 74) | At 108 hour (n= 111, 105, 75, 74) | At 120 hour (n= 111, 107, 74, 72) | At 132 hour (n= 110, 107, 73, 74) | At 144 hour (n= 110, 107, 74, 73) | At 156 hour (n= 109, 106, 74, 74) | At 168 hour (n= 105, 103, 73, 73) | |
| 1% Diclofenac Sodium | 0.29 | 0.36 | 0.46 | 0.45 | 0.54 | 0.72 | 0.73 | 0.74 | 0.84 | 0.84 | 1.00 | 1.06 | 1.00 | 1.03 | 1.13 | 1.14 | 1.24 | 1.21 | 1.30 | 1.31 |
| 1% Diclofenac Sodium+3% Menthol | 0.33 | 0.44 | 0.48 | 0.47 | 0.50 | 0.60 | 0.71 | 0.79 | 0.84 | 0.90 | 1.07 | 0.93 | 1.07 | 1.09 | 1.18 | 1.11 | 1.34 | 1.21 | 1.41 | 1.41 |
| 3% Menthol | 0.32 | 0.49 | 0.57 | 0.51 | 0.63 | 0.74 | 0.83 | 0.90 | 0.88 | 0.99 | 1.16 | 1.16 | 1.25 | 1.01 | 1.28 | 1.24 | 1.34 | 1.30 | 1.47 | 1.34 |
| Placebo | 0.36 | 0.44 | 0.40 | 0.49 | 0.45 | 0.62 | 0.70 | 0.81 | 0.78 | 0.99 | 0.96 | 0.97 | 1.11 | 1.09 | 1.15 | 1.10 | 1.30 | 1.27 | 1.32 | 1.40 |
Patient's Global Assessment in Response to Treatment (PGART)
PGART was measured at the end of study in a scale from 0-4 (Where: 0- Poor; 1- Fair; 2- Good; 3- Very Good; 4- Excellent) (NCT02100670)
Timeframe: up to Day 10
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Poor=0 | Fair=1 | Good=2 | Very Good=3 | Excellent=4 | |
| 1% Diclofenac Sodium | 13 | 20 | 46 | 26 | 6 |
| 1% Diclofenac Sodium+3% Menthol | 3 | 24 | 44 | 35 | 9 |
| 3% Menthol | 6 | 12 | 26 | 26 | 5 |
| Placebo | 9 | 14 | 27 | 21 | 4 |
PID at Rest
"PID at rest was calculated as PI at a given time point't' (at rest) subtracted by the PI at baseline. Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain).~PI was measured at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing." (NCT02100670)
Timeframe: Baseline to 10 days
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PI at Baseline (n=117, 112, 77, 75) | PID at 10 min. (n=117, 112, 77, 75) | PID at 30 min. (n=117, 112, 77, 75) | PID at 1 hour (n=117, 112, 77, 75) | PID at 4 hour (n=117, 112, 77, 75) | PID at 6 hour (n= 117, 112, 77, 75) | PID at 12 hour (n= 117, 112, 77, 75) | PID at 18 hour (n= 117, 112, 77, 75) | PID at 24 hour (n= 117, 112, 77, 75) | PID at 36 hour (n= 117, 112, 77, 75) | PID at 48 hour (n=117, 112, 77, 75) | PID at 60 hour (n= 117, 112, 77, 75) | PID at 72 hour (n= 117, 112, 77, 75) | PID at 84 hour (n= 113, 107, 75, 75) | PID at 96 hour (n= 112, 107, 75, 74) | PID at 108 hour (n=112, 107, 75, 74) | PID at 120 hour (n= 111, 107, 74, 74) | PID at 132 hour (n= 110, 107, 74, 74) | PID at 144 hour (n= 110, 107, 74, 74) | PID at 156 hour (n= 109, 107, 74, 74) | PID at 168 hour (n= 105, 104, 73, 74) | PID at 180 hour (n= 105, 104, 73, 72) | PID at 192 hour (n= 101, 102, 71, 72) | PID at 204 hour (n= 101, 100, 71, 72) | PID at 216 hour (n= 95, 100, 69, 72) | PID at 228 hour (n= 95, 100, 69, 72) | PID at 240 hour (n= 32, 43, 22, 42) | |
| 1% Diclofenac Sodium | 7.4 | 0.43 | 0.45 | 0.62 | 0.53 | 0.62 | 0.86 | 1.14 | 1.39 | 1.32 | 1.53 | 1.83 | 1.91 | 2.19 | 2.17 | 2.43 | 2.48 | 2.78 | 2.77 | 3.11 | 3.15 | 3.38 | 3.30 | 3.61 | 3.87 | 4.02 | 4.23 |
| 1% Diclofenac Sodium+3% Menthol | 7.8 | 0.34 | 0.56 | 0.64 | 0.62 | 0.68 | 0.76 | 1.03 | 1.32 | 1.20 | 1.43 | 1.91 | 1.91 | 2.11 | 2.26 | 2.46 | 2.59 | 2.76 | 2.77 | 3.06 | 3.08 | 3.37 | 3.38 | 3.67 | 3.77 | 4.09 | 3.94 |
| 3% Menthol | 7.8 | 0.17 | 0.32 | 0.48 | 0.66 | 0.75 | 0.90 | 1.10 | 1.47 | 1.22 | 1.51 | 1.88 | 1.86 | 2.19 | 2.23 | 2.48 | 2.30 | 2.68 | 2.59 | 2.77 | 2.75 | 2.95 | 2.90 | 3.37 | 3.22 | 3.64 | 3.36 |
| Placebo | 7.7 | 0.25 | 0.44 | 0.41 | 0.43 | 0.53 | 0.68 | 0.85 | 1.13 | 1.09 | 1.45 | 1.64 | 1.76 | 2.03 | 2.00 | 2.27 | 2.09 | 2.49 | 2.49 | 2.65 | 2.64 | 2.88 | 3.00 | 3.21 | 3.26 | 3.53 | 3.67 |
Skin Temperature
Skin temperature was measured by thermal imaging. (NCT02100670)
Timeframe: At 10, 30, 60 minutes, 4 and 6 hours
| Intervention | degree celsius (°C) (Mean) | ||||
|---|---|---|---|---|---|
| At 10 min. | At 30 min. | At 60 min. | At 240 min. | At 360 min. | |
| 1% Diclofenac Sodium | 29.31 | 29.81 | 30.74 | 31.26 | 31.53 |
| 1% Diclofenac Sodium+3% Menthol | 27.69 | 28.26 | 28.64 | 30.52 | 31.02 |
| 3% Menthol | 29.92 | 30.50 | 30.22 | 31.15 | 31.27 |
| Placebo | 30.93 | 31.47 | 31.78 | 31.57 | 32.07 |
Sum of Pain Intensity Difference (SPID)
SPID was calculated as the time weighted sum of pain intensity differences (PID) from 0 to 7 Days. PID was calculated as PI at a given time point 't' subtracted by the PI at baseline. PI was measured on NRS scale from 0 (no pain) to 10 (extreme pain). The possible range of SPID for 0-6 hours was from -60 to 60, for 0-12 hours was from -120 to 120, for 0-1 day was from -240 to 240, for 0-3 days was from -720 to 720, for 0-7 days was from -1680 to 1680. A higher value of SPID indicates greater pain relief. (NCT02100670)
Timeframe: Baseline to Day 7
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| At 0-6 hours | At 0-12 hours | At 0-1 days | At 1 to 3 days | At 0 to 7 days | |
| 1% Diclofenac Sodium | 3.19 | 9.13 | 26.54 | 100.07 | 452.44 |
| 1% Diclofenac Sodium+3% Menthol | 4.16 | 9.19 | 26.01 | 101.54 | 451.12 |
| 3% Menthol | 4.72 | 11.74 | 30.91 | 104.26 | 464.96 |
| Placebo | 4.37 | 10.05 | 26.21 | 90.88 | 438.45 |
Total Pain Relief (TOTPAR)
TOTPAR was calculated as sum of the products of PRS with time interval from one time point to the other. PRS was measured at each time point on a scale: 0= No pain relief, 1= A little or perceptible pain relief, 2= Meaningful pain relief, 3= A lot of relief, 4= Complete relief. The possible range of TOTPAR for 0-6 hours was from 0 to 24, for 0-12 hours was from 0 to 48, for 0-24 hours was from 0 to 96, for 0-72 hours was from 0 to 288, for 24-72 hours was from 0 to 192 and for 0-168 hours was from 0 to 672. (NCT02100670)
Timeframe: Baseline to 168 hours
| Intervention | PRS Score (0 - 4 scale) (Mean) | |||||
|---|---|---|---|---|---|---|
| 0-6 hours | 0-12 hours | 0- 24 hours | 0-72 hours | 24-72 hours | 0-168 hours | |
| 1% Diclofenac Sodium | 2.64 | 6.81 | 16.14 | 61.24 | 45.11 | 170.73 |
| 1% Diclofenac Sodium+3% Menthol | 2.81 | 6.86 | 16.04 | 60.14 | 44.10 | 172.97 |
| 3% Menthol | 3.27 | 8.02 | 18.85 | 66.69 | 47.84 | 184.17 |
| Placebo | 2.75 | 6.35 | 15.71 | 58.75 | 43.04 | 174.00 |
Number of Participants Who Discontinued Due to Lack of Efficacy
Number of participants who discontinued due to lack of efficacy were reported. (NCT00864097)
Timeframe: Baseline up to end of study (Week 32)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Diclofenac | 9 |
| Tanezumab 2.5 mg + Diclofenac | 3 |
| Tanezumab 5 mg + Diclofenac | 7 |
| Tanezumab 10 mg + Diclofenac | 2 |
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12 and 24
SF-36v2 was a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and role limitations due to emotional problems, bodily pain, general health, vitality, and mental health. The total score and the score for a section was an average of the individual question scores, which were scaled 0-100. Higher scores reflected better participant status and positive change indicated an improvement. (NCT00864097)
Timeframe: Baseline, Week 12, and 24
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: General Health | Baseline: Physical Function | Baseline: Role Physical | Baseline: Bodily Pain | Baseline: Vitality | Baseline: Social Function | Baseline: Role Emotional | Baseline: Mental Health | Change at Week 12: General Health | Change at Week 12: Physical Function | Change at Week 12: Role Physical | Change at Week 12: Bodily Pain | Change at Week 12: Vitality | Change at Week 12: Social Function | Change at Week 12: Role Emotional | Change at Week 12: Mental Health | Change at Week 24: General Health | Change at Week 24: Physical Function | Change at Week 24: Role Physical | Change at Week 24: Bodily Pain | Change at Week 24: Vitality | Change at Week 24: Social Function | Change at Week 24: Role Emotional | Change at Week 24: Mental Health | |
| Placebo + Diclofenac | 46.37 | 33.51 | 46.67 | 32.99 | 49.08 | 61.02 | 68.15 | 62.80 | 4.67 | 7.36 | 7.61 | 8.76 | 3.80 | 5.02 | 1.92 | 3.13 | 2.41 | 6.21 | 5.17 | 9.14 | 1.66 | 4.36 | -0.55 | 1.27 |
| Tanezumab 10 mg + Diclofenac | 49.31 | 36.52 | 47.46 | 35.06 | 51.29 | 66.55 | 69.77 | 65.48 | 4.96 | 9.90 | 8.49 | 12.76 | 5.34 | 4.22 | -1.26 | 1.66 | 3.08 | 8.50 | 5.91 | 11.52 | 2.76 | 1.38 | -1.95 | 0.45 |
| Tanezumab 2.5 mg + Diclofenac | 49.41 | 36.22 | 47.44 | 35.66 | 52.22 | 67.63 | 68.96 | 66.57 | 5.29 | 10.96 | 8.81 | 12.51 | 4.23 | 6.25 | 2.24 | 1.55 | 4.51 | 8.78 | 8.41 | 12.54 | 2.43 | 4.09 | 0.69 | 2.06 |
| Tanezumab 5 mg + Diclofenac | 47.00 | 34.70 | 48.50 | 33.95 | 53.00 | 65.83 | 68.44 | 64.63 | 6.55 | 12.83 | 7.71 | 15.18 | 3.79 | 4.17 | 2.17 | 2.20 | 4.94 | 10.50 | 6.96 | 13.27 | 2.58 | 3.67 | -1.33 | 1.63 |
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 12 and 24
SF-36v2: standardized survey evaluating 8 aspects of functional health and wellbeing (physical and social functioning, role limitations due to physical and emotional problems, bodily pain, general health, vitality, mental health). Total score for each aspect were scaled 0-100. Higher scores reflect better participant status and positive change indicated an improvement. For obtaining physical and mental component scores, z-score for each scale=(observed score - mean score for general 1990 United States [US] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score [better functioning])/lower (in case of negative z-score [worse functioning]) participant's value was relative to the mean of the reference population. (NCT00864097)
Timeframe: Baseline, Week 12 and 24
| Intervention | z-score (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Physical Component Score | Baseline: Mental Component Score | Change at Week 12: Physical Component Score | Change at Week 12: Mental Component Score | Change at Week 24: Physical Component Score | Change at Week 24: Mental Component Score | |
| Placebo + Diclofenac | -1.84 | -0.30 | 0.35 | 0.08 | 0.32 | -0.03 |
| Tanezumab 10 mg + Diclofenac | -1.76 | -0.15 | 0.51 | -0.06 | 0.43 | -0.14 |
| Tanezumab 2.5 mg + Diclofenac | -1.76 | -0.11 | 0.50 | 0.01 | 0.45 | -0.03 |
| Tanezumab 5 mg + Diclofenac | -1.80 | -0.17 | 0.56 | -0.03 | 0.50 | -0.10 |
Change From Baseline in Average Pain Score in the Index Knee or Hip at Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24
Participants were asked to assess index joint (knee/hip) pain during the past 24 hours on an 0-10 point integer scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline score was calculated as the mean of the scores in the index joint over the 3 days days in the initial pain assessment period and a weekly mean was calculated using the daily pain scores in the index joint within each study week. The change from Baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score, where negative change indicated an improvement. (NCT00864097)
Timeframe: Baseline, Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 1 | Change at Week 2 | Change at Week 3 | Change at Week 4 | Change at Week 6 | Change at Week 8 | Change at Week 10 | Change at Week 12 | Change at Week 16 | Change at Week 20 | Change at Week 24 | |
| Placebo + Diclofenac | 6.31 | -0.55 | -0.95 | -1.19 | -1.28 | -1.38 | -1.41 | -1.41 | -1.49 | -1.53 | -1.61 | -1.65 |
| Tanezumab 10 mg + Diclofenac | 6.34 | -0.96 | -1.03 | -1.08 | -1.44 | -1.69 | -1.80 | -2.06 | -2.06 | -2.15 | -2.15 | -2.03 |
| Tanezumab 2.5 mg + Diclofenac | 6.29 | -0.74 | -0.91 | -1.19 | -1.45 | -1.57 | -1.62 | -1.79 | -1.91 | -1.87 | -1.95 | -1.84 |
| Tanezumab 5 mg + Diclofenac | 6.38 | -1.22 | -1.28 | -1.40 | -1.77 | -1.88 | -1.84 | -2.09 | -2.06 | -2.07 | -2.19 | -2.07 |
Change From Baseline in European Quality of Life - 5 Dimension (EQ-5D) Index Score at Week 24
EQ-5D was a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme dysfunction) and a single index value characterizing current health status using a visual analog scale with score ranging from 0 (worst) to 100 (best). EQ-5D summary index was obtained with a formula that weights each level of the dimensions. The index-based score was interpreted along a continuum of 0 (death) to 1 (perfect health). Negative change from baseline represented worsening. (NCT00864097)
Timeframe: Baseline, Week 24
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline: Index Score | Change at Week 24: Index Score | |
| Placebo + Diclofenac | 0.45 | 0.11 |
| Tanezumab 10 mg + Diclofenac | 0.47 | 0.16 |
| Tanezumab 2.5 mg + Diclofenac | 0.48 | 0.15 |
| Tanezumab 5 mg + Diclofenac | 0.47 | 0.14 |
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis Score at Week 16
"Participants answered: Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today? Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition." (NCT00864097)
Timeframe: Baseline, Week 16
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 16 | |
| Placebo + Diclofenac | 3.39 | -0.41 |
| Tanezumab 10 mg + Diclofenac | 3.37 | -0.63 |
| Tanezumab 2.5 mg + Diclofenac | 3.28 | -0.49 |
| Tanezumab 5 mg + Diclofenac | 3.43 | -0.61 |
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis Score at Weeks 2, 4, 8, 12, and 24
"Participants answered: Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today? Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition." (NCT00864097)
Timeframe: Baseline, Weeks 2, 4, 8, 12, and 24
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 24 | |
| Placebo + Diclofenac | -0.36 | -0.40 | -0.37 | -0.45 | -0.45 |
| Tanezumab 10 mg + Diclofenac | -0.28 | -0.54 | -0.66 | -0.61 | -0.57 |
| Tanezumab 2.5 mg + Diclofenac | -0.37 | -0.45 | -0.44 | -0.52 | -0.46 |
| Tanezumab 5 mg + Diclofenac | -0.40 | -0.65 | -0.71 | -0.69 | -0.57 |
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24
WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. (NCT00864097)
Timeframe: Baseline, Weeks 2, 4, 8, 12, and 24
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 24 | |
| Placebo + Diclofenac | -1.30 | -1.51 | -1.63 | -1.81 | -1.81 |
| Tanezumab 10 mg + Diclofenac | -0.86 | -1.93 | -2.34 | -2.42 | -2.19 |
| Tanezumab 2.5 mg + Diclofenac | -1.22 | -1.76 | -1.88 | -2.23 | -2.11 |
| Tanezumab 5 mg + Diclofenac | -1.21 | -2.12 | -2.22 | -2.50 | -2.24 |
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, and 24
WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living. (NCT00864097)
Timeframe: Baseline, Weeks 2, 4, 8, 12, and 24
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 24 | |
| Placebo + Diclofenac | -1.31 | -1.46 | -1.59 | -1.75 | -1.70 |
| Tanezumab 10 mg + Diclofenac | -1.06 | -1.81 | -2.13 | -2.28 | -2.08 |
| Tanezumab 2.5 mg + Diclofenac | -1.18 | -1.58 | -1.76 | -2.13 | -1.99 |
| Tanezumab 5 mg + Diclofenac | -1.30 | -2.09 | -2.22 | -2.43 | -2.17 |
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, and 24
WOMAC Index: self-administered, disease-specific 24 item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items), and physical function (17 items) in participants with osteoarthritis of the hip and/or knee. WOMAC average score is the mean of the WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, with higher score indicating worse response. Greater reduction in WOMAC average score indicated greater improvement. (NCT00864097)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, and 24
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 24 | |
| Placebo + Diclofenac | 6.05 | -1.31 | -1.45 | -1.59 | -1.74 | -1.80 | -1.74 |
| Tanezumab 10 mg + Diclofenac | 5.80 | -1.06 | -1.92 | -2.27 | -2.42 | -2.43 | -2.17 |
| Tanezumab 2.5 mg + Diclofenac | 5.75 | -1.23 | -1.68 | -1.83 | -2.24 | -2.19 | -2.05 |
| Tanezumab 5 mg + Diclofenac | 5.72 | -1.30 | -2.14 | -2.21 | -2.45 | -2.22 | -2.16 |
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Downstairs at Weeks 2, 4, 8, 12, 16, and 24
"Participants answered the question: How much pain have you had when going up or down the stairs? Participants responded by using an 11-point scale, where 0 = no pain and 10 = extreme pain. Where 0 is the best response and negative change indicated an improvement." (NCT00864097)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, and 24
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 24 | |
| Placebo + Diclofenac | 7.24 | -1.38 | -1.58 | -1.78 | -2.03 | -2.00 | -1.95 |
| Tanezumab 10 mg + Diclofenac | 7.06 | -1.21 | -2.10 | -2.64 | -2.77 | -2.79 | -2.56 |
| Tanezumab 2.5 mg + Diclofenac | 7.04 | -1.49 | -2.10 | -2.15 | -2.54 | -2.54 | -2.44 |
| Tanezumab 5 mg + Diclofenac | 7.05 | -1.55 | -2.39 | -2.51 | -2.86 | -2.53 | -2.53 |
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, and 24
"Participants answered the question: How much pain have you had when walking on a flat surface? Participants responded by using an 11-point scale where 0 = no pain and 10 = extreme pain. Where 0 is the best response and negative change indicated an improvement." (NCT00864097)
Timeframe: Baseline, Week 2, 4, 8, 12, 16, 24
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 24 | |
| Placebo + Diclofenac | 6.12 | -1.34 | -1.47 | -1.62 | -1.83 | -1.95 | -1.84 |
| Tanezumab 10 mg + Diclofenac | 5.99 | -0.89 | -1.87 | -2.25 | -2.41 | -2.34 | -2.10 |
| Tanezumab 2.5 mg + Diclofenac | 5.91 | -1.23 | -1.75 | -1.81 | -2.15 | -2.14 | -2.08 |
| Tanezumab 5 mg + Diclofenac | 5.81 | -1.07 | -2.01 | -2.05 | -2.35 | -2.09 | -2.09 |
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16
WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. (NCT00864097)
Timeframe: Baseline, Week 16
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 16 | |
| Placebo + Diclofenac | 6.06 | -1.91 |
| Tanezumab 10 mg + Diclofenac | 5.87 | -2.42 |
| Tanezumab 2.5 mg + Diclofenac | 5.78 | -2.18 |
| Tanezumab 5 mg + Diclofenac | 5.76 | -2.28 |
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16
WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living. (NCT00864097)
Timeframe: Baseline, Week 16
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Change at Week 16 | |
| Placebo + Diclofenac | 6.24 | -1.76 |
| Tanezumab 10 mg + Diclofenac | 5.91 | -2.35 |
| Tanezumab 2.5 mg + Diclofenac | 5.86 | -2.11 |
| Tanezumab 5 mg + Diclofenac | 5.90 | -2.23 |
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, and 24
WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of (no stiffness) to 10 (extreme stiffness), with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is (no stiffness) to 10 (extreme stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee/hip. Negative change indicated an improvement. (NCT00864097)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, and 24
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | Change at Week 16 | Change at Week 24 | |
| Placebo + Diclofenac | 5.84 | -1.31 | -1.37 | -1.56 | -1.66 | -1.72 | -1.70 |
| Tanezumab 10 mg + Diclofenac | 5.60 | -1.27 | -2.01 | -2.34 | -2.55 | -2.53 | -2.22 |
| Tanezumab 2.5 mg + Diclofenac | 5.61 | -1.29 | -1.71 | -1.86 | -2.36 | -2.27 | -2.06 |
| Tanezumab 5 mg + Diclofenac | 5.51 | -1.38 | -2.21 | -2.20 | -2.42 | -2.15 | -2.08 |
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 112 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial. (NCT00864097)
Timeframe: Baseline up to 112 days after last intravenous dose (up to Week 32)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| Placebo + Diclofenac | 53 | 8 |
| Tanezumab 10 mg + Diclofenac | 72 | 10 |
| Tanezumab 2.5 mg + Diclofenac | 71 | 12 |
| Tanezumab 5 mg + Diclofenac | 73 | 8 |
Number of Participants With Change From Baseline in European Quality of Life - 5 Dimension (EQ-5D) Individual Health State Profile at Week 24
"EQ-5D was a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme dysfunction) and a single index value characterizing current health status using a visual analog scale with score ranging from 0 (worst) to 100 (best). Baseline EQ-5D individual health state profile was determined as number of participants no dysfunction, moderate or some dysfunction and extreme dysfunction and change from baseline in EQ-5D individual health state profile was determined as number of participants improved, no change or worsened." (NCT00864097)
Timeframe: Baseline, Week 24
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Mobility-No Dysfunction | Baseline: Mobility-Moderate Dysfunction | Baseline: Mobility-Extreme Dysfunction | Baseline: Self Care-No Dysfunction | Baseline: Self Care-Moderate Dysfunction | Baseline: Self Care-Extreme Dysfunction | Baseline: Usual Activities-No Dysfunction | Baseline: Usual Activities-Moderate Dysfunction | Baseline: Usual Activities-Extreme Dysfunction | Baseline: Pain/Discomfort-No Dysfunction | Baseline: Pain/Discomfort-Moderate Dysfunction | Baseline: Pain/Discomfort-Extreme Dysfunction | Baseline: Anxiety/Depression-No Dysfunction | Baseline: Anxiety/Depression-Moderate Dysfunction | Baseline: Anxiety/Depression-Extreme Dysfunction | Change at Week 24: Mobility-Improved | Change at Week 24: Mobility-No Change | Change at Week 24: Mobility-Worsened | Change at Week 24: Self Care-Improved | Change at Week 24: Self Care-No Change | Change at Week 24: Self Care-Worsened | Change at Week 24: Usual Activities-Improved | Change at Week 24: Usual Activities-No Change | Change at Week 24: Usual Activities-Worsened | Change at Week 24: Pain/Discomfort-Improved | Change at Week 24: Pain/Discomfort-No Change | Change at Week 24: Pain/Discomfort-Worsened | Change at Week 24: Anxiety/Depression-Improved | Change at Week 24: Anxiety/Depression-No Change | Change at Week 24: Anxiety/Depression-Worsened | |
| Placebo + Diclofenac | 8 | 143 | 1 | 65 | 87 | 0 | 25 | 116 | 11 | 0 | 114 | 38 | 74 | 72 | 6 | 21 | 127 | 4 | 19 | 118 | 15 | 16 | 125 | 11 | 28 | 116 | 8 | 27 | 106 | 19 |
| Tanezumab 10 mg + Diclofenac | 10 | 135 | 0 | 52 | 92 | 1 | 18 | 123 | 4 | 1 | 111 | 33 | 73 | 66 | 6 | 25 | 120 | 0 | 30 | 104 | 11 | 27 | 111 | 7 | 33 | 105 | 7 | 19 | 107 | 19 |
| Tanezumab 2.5 mg + Diclofenac | 7 | 148 | 1 | 61 | 92 | 3 | 13 | 141 | 2 | 0 | 125 | 31 | 82 | 72 | 2 | 25 | 129 | 2 | 33 | 112 | 11 | 27 | 125 | 4 | 29 | 125 | 2 | 26 | 111 | 19 |
| Tanezumab 5 mg + Diclofenac | 14 | 136 | 0 | 53 | 96 | 1 | 20 | 126 | 4 | 2 | 115 | 33 | 70 | 75 | 5 | 30 | 114 | 6 | 32 | 110 | 8 | 31 | 106 | 13 | 34 | 109 | 7 | 28 | 109 | 13 |
Number of Participants With Intravenous Doses of Study Medication
Number of participants were reported based on the maximum number of intravenous (IV) doses of either tanezumab or placebo received. (NCT00864097)
Timeframe: Day 1 up to Week 16
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Number of IV Doses: 1 | Number of IV Doses: 2 | Number of IV Doses: 3 | |
| Placebo + Diclofenac | 14 | 38 | 100 |
| Tanezumab 10 mg + Diclofenac | 13 | 31 | 101 |
| Tanezumab 2.5 mg + Diclofenac | 9 | 34 | 114 |
| Tanezumab 5 mg + Diclofenac | 15 | 26 | 109 |
Percentage of Participants With At Least 30%, 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score; LOCF
WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Greater percentage reduction indicates greater improvement. Percentage of participants with reduction in WOMAC pain intensity of at least (>=) 30%, 50%, 70% and 90% at Weeks 2, 4, 8, 12, 16, 24 and 32 compared to baseline were classified as responders to WOMAC pain subscale and are reported here. (NCT00864097)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, and 24
| Intervention | percentage of participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2: At least 30% reduction | Week 2: At least 50% reduction | Week 2: At least 70% reduction | Week 2: At least 90% reduction | Week 4: At least 30% reduction | Week 4: At least 50% reduction | Week 4: At least 70% reduction | Week 4: At least 90% reduction | Week 8: At least 30% reduction | Week 8: At least 50% reduction | Week 8: At least 70% reduction | Week 8: At least 90% reduction | Week 12: At least 30% reduction | Week 12: At least 50% reduction | Week 12: At least 70% reduction | Week 12: At least 90% reduction | Week 16: At least 30% reduction | Week 16: At least 50% reduction | Week 16: At least 70% reduction | Week 16: At least 90% reduction | Week 24: At least 30% reduction | Week 24: At least 50% reduction | Week 24: At least 70% reduction | Week 24: At least 90% reduction | |
| Placebo + Diclofenac | 30.3 | 13.8 | 4.6 | 2.0 | 42.1 | 17.1 | 5.9 | 2.0 | 43.4 | 25.0 | 3.9 | 2.0 | 48.7 | 27.0 | 7.2 | 2.0 | 50.0 | 30.9 | 13.2 | 2.0 | 48.0 | 28.3 | 12.5 | 3.9 |
| Tanezumab 10 mg + Diclofenac | 24.1 | 9.0 | 2.8 | 0.7 | 50.3 | 30.3 | 11.7 | 2.1 | 63.4 | 38.6 | 19.3 | 6.2 | 63.4 | 42.8 | 24.8 | 4.8 | 66.2 | 49.0 | 19.3 | 6.9 | 59.3 | 42.1 | 21.4 | 8.3 |
| Tanezumab 2.5 mg + Diclofenac | 28.8 | 16.0 | 6.4 | 1.3 | 51.9 | 26.9 | 10.3 | 1.9 | 51.9 | 27.6 | 9.6 | 5.1 | 57.1 | 36.5 | 16.7 | 6.4 | 54.5 | 35.9 | 17.3 | 5.8 | 58.3 | 38.5 | 18.6 | 8.3 |
| Tanezumab 5 mg + Diclofenac | 32.0 | 16.7 | 7.3 | 1.3 | 57.3 | 34.0 | 12.7 | 6.0 | 57.3 | 38.0 | 17.3 | 4.7 | 64.0 | 46.7 | 24.0 | 8.7 | 61.3 | 40.0 | 20.0 | 6.7 | 59.3 | 40.0 | 22.7 | 8.0 |
Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 and 24
WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Greater percentage reduction indicates greater improvement. Percentage of participants with cumulative reduction (as percent) (greater than 0%; >= 10, 20, 30, 40, 50, 60, 70, 80 and 90%; = 100 %) in WOMAC pain subscale from Baseline to Weeks 16 and 24 were reported. (NCT00864097)
Timeframe: Baseline, Week 16 and 24
| Intervention | percentage of participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 16: Greater than 0% reduction | Week 16: >=10% reduction | Week 16: >=20% reduction | Week 16: >=30% reduction | Week 16: >=40% reduction | Week 16: >=50% reduction | Week 16: >=60% reduction | Week 16: >=70% reduction | Week 16: >=80% reduction | Week 16: >=90% reduction | Week 16: 100% reduction | Week 24: Greater than 0% reduction | Week 24: >=10% reduction | Week 24: >=20% reduction | Week 24: >=30% reduction | Week 24: >=40% reduction | Week 24: >=50% reduction | Week 24: >=60% reduction | Week 24: >=70% reduction | Week 24: >=80% reduction | Week 24: >=90% reduction | Week 24: 100% reduction | |
| Placebo + Diclofenac | 84.2 | 73.7 | 61.8 | 50.0 | 38.8 | 30.9 | 21.7 | 13.2 | 5.9 | 2.0 | 0.7 | 81.6 | 72.4 | 60.5 | 48.0 | 35.5 | 28.3 | 20.4 | 12.5 | 6.6 | 3.9 | 0.7 |
| Tanezumab 10 mg + Diclofenac | 84.1 | 77.9 | 75.2 | 66.2 | 60.7 | 49.0 | 31.7 | 19.3 | 13.8 | 6.9 | 2.8 | 84.8 | 75.2 | 69.7 | 59.3 | 51.0 | 42.1 | 31.7 | 21.4 | 13.8 | 8.3 | 2.8 |
| Tanezumab 2.5 mg + Diclofenac | 88.5 | 82.7 | 69.9 | 54.5 | 48.7 | 35.9 | 26.3 | 17.3 | 9.0 | 5.8 | 2.6 | 82.7 | 76.9 | 67.3 | 58.3 | 47.4 | 38.5 | 26.3 | 18.6 | 11.5 | 8.3 | 3.8 |
| Tanezumab 5 mg + Diclofenac | 88.7 | 76.7 | 68.7 | 61.3 | 50.7 | 40.0 | 28.7 | 20.0 | 10.7 | 6.7 | 2.0 | 82.0 | 74.7 | 65.3 | 59.3 | 47.3 | 40.0 | 34.0 | 22.7 | 14.7 | 8.0 | 3.3 |
Percentage of Participants With Improvement of at Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis; Baseline Observation Carried Forward (BOCF)
"Participants answered: Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today? Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition. A decrease of at least 2 points on the 5-point scale relative to baseline value indicates improvement." (NCT00864097)
Timeframe: Weeks 2, 4, 8, 12, 16, and 24
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | |
| Placebo + Diclofenac | 5.9 | 6.6 | 5.3 | 6.6 | 4.6 | 5.3 |
| Tanezumab 10 mg + Diclofenac | 5.5 | 11.7 | 13.8 | 10.3 | 14.5 | 9.7 |
| Tanezumab 2.5 mg + Diclofenac | 5.8 | 3.2 | 6.4 | 6.4 | 5.8 | 4.5 |
| Tanezumab 5 mg + Diclofenac | 4.7 | 14.7 | 17.3 | 13.3 | 14.0 | 10.0 |
Percentage of Participants With Improvement of at Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis; LOCF
"Participants answered: Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today? Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition. A decrease of at least 2 points on the 5-point scale relative to baseline value indicated improvement." (NCT00864097)
Timeframe: Weeks 2, 4, 8, 12, 16, and 24
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | |
| Placebo + Diclofenac | 5.9 | 6.6 | 5.3 | 6.6 | 4.6 | 5.9 |
| Tanezumab 10 mg + Diclofenac | 5.5 | 12.4 | 14.5 | 12.4 | 16.6 | 12.4 |
| Tanezumab 2.5 mg + Diclofenac | 5.8 | 3.2 | 6.4 | 6.4 | 5.8 | 5.8 |
| Tanezumab 5 mg + Diclofenac | 4.7 | 14.7 | 18.0 | 14.0 | 14.7 | 12.7 |
Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response; LOCF
OMERACT-OARSI responder: participant has >=50 percent (%) change and >=2 absolute change from Baseline in either WOMAC pain or physical function subscale scores or at least 2 of the following being true: >=20% change and >=1 absolute change from Baseline in WOMAC pain subscale; >=20% change and >=1 absolute change from Baseline in the WOMAC physical function subscale; >=20% change and >=1 absolute change from Baseline in PGA of osteoarthritis. WOMAC pain and physical function score: 0 to 10 with higher score = worse response. PGA score: 1 = very good and 5 = very poor. (NCT00864097)
Timeframe: Weeks 2, 4, 8, 12, 16, and 24
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | |
| Placebo + Diclofenac | 44.7 | 51.3 | 57.2 | 60.5 | 57.9 | 55.3 |
| Tanezumab 10 mg + Diclofenac | 34.5 | 59.3 | 69.7 | 73.1 | 72.4 | 67.6 |
| Tanezumab 2.5 mg + Diclofenac | 37.2 | 57.1 | 58.3 | 67.3 | 66.7 | 65.4 |
| Tanezumab 5 mg + Diclofenac | 43.3 | 65.3 | 68.0 | 73.3 | 66.7 | 64.7 |
Time to Discontinuation (TTD) Due to Lack of Efficacy
Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method. (NCT00864097)
Timeframe: Baseline up to Week 16 and 24
| Intervention | days (Median) | |
|---|---|---|
| Week 16 | Week 24 | |
| Placebo + Diclofenac | NA | NA |
| Tanezumab 10 mg + Diclofenac | NA | NA |
| Tanezumab 2.5 mg + Diclofenac | NA | NA |
| Tanezumab 5 mg + Diclofenac | NA | NA |
Percent Change From Baseline in Pain Score During Week 1
Participants assessed their knee pain using a visual analog scale (VAS) where 0=no pain and 100=worst possible pain. Pain scores were recorded in an electronic diary prior to and 4 hours after the first daily application of diclofenac gel for breakthrough pain. The daily percent change in pain scores over the 7 days prior to Week 1 were averaged. Percent change from Baseline (average pain score 7 days prior to first treatment) was calculated as (value at baseline - value at post-baseline visit) / (value at baseline) x 100. A positive change from Baseline indicates improvement. (NCT01383954)
Timeframe: Baseline and Week 1
| Intervention | percent change (Mean) |
|---|---|
| Diclofenac Gel | 33.3 |
Percent Change From Baseline in Pain Score During Week 2
Participants assessed their knee pain using a visual analog scale (VAS) where 0=no pain and 100=worst possible pain. Pain scores were recorded in an electronic diary prior to and 4 hours after the first daily application of diclofenac gel for breakthrough pain. The daily percent change in pain scores over the 7 days prior to Week 2 were averaged. Percent change from baseline (average pain score 7 days prior to first treatment) was calculated as (value at baseline - value at post-baseline visit)/ (value at baseline) x 100. A positive change from baseline indicates improvement. (NCT01383954)
Timeframe: Baseline and Week 2
| Intervention | percent change (Mean) |
|---|---|
| Diclofenac Gel | 33.3 |
Pain Scores on Standardized Experimental Pain Testing
Pain scores on standardized experimental pain testing, with collection of Visual analog scales (VAS) on a 0-100 scale 0 (no pain)- 100 (worst pain imaginable) Higher values represent a worse outcome (more pain) (NCT02194088)
Timeframe: baseline and 1 hour pain measurement
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 hour Assessment | |
| Pain Medication: Diclofenac and Atropine | 59.6 | 44.1 |
| Placebo | 54.0 | 45.3 |
Patient Pain Level
Pain level will be measured on a numeric visual analogue scale of 0-10 with 0 being no pain and 10 being the worst pain ever. (NCT02046317)
Timeframe: 60 minutes after initial femoral block
| Intervention | units on a scale (Mean) |
|---|---|
| Echogenic Needle | 1.25 |
| Standard of Care Needle | 3.75 |
Patient Pain Level
Pain level will be measured on a numeric visual analogue scale of 0-10 with 0 being no pain and 10 being the worst pain ever. (NCT02046317)
Timeframe: baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Echogenic Needle | 7.50 |
| Standard of Care Needle | 8.00 |
Flow-Mediated Dilation (FMD)
Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post FMD was taken approximately 110 min after baseline
| Intervention | percentage of change in FMD (Mean) | |
|---|---|---|
| Placebo | AOC Treatment | |
| All Controls | 6.7 | 6.9 |
| All COPD Patients | 3.1 | 4.7 |
Pulse Wave Velocity
A measure of vascular stiffness at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post PWV was taken approximately 90 min after baseline
| Intervention | m/sec (Mean) | |
|---|---|---|
| Placebo | AOC Treatment | |
| All Controls | 11 | 10 |
| All COPD Patients | 14 | 11 |
Number of Participants With a Responder Rate Greater Than 50% on the Numeric Rating Pain Scale (NRS) Improvement
Participants in this study underwent TPIs by the following method. The needle was inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. This was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain, one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Post Injections Up to Three Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac | 1 |
| Lidocaine | 0 |
| Dexamethasone | 0 |
Brief Pain Inventory (BPI) - Modified
The BPI was evaluated on a scale from 0-10. Zero would mean no interference and 10 would be calculated at complete interferences. We used a 7-point questionnaire about pain. All scores were calculated at baseline and three months. (NCT03028012)
Timeframe: Baseline and Three Months
| Intervention | score on a scale (Number) | |||
|---|---|---|---|---|
| Participant Number #3 at Baseline | Participant Number #3 at 3 Months | Participant Number #8 at Baseline | Participant #8 at 3 Months | |
| Ketorolac | 8 | 3 | 5 | 3 |
Numeric Rating Pain Scale (NRS) at Baseline and Three Months.
TPI were treated with a needle inserted into the trigger point with the goal of eliciting a local twitch responses(LTRs). When a LTR was obtained, 0.1mL of randomized drug was injected into that location within the muscle. This was repeated until LTRs disappeared, or 1.0mL had been injected, whichever came first. Such was performed in a similar manner for all affected muscles, up to a maximum of 2mL. Participants self-report their brief pain inventory at each of their injections (up to four subsequent injections) based off of the standardized Numeric Rating pain Scale (NRS). The NRS is nationally recognized numeric scale from zero to ten, with zero being an example of no pain,one to three would demonstrate mild pain, four to six would be moderate pain, seven to nine would be severe pain and a ten would be the worst pain possible. Improvement in BPI was determined if their NRS score went down with each injection(s). (NCT03028012)
Timeframe: Pre-Injection and Three Month Post Injection(s)
| Intervention | score on a scale (Number) | |||
|---|---|---|---|---|
| Participant Number 3 at Baseline | Participant Number 3 at 3 Months | Participant Number 8 at Baseline | Participant Number 8 at 3 Months | |
| Ketorolac | 8 | 3 | 5 | 3 |
Reviews
49 reviews available for diclofenac and Ache
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
Efficacy of ultramicronised diclofenac in patients with osteoarthritis - systematic review with network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Network Meta-Analysis; Osteo | 2021 |
Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis.
Topics: Caffeine; Dexamethasone; Diclofenac; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Pain; Ph | 2022 |
Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features.
Topics: Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Etori | 2022 |
Sterile water injections for management of renal colic pain: a systematic review.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Morphine Derivatives; Pa | 2022 |
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; C | 2022 |
Comparison of different nonsteroidal anti-inflammatory drugs for cesarean section: a systematic review and network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cesarean Section; Diclofenac; Female; Humans; In | 2023 |
Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis.
Topics: Celecoxib; Diclofenac; Humans; Osteoarthritis, Knee; Pain; Treatment Outcome | 2021 |
Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Knee Joint; Osteoarthritis, Knee; Pain | 2021 |
Rationale and evidence for the incorporation of heparin into the diclofenac epolamine medicated plaster.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Heparin; Humans; Inflammation; Osteoarthritis, | 2019 |
Current methods of analgesia for transrectal ultrasonography (TRUS)-guided prostate biopsy -- a systematic review.
Topics: Administration, Rectal; Analgesia; Anesthesia, Local; Anesthetics, Local; Biopsy; Diclofenac; Gels; | 2014 |
[Diclofenac up2date - Part 1: Pharmacology and comparison with other drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Contraindications; Diclofenac; H | 2014 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2015 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2015 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2015 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2015 |
Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adult; Anti-Inflammatory Agents, Non-Steroidal; beta-Cyclodextrin | 2015 |
WITHDRAWN: Diclofenac for acute pain in children.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Diclofenac; Humans; Pain; | 2015 |
Efficacy and Safety Profile of Diclofenac/Cyclodextrin and Progesterone/Cyclodextrin Formulations: A Review of the Literature Data.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; beta-Cyclodextrins; Biological Availability; Cyclodextrins; Diclo | 2016 |
Alpha blockers in the management of ureteric lithiasis: A meta-analysis.
Topics: Adrenergic alpha-Antagonists; Analgesics; Diclofenac; Humans; Pain; Pain Measurement; Time Factors; | 2017 |
Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Bone Diseases; Delayed-Action Prep | 2008 |
Diclofenac epolamine (Flector) patch: evidence for topical activity.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Musculoskeleta | 2009 |
Diclofenac for acute pain in children.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Diclofenac; Humans; Pain; | 2009 |
Diclofenac: an update on its mechanism of action and safety profile.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Models, Biological; Pain; Signal Transd | 2010 |
Evidence-based intravenous pain treatment with analgesic infusion regimens.
Topics: Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Diazepam; Diclofenac; Drug | 2010 |
Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries.
Topics: Acute Disease; Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials a | 2010 |
Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Contusions; Diclofenac; Humans; Pain; Soft Tiss | 2010 |
Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Design; Drug Interactions; Drug S | 2012 |
Evidence-based emergency medicine. Update: do ophthalmic nonsteroidal anti-inflammatory drugs reduce the pain associated with simple corneal abrasion without delaying healing?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Anti-Bacterial Agents; Anti-Inflammatory Age | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2003 |
Aceclofenac in the management of inflammatory pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac | 2004 |
Lumiracoxib (Prexige): a new selective COX-2 inhibitor.
Topics: Acute Disease; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibi | 2004 |
[Assessment of a topical NSAIDs in the treatment of pain and inflammation. The example of Flector Plaster, a local bioadhesive plaster containing diclofenac epolamine].
Topics: Administration, Topical; Animals; Ankle Injuries; Anti-Inflammatory Agents, Non-Steroidal; Athletic | 2004 |
The use of topical diclofenac for pain in osteoarthritis of the knee: a review.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, | 2006 |
Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety.
Topics: Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Fever; Humans; Molecular St | 2007 |
Lumiracoxib in the management of osteoarthritis and acute pain.
Topics: Acute Disease; Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Appro | 2007 |
Pain relief in osteoarthritis and rheumatoid arthritis: TENS.
Topics: Adjuvants, Immunologic; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; C | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito | 2008 |
Topical diclofenac and its role in pain and inflammation: an evidence-based review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Metho | 2008 |
Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin.
Topics: Adult; Animals; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; Diclofenac; Drug Interact | 1980 |
Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Behavior, Animal; Brain; | 1995 |
Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease.
Topics: Acute Disease; Adult; beta-Cyclodextrins; Controlled Clinical Trials as Topic; Cyclodextrins; Diclof | 1993 |
[Singular diaphragm-like colonic stricture and short-term administration of a non-steroidal anti-inflammatory drug].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Colonic Diseases; Col | 1994 |
Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Delay | 1993 |
Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Diclofenac; Humans; Pain | 1996 |
Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action.
Topics: Animals; Carcinoma, Basal Cell; Carotid Stenosis; Diclofenac; Drug Delivery Systems; Humans; Hyaluro | 1995 |
[Pharma-clinics. The drug of the month. Aceclofenac (Biofenac)].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Joint Diseases; Pain | 1999 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage Oligomeric Matrix Protein; Diclofenac; D | 2001 |
[What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cartilage; Chronic Disease; Diclofen | 2001 |
Overall safety of Arthrotec.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Constipation; Diarrhea; | 1992 |
Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Clinical Trials as Topic; Diclofenac; D | 1988 |
Trials
176 trials available for diclofenac and Ache
| Article | Year |
|---|---|
Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Humans; Ketoprofen; | 2021 |
Pain Relief for Hysterosalpingography: A Randomized Controlled, Double Blinded Trial Comparing Suppository Diclofenac, Prilocaine/Lignocaine (EMLA) Cream And Placebo.
Topics: Diclofenac; Female; Humans; Hysterosalpingography; Lidocaine; Pain; Prilocaine; Prospective Studies | 2021 |
Efficacy and safety of S-flurbiprofen plaster in knee osteoarthritis patients: A 2-week randomized controlled Phase III clinical trial compared to diclofenac gel.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Flurbiprofen; Humans; Oste | 2022 |
Diclofenac-hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial.
Topics: Ankle; Diclofenac; Double-Blind Method; Elbow; Humans; Hyaluronic Acid; Injections, Intra-Articular; | 2022 |
Efficacy of Cabbage Leaf versus Cooling Gel Pad or Diclofenac Gel for Patients with Knee Osteoarthritis: A Randomized Open-Labeled Controlled Clinical Trial.
Topics: Aged; Brassica; Diclofenac; Humans; Osteoarthritis, Knee; Pain; Plant Leaves; Quality of Life; Treat | 2022 |
Effect of Adjunctive Acupuncture on Pain Relief Among Emergency Department Patients With Acute Renal Colic Due to Urolithiasis: A Randomized Clinical Trial.
Topics: Acupuncture Therapy; Diclofenac; Emergency Service, Hospital; Humans; Male; Middle Aged; Pain; Renal | 2022 |
Randomized, double-blind, noninferiority study of diclofenac diethylamine 2.32% gel applied twice daily versus diclofenac diethylamine 1.16% gel applied four times daily in patients with acute ankle sprain.
Topics: Ankle Injuries; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Humans; Pa | 2022 |
Dry needling on latent and active myofascial trigger points versus oral diclofenac in patients with knee osteoarthritis: a randomized controlled trial.
Topics: Diclofenac; Dry Needling; Humans; Myofascial Pain Syndromes; Osteoarthritis, Knee; Pain; Trigger Poi | 2023 |
The efficacy of intradermal sterile water application in severe renal colic: a randomised clinical trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Fentanyl; Humans; Injectio | 2023 |
Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Humans; Pai | 2020 |
A novel diclofenac gel (AMZ001) applied once or twice daily in subjects with painful knee osteoarthritis: A randomized, placebo-controlled clinical trial.
Topics: Diclofenac; Humans; Knee Joint; Osteoarthritis, Knee; Pain; Treatment Outcome | 2020 |
Topical diclofenac vs placebo for the treatment of chronic Achilles tendinopathy: A randomized controlled clinical trial.
Topics: Administration, Topical; Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Chron | 2021 |
Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Ankle; Ankle Injuries; Anti-Inflammatory Agents, Non-S | 2017 |
Diclofenac for pain associated with intravitreal injections: a prospective, randomized, placebo-controlled study.
Topics: Administration, Oral; Administration, Topical; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agen | 2017 |
Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.
Topics: Adalimumab; Aged; Antirheumatic Agents; Celecoxib; Diclofenac; Female; Humans; Hyaluronic Acid; Ibup | 2018 |
Comparison of three analgesic drug regimens with twelfth subcostal nerve block for pain control during extracorporeal shock wave lithotripsy.
Topics: Adult; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; | 2018 |
Effect of the Buzzy Application on Pain and Injection Satisfaction in Adult Patients Receiving Intramuscular Injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Fear; Female; H | 2018 |
Comparison of diclofenac gel, ibuprofen gel, and ibuprofen gel with levomenthol for the topical treatment of pain associated with musculoskeletal injuries.
Topics: Administration, Topical; Adolescent; Adult; Aged; Diclofenac; Female; Gels; Humans; Ibuprofen; Male; | 2019 |
Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Drug Therapy, | 2013 |
[Case-control study on stiletto needle and Dichofenac Diethylammon for the treatment of knee osteoarthritis pain].
Topics: Adult; Aged; Biomechanical Phenomena; Case-Control Studies; Diclofenac; Female; Humans; Male; Middle | 2012 |
Sublingual misoprostol prior to insertion of a T380A intrauterine device in women with no previous vaginal delivery.
Topics: Administration, Sublingual; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; | 2013 |
Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Hum | 2014 |
A randomized, double-blind, placebo-controlled multicentre study to evaluate the efficacy and safety of diclofenac 4% spray gel in the treatment of acute uncomplicated ankle sprain.
Topics: Acute Disease; Administration, Topical; Adult; Ankle Injuries; Anti-Inflammatory Agents, Non-Steroid | 2013 |
Comparative study between three analgesic agents for the pain management during extracorporeal shock wave lithotripsy.
Topics: Adult; Analgesia; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; H | 2013 |
[Impact of combined therapy using glucosamine sulfate and anti-inflammatory agent on pain severity in patients with osteoarthritis: prospective, non-controlled postmarketing study].
Topics: Aged; Anti-Inflammatory Agents; Cardiovascular Agents; Diclofenac; Drug Therapy, Combination; Escin; | 2013 |
The 24-h progression of menstrual pain in women with primary dysmenorrhea when given diclofenac potassium: a randomized, double-blinded, placebo-controlled crossover study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Diclofenac; Dose-Response Relati | 2014 |
The effect on pain of three different methods of intramuscular injection: A randomized controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Nursing Research; Diclofenac; F | 2016 |
Dermal scarification versus intramuscular diclofenac sodium injection for the treatment of renal colic: a prospective randomized clinical trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Complementary Therapies; Diclofenac; Female; Humans; | 2014 |
Effect of local infusion of NSAID analgesics administered alone or in combination on the pain associated with band castration in calves.
Topics: Age Factors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Behavior, Animal; C | 2015 |
Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, 4 week study.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; D | 2016 |
Effect of paracetamol, dexketoprofen trometamol, lidocaine spray, pethidine & diclofenac sodium application for pain relief during fractional curettage: A randomized controlled trial.
Topics: Acetaminophen; Adult; Aged; Analgesia; Curettage; Diclofenac; Female; Gynecologic Surgical Procedure | 2015 |
Diclofenac plus lidocaine gel for pain relief during intrauterine device insertion. A randomized, double-blinded, placebo-controlled study.
Topics: Administration, Intravaginal; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Di | 2016 |
Double-blind Randomized Placebo-controlled Clinical Trial of Efficiency of Nonsteroidal Anti-inflammatory Drugs in the Control of Post-endodontic Pain.
Topics: Acetaminophen; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose- | 2016 |
Double-blind Randomized Placebo-controlled Clinical Trial of Efficiency of Nonsteroidal Anti-inflammatory Drugs in the Control of Post-endodontic Pain.
Topics: Acetaminophen; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose- | 2016 |
Double-blind Randomized Placebo-controlled Clinical Trial of Efficiency of Nonsteroidal Anti-inflammatory Drugs in the Control of Post-endodontic Pain.
Topics: Acetaminophen; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose- | 2016 |
Double-blind Randomized Placebo-controlled Clinical Trial of Efficiency of Nonsteroidal Anti-inflammatory Drugs in the Control of Post-endodontic Pain.
Topics: Acetaminophen; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose- | 2016 |
Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; | 2016 |
Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; | 2016 |
Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; | 2016 |
Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; | 2016 |
A comparison of efficacy of doxazosin 4 and 8 mg in medical expulsive therapy of distal ureteral stones: a prospective randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Analgesics; Diclofenac; Dose-Response Relationship, | 2017 |
Side effects can enhance treatment response through expectancy effects: an experimental analgesic randomized controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticipation, Psychological; Atropine; D | 2017 |
Comparison of efficacy between oral morphine sulphate and diclofenac suppository for analgesia during transrectal ultrasound-guided prostate biopsy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Anti-Inflammatory Age | 2008 |
A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
Topics: Acute Disease; Adult; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Dou | 2008 |
Comparison of three analgesic treatment protocols for pain management during extracorporeal shock wave lithotripsy.
Topics: Adult; Analgesia; Anesthetics, Combined; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal | 2009 |
Succinylcholine-induced myalgia in obstetric patients scheduled for caesarean section--diclofenac vs placebo patches.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Diclofe | 2009 |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2010 |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2010 |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2010 |
Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2010 |
'Multimodal' approach to management of prostate biopsy pain and effects on sexual function: efficacy of levobupivacaine adjuvant to diclofenac sodium - a prospective randomized trial.
Topics: Aged; Analgesia; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Biopsy, Needle; Bupiva | 2010 |
Extent and time course of pain intensity upon treatment with a topical diclofenac sodium patch versus placebo in acute traumatic injury based on a validated end point: post hoc analysis of a randomized placebo-controlled trial.
Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
Transrectal ultrasound-guided prostate biopsy, periprostatic local anesthesia and pain tolerance.
Topics: Aged; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Biopsy, Needle; Diclofenac; Human | 2010 |
Comparison of the analgesic effects of dexketoprofen and diclofenac during shockwave lithotripsy: a randomized, double-blind clinical trial.
Topics: Adult; Aged; Analgesics; Diclofenac; Double-Blind Method; Humans; Ketoprofen; Lithotripsy; Male; Mid | 2010 |
Effect on pain of changing the needle prior to administering medicine intramuscularly: a randomized controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Nursing Research; Diclofenac; F | 2011 |
A comparative assessment of the clinical efficacy of intranasal desmopressin spray and diclofenac in the treatment of renal colic.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antidiuretic Agents; Deamino Arginine Vasopress | 2011 |
[Comparative observation on hip osteoarthritis treated with electroacupuncture and medication].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Electroacupunct | 2010 |
Zaltoprofen, a noninferior alternative to diclofenac for the treatment of primary knee osteoarthritis -- a comparative evaluation of efficacy and safety in a 4-week, multicentric, randomized, double-blind, double-dummy trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Benzopyrans; Diclofenac; Double-Blind Method; Drug A | 2011 |
Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non | 2011 |
Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, | 2011 |
[Application of a seven-day buprenorphine transdermal patch in multimorbid patients on long-term ibuprofen or diclofenac].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, No | 2011 |
A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Female | 2011 |
Comparison of ocular tolerability between preserved and preservative-free diclofenac sodium drops.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Male; Middle Aged; Ophth | 2011 |
Treatment of acute, non-traumatic pain using a combination of diclofenac-cholestyramine, uridine triphosphate, cytidine monophosphate, and hydroxycobalamin.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cholestyramine Resin; Cytidine Monoph | 2010 |
Efficacy and safety of diclofenac diethylamine 2.32% gel in acute ankle sprain.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Ankle Injuries; Diclofenac; Dou | 2012 |
Efficacy and tolerability of DHEP-heparin plaster in reducing pain in mild-to-moderate muscle contusions: a double-blind, randomized trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroida | 2012 |
A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Binding Sites; Butanones; Cyclooxygenase Inhibitors; Diclofenac; Drug M | 2013 |
Preliminary study of highly cross-linked hyaluronic acid-based combination therapy for management of knee osteoarthritis-related pain.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Blood Sedimentation; C-Reactive Pro | 2013 |
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Topics: Adult; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Dicl | 2002 |
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cyclo | 2002 |
A comparison of intraoperative celiac plexus block with pharmacological therapy as a treatment for pain of unresectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nerv | 2002 |
A study of co-treatment of nonsteroidal anti-inflammatory drugs (NSAIDs) with misoprostol for cervical priming before suction termination of first trimester pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adolescent; Adult; Anti-Inflammatory Agents, | 2003 |
Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment.
Topics: Administration, Topical; Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; | 2003 |
A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Drug Administration | 2003 |
Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Central Nervous System; Cross-Over | 2003 |
Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Knee | 2003 |
Randomised controlled trial of the onset of analgesic efficacy of dexketoprofen and diclofenac in lower limb injury.
Topics: Acute Disease; Administration, Oral; Adult; Analgesics; Diclofenac; Double-Blind Method; Female; Hum | 2003 |
Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones.
Topics: Administration, Oral; Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagoni | 2003 |
Diclofenac suppository analgesia for transrectal ultrasound guided biopsies of the prostate: a double-blind, randomized controlled trial.
Topics: Aged; Analgesia; Biopsy, Needle; Diclofenac; Double-Blind Method; Humans; Male; Pain; Prospective St | 2004 |
[Using prostaglandin inhibitor dicloberl in patients with ureteral calculi].
Topics: Adult; Aged; Analgesics, Opioid; Diclofenac; Drug Therapy, Combination; Female; Humans; Male; Middle | 2004 |
Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee--a double-blind prospective randomized study.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Bromelains; Diclofenac; Double-Blind | 2004 |
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Health Status; Humans; Mal | 2004 |
Rectal analgesia for the relief of perineal pain after childbirth: a randomised controlled trial of diclofenac suppositories.
Topics: Administration, Rectal; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Doub | 2004 |
Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Are | 2004 |
Lumiracoxib.
Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Doubl | 2004 |
Acupuncture as a complementary therapy to the pharmacological treatment of osteoarthritis of the knee: randomised controlled trial.
Topics: Acupuncture Therapy; Aged; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Diclo | 2004 |
[Ocular tolerance of a new formulation of nonpreserved diclofenac].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Administration Schedule; Dry Eye Sy | 2004 |
[Proof of the pharmacodynamic activity of Flector Plaster in healthy volunteers and patients suffering from osteo-arthritis of the knee].
Topics: Administration, Topical; Adult; Diclofenac; Double-Blind Method; Female; Humans; Knee Joint; Male; O | 2004 |
Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dizziness; Double-Blind Method; Drugs, C | 2004 |
Effect of diclofenac pretreatment on pain during propofol injection.
Topics: Adolescent; Adult; Anesthetics, Intravenous; Chi-Square Distribution; Diclofenac; Dose-Response Rela | 2004 |
The effect on mechanical pain threshold over human muscles by oral administration of granisetron and diclofenac-sodium.
Topics: Administration, Oral; Adult; Case-Control Studies; Cyclooxygenase Inhibitors; Diclofenac; Female; Gr | 2005 |
Topical versus systemic diclofenac in the treatment of temporo-mandibular joint dysfunction symptoms.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclo | 2004 |
Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentials fro
Topics: Adult; Analgesics; Capsaicin; Cross-Over Studies; Diclofenac; Double-Blind Method; Drug Combinations | 2005 |
Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2005 |
Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2005 |
Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2005 |
Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Di | 2005 |
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Celecoxib; C | 2006 |
Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dizziness; Female; Humans | 2005 |
Analgesic efficacy of a lecithin-vehiculated diclofenac epolamine gel in shoulder periarthritis and lateral epicondylitis: a placebo-controlled, multicenter, randomized, double-blind clinical trial.
Topics: Analgesics; Diclofenac; Double-Blind Method; Gels; Humans; Pain; Periarthritis; Placebos; Shoulder; | 2005 |
Diclofenac suppository administration in conjunction with lidocaine gel during transrectal ultrasound-guided prostate biopsy: prospective, randomized, placebo-controlled study.
Topics: Analgesia; Anesthetics, Local; Biopsy; Diclofenac; Drug Therapy, Combination; Gels; Humans; Lidocain | 2005 |
Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Female; Gels; Humans | 2005 |
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Bl | 2006 |
Evaluation of a diclofenac transdermal patch for the attenuation of venous cannulation pain: a prospective, randomised, double-blind, placebo-controlled study.
Topics: Administration, Cutaneous; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Buttocks; Dic | 2006 |
Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Diclofenac | 2006 |
Pre-surgical child behavior ratings and pain management after two different techniques of tonsil surgery.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthesia; Anti-Inflammato | 2006 |
Topical ketoprofen TDS patch versus diclofenac gel: efficacy and tolerability in benign sport related soft-tissue injuries.
Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Athletic Injuri | 2007 |
Transdermal diclofenac patch vs eutectic mixture of local anesthetics for venous cannulation pain.
Topics: Adult; Anesthesia, Local; Anesthetics, Local; Catheterization, Peripheral; Diclofenac; Double-Blind | 2007 |
Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Delayed-Action Preparations; Dic | 2007 |
Pain relieving effect of short-course, pulse prednisolone in managing frozen shoulder.
Topics: Adult; Aged; Anti-Inflammatory Agents; Bursitis; Diclofenac; Female; Humans; Male; Middle Aged; Pain | 2007 |
A randomized comparison of different methods of analgesia in abortion using manual vacuum aspiration.
Topics: Abortion, Incomplete; Adult; Analgesia, Obstetrical; Anesthesia, Obstetrical; Anti-Inflammatory Agen | 2007 |
[Comparison of the time to analgetic and anti-inflammatory effect in the treatment of gouty arthritis with nimesulide and sodium diclofenac].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Diclofenac; Female; Humans; Male; Pain; P | 2007 |
The efficacy of paracetamol in the treatment of ankle sprains in comparison with diclofenac sodium.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Ankle Injuries; Anti-Inflammatory Agents, Non-Steroi | 2007 |
Comfrey extract ointment in comparison to diclofenac gel in the treatment of acute unilateral ankle sprains (distortions).
Topics: Acute Disease; Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under C | 2007 |
Diclofenac gel for osteoarthritis.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Administration Sc | 2008 |
Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure | 2008 |
[Evaluation of the efficacy of a single daily administration of slow-release diclofenac in the treatment of degenerative and non-degenerative arthropathies. Multicenter study concerning 643 patients].
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Drug Administr | 1984 |
A short-term, double-blind comparison between indoprofen and diclofenac in osteoarthritis.
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Indoprofen; | 1983 |
Comparison of diclofenac and indomethacin suppositories in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Tolerance; Hu | 1984 |
Treatment of primary dysmenorrhea with diclofenac sodium.
Topics: Adult; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Dysmenorrhea; Female; Humans; Mens | 1981 |
Comparison of the onset and duration of the analgesic effect of dipyrone, 1 or 2 g, by the intramuscular or intravenous route, in acute renal colic.
Topics: Adult; Diclofenac; Dipyrone; Double-Blind Method; Female; Humans; Injections, Intramuscular; Injecti | 1995 |
Femoral nerve block in extracapsular femoral neck fractures.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Bupivacaine; Diclofenac; Female; Femoral Neck Fractures | 1995 |
Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antineop | 1995 |
Double-blind study evaluating by endoscopy the tolerability of nimesulide and diclofenac on the gastric mucosa in osteoarthritic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Endoscopy; Female; Gastric | 1994 |
Efficacy and tolerability of diclofenac dispersible in painful osteoarthrosis.
Topics: Diclofenac; Double-Blind Method; Female; Hip Joint; Humans; Knee Joint; Male; Middle Aged; Osteoarth | 1993 |
Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group.
Topics: Aged; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Mul | 1995 |
Comparative studies with tolfenamic acid in rheumatic disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Dru | 1994 |
A comparative study of signal versus aggregate methods of outcome measurement based on the WOMAC Osteoarthritis Index. Western Ontario and McMaster Universities Osteoarthritis Index.
Topics: Aged; Data Interpretation, Statistical; Diclofenac; Double-Blind Method; Health Status Indicators; H | 1994 |
n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesia; Capsules; Diclofenac; Double-Blind Method; | 1994 |
Choosing the correct pain relief for extracorporeal lithotripsy.
Topics: Adult; Aged; Analgesia; Diclofenac; Female; Humans; Infusions, Intravenous; Lithotripsy; Male; Meper | 1994 |
Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer-blind multicenter study.
Topics: Adult; Diclofenac; Dipyrone; Female; Hemodynamics; Humans; Injections, Intramuscular; Low Back Pain; | 1994 |
Effect of preoperative i.m. administration of diclofenac on suxamethonium-induced myalgia.
Topics: Adult; Diclofenac; Double-Blind Method; Elective Surgical Procedures; Humans; Injections, Intramuscu | 1993 |
Worldwide experience with etodolac (Lodine) 300 mg b.i.d. in the treatment of osteoarthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Diclofenac; Double-Blind Me | 1993 |
Diclofenac evaluated in a human experimental model of central pain.
Topics: Adolescent; Adult; Diclofenac; Double-Blind Method; Electric Stimulation; Electrophysiology; Female; | 1993 |
Diclofenac for pain relief after arthroscopy: a comparison of early and delayed treatment.
Topics: Arthroscopy; Diclofenac; Double-Blind Method; Female; Humans; Knee Joint; Male; Pain; Time Factors | 1993 |
Morphine-sparing effect of diclofenac in cancer pain.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Diclofenac; Double-Blind Method; Drug Therapy, Combinati | 1993 |
Effect of intravenous diclofenac on pain and recovery profile after day-case laparoscopy.
Topics: Acetaminophen; Adult; Ambulatory Care; Diclofenac; Double-Blind Method; Female; Fentanyl; Humans; In | 1993 |
Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double-blind, within-patient, placebo-controlled study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Diclofenac; Double-B | 1995 |
Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; | 1995 |
A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis.
Topics: Administration, Oral; Administration, Topical; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; | 1995 |
[Use of sodium diclofenac in acute renal colic].
Topics: Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Colic; Diclofenac; Female; Humans; Kidne | 1996 |
Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 1996 |
Effects of four analgesic treatments on the behavioural and cortisol responses of 3-week-old lambs to tail docking.
Topics: Administration, Topical; Aging; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavi | 1997 |
Opioid-sparing effect of diclofenac in cancer pain.
Topics: Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Di | 1997 |
The effectiveness of topical diclofenac in relieving discomfort following traumatic corneal abrasions.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Corneal Injuries; Dic | 1997 |
Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial.
Topics: Administration, Topical; Adolescent; Adult; Analgesics; Analysis of Variance; Anesthetics, Local; An | 1997 |
Topical analgesics for knee arthrosis: a parallel study of ketoprofen gel and diclofenac emulgel.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Chi-Square Distribution; Diclofenac; Female; Gel | 1997 |
Diclofenac dispersible provides superior analgesia with faster onset of action compared to naproxen granular in patients with acute, painful, minor sports injuries.
Topics: Acute Disease; Adolescent; Adult; Aged; Ambulatory Care; Analgesics; Anti-Inflammatory Agents, Non-S | 1997 |
Therapeutic equivalence of diclofenac sustained-released 75 mg tablets and diclofenac enteric-coated 50 mg tablets in the treatment of painful osteoarthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Diclo | 1997 |
[Diclofenac for treatment of postoperative pain after hip arthroplasty in older patients].
Topics: Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; D | 1997 |
Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nerve Block; Celiac Plexus; Diclofen | 1998 |
Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1998 |
The effect of diclofenac sodium on the initial comfort of RGP contact lenses: a pilot study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Contact Lenses; Cross-Over Studies; Diclofenac; Doub | 1999 |
Double-blind controlled clinical study of the efficacy and tolerability of diclofenac-N-(2-hydroxyethyl)-pyrrolidine lecithin gel compared with diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel in patients with peri and extraarticular inflammatory diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Phar | 1999 |
Comparison of therapeutic efficacy of nimesulide and diclofenac in patients with degenerative joint diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dou | 1999 |
Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model.
Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies | 2000 |
Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Athletic | 2000 |
Postoperative pain therapy after lumbar disc surgery.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Diskectomy; Dr | 1999 |
Intrathecal methylprednisolone for intractable postherpetic neuralgia.
Topics: Aged; Anesthetics, Local; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofe | 2000 |
A prospective, open, single blind, randomized study comparing four analgesics in the treatment of peripheral injury in the emergency department.
Topics: Acetaminophen; Adult; Aged; Analgesics; Analysis of Variance; Arm Injuries; Diclofenac; Emergency Se | 2000 |
Endoscopic evaluation of the gastrotolerance of short-term antalgic treatment with low dose k-diclofenac: a comparison of ibuprofen and aspirin.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Duodenum; Endoscopy, Gastrointe | 2001 |
Comparison of the morphine-sparing effects of diclofenac sodium and ketorolac tromethamine after major orthopedic surgery.
Topics: Adult; Aged; Aged, 80 and over; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory | 2002 |
[Diclofenac in the treatment of inflammatory and degenerative diseases of the locomotor system].
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Drug Evaluation; Humans; Indomethacin; Inflammati | 1977 |
Four commonly prescribed non-steroidal anti-inflammatory drugs for rheumatoid arthritis.
Topics: Administration, Oral; Arthritis, Rheumatoid; Cross-Over Studies; Delayed-Action Preparations; Diclof | 1991 |
Double-blind, randomized and parallel comparison between droxicam and diclofenac sodium in patients with coxarthrosis and gonarthrosis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Female; Human | 1991 |
[Drug therapy in severe tumor pain. Comparative study of a new combination preparation versus diclofenac-Na].
Topics: Adult; Aged; Aged, 80 and over; Codeine; Diclofenac; Double-Blind Method; Drug Combinations; Female; | 1992 |
Overall safety of Arthrotec.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Constipation; Diarrhea; | 1992 |
Pharmacokinetics and efficacy of carbamoylphenoxyacetid acid.
Topics: Analgesics; Diclofenac; Humans; Pain; Salicylamides | 1992 |
[Gonalgia: treatment with therapeutic local anesthesia. Results of a controlled comparative study versus diclofenac].
Topics: Adult; Anesthesia, Local; Diclofenac; Female; Humans; Knee Joint; Lidocaine; Male; Middle Aged; Pain | 1991 |
Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers.
Topics: Adult; Candidiasis; Diclofenac; Double-Blind Method; Duodenoscopy; Duodenum; Esophageal Diseases; Es | 1991 |
An observer-blind comparison of diclofenac potassium, piroxicam and placebo in the treatment of ankle sprains.
Topics: Adult; Ankle Injuries; Diclofenac; Female; Humans; Male; Middle Aged; Pain; Piroxicam; Single-Blind | 1990 |
Intramuscular diclofenac sodium versus intravenous Baralgin in the treatment of renal colic.
Topics: Adult; Aminopyrine; Benzophenones; Blood Pressure; Colic; Diclofenac; Dipyrone; Double-Blind Method; | 1990 |
Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of osteoarthritis: a comparative controlled clinical trial in general practice.
Topics: Adult; Aged; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Female; Humans; Indometha | 1990 |
Controlled-release indomethacin and sustained-release diclofenac sodium in the treatment of rheumatoid arthritis: a comparative controlled clinical trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Fe | 1990 |
Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Aspirin; Chronic Disea | 1989 |
Joint pain and quality of life; results of a randomised trial.
Topics: Acetaminophen; Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Dextropropoxyphen | 1989 |
[Acute pain due to kidney/ureter stones treated with intramuscular Voltaren or Ketogan].
Topics: Adult; Aged; Allylamine; Amines; Analgesics, Opioid; Diclofenac; Drug Combinations; Female; Humans; | 1987 |
Use of diclofenac in analgesia.
Topics: Analgesia; Back Pain; Biliary Tract Diseases; Clinical Trials as Topic; Colic; Diclofenac; Double-Bl | 1986 |
[Sodium diclofenac in the treatment of biliary pain: a controlled study using hyoscine N-butylbromide].
Topics: Adult; Aged; Butylscopolammonium Bromide; Cholecystitis; Cholelithiasis; Clinical Trials as Topic; C | 1988 |
Treatment of pain owing to acute ureteral obstruction with prostaglandin-synthetase inhibitor: a prospective randomized study.
Topics: Adolescent; Adult; Butylscopolammonium Bromide; Clinical Trials as Topic; Cyclooxygenase Inhibitors; | 1986 |
Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Clinical Trials as Topic; Diclofenac; D | 1988 |
Effects of a non-steroidal anti-inflammatory drug on delayed onset muscle soreness and indices of damage.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Creatine Kinase; Creatinine; Diclofenac; Double-Blin | 1988 |
Efficacy of diclofenac in ankylosing spondylitis.
Topics: Adult; Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Gastrointestinal Dis | 1986 |
[New etiopathologic and therapeutic perspectives in ureteral colic. Evaluation of clinical experience with diclofenac sodium and indomethacin].
Topics: Clinical Trials as Topic; Diclofenac; Double-Blind Method; Humans; Indomethacin; Narcotics; Pain; Pa | 1986 |
Diclofenac versus lidocaine as injection therapy in myofascial pain.
Topics: Diclofenac; Female; Humans; Injections, Intramuscular; Lidocaine; Male; Middle Aged; Myofascial Pain | 1986 |
Double-blind preference and compliance multicentre study in osteoarthritis: once-a-day treatment.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Drug Administration | 1985 |
Experimental pain induced by electrical and thermal stimulation of the skin in healthy man: sensitivity to 75 and 150 mg diclofenac sodium in comparison with 60 mg codeine and placebo.
Topics: Acoustic Stimulation; Adult; Codeine; Diclofenac; Electric Stimulation; Female; Hot Temperature; Hum | 1986 |
Diclofenac in the treatment of ankylosing spondylitis: review of worldwide clinical experience and report of a double-blind comparison with indomethacin.
Topics: Adolescent; Adult; Aged; Diclofenac; Double-Blind Method; Female; Humans; Indomethacin; Male; Middle | 1985 |
Other Studies
206 other studies available for diclofenac and Ache
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted-3H-quinazolin-4-one as analgesic, anti-inflammatory agents.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents; Carrageenan; Dose-Response Rela | 2007 |
Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
Topics: Amines; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Histamine Antagonists; Ligands; M | 2008 |
Regioselective reaction: synthesis and pharmacological study of Mannich bases containing ibuprofen moiety.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspergillus; Edema; Esch | 2009 |
Discovery and optimization of novel purines as potent and selective CB2 agonists.
Topics: Animals; Drug Evaluation, Preclinical; Furans; Half-Life; Humans; Pain; Purines; Rats; Receptor, Can | 2012 |
Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Chromones; Cyclooxygenase 1; Cyclooxyge | 2014 |
Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile.
Topics: Animals; Benzoic Acid; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Half-Life; Humans | 2016 |
Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophysiology; Ev | 2016 |
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carbonic Anhydrase Inhibito | 2020 |
One-Step Fabrication of Hollow Spherical Cellulose Beads: Application in pH-Responsive Therapeutic Delivery.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biocompatible Materials; Cellulose; Diclofenac; Drug Carrie | 2022 |
Complete Plaque Regression in Patients with Peyronie's Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases.
Topics: Antioxidants; Combined Modality Therapy; Diclofenac; Humans; Male; Middle Aged; Pain; Penile Indurat | 2022 |
Venlafaxine HCl Encapsulated in Niosome: Green and Eco-friendly Formulation for the Management of Pain.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cholesterol; Diclofenac; Liposomes; Pain; Rats; Surfa | 2022 |
Reduced risk of NSAID-Induced adverse events with concomitant use of misoprostol (MICRO study).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Misoprostol; Pain; Proportional Hazards | 2022 |
Comparison of Therapeutic Effects of Topical Application of Diclofenac Sodium Nanoparticles and Conventional Placebo on Knee Osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Liposomes; Nanoparticles; Osteoarthriti | 2022 |
Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.
Topics: Adult; Antioxidants; Combined Modality Therapy; Diclofenac; Humans; Male; Middle Aged; Pain; Penile | 2022 |
Preclinical comparison of antinociceptive effects between ibuprofen, diclofenac, naproxen, and acetaminophen on acid-stimulated body stretching and acid-depressed feeding behaviors in rats.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Feeding Beh | 2022 |
Development of zinc ferrite nanoparticles with enhanced photocatalytic performance for remediation of environmentally toxic pharmaceutical waste diclofenac sodium from wastewater.
Topics: Diclofenac; Ferric Compounds; Humans; Nanoparticles; Pain; Wastewater; Zinc Oxide | 2023 |
[Evaluation of topical therapy of patients with osteoarthritis of small joints of the hands with Voltaren® Emulgel® 2% (diclofenac diethylamine 2%)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diclofenac; Female; Humans; Male; Osteoarthriti | 2021 |
Analgesic effects and arthritic changes following intra-articular injection of diclofenac etalhyaluronate in a rat knee osteoarthritis model.
Topics: Analgesics; Animals; Calcitonin Gene-Related Peptide; Diclofenac; Disease Models, Animal; Hyaluronic | 2022 |
Influence of Poloxamer 188 on Anti-Inflammatory and Analgesic Effects of Diclofenac-Loaded Nanoemulsion: Formulation, Optimization and in Vitro/in Vivo Evaluation.
Topics: Analgesics; Anti-Inflammatory Agents; Diclofenac; Edema; Emulsions; Humans; Pain; Poloxamer; Seizure | 2023 |
Diclofenac sodium and dexamethasone co-therapy restores brain neuron-specific enolase (NSE), S-100 Beta and glial fibrillary acid protein (GFAP) proteins in experimental rat's model: A possible inhibition of P-glycoprotein.
Topics: Animals; Anti-Inflammatory Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; D | 2023 |
Diclofenac Mouthwash as a potential therapy for reducing pain and discomfort in chemo-radiotherapy-induced oral mucositis.
Topics: Chemoradiotherapy; Diclofenac; Head and Neck Neoplasms; Humans; Mouthwashes; Pain; Prospective Studi | 2020 |
[The chemoreactomic analysis of the central mechanisms of action of non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Ketoprofen; Opiate Alkaloids; Pain; Pir | 2020 |
The authors reply: ISWI vs diclofenac for renal colic.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Pain; Renal Colic | 2020 |
Intradermal sterile water injection in acute renal colic.
Topics: Diclofenac; Humans; Injections, Intradermal; Pain; Renal Colic; Water | 2021 |
Citryl-imine-PEG-ylated chitosan hydrogels - Promising materials for drug delivery applications.
Topics: Animals; Chitosan; Diclofenac; Disease Models, Animal; Drug Delivery Systems; Hydrogels; Pain; Polye | 2020 |
Intradermal sterile water injection for acute renal colic pain.
Topics: Diclofenac; Humans; Pain; Pain Management; Renal Colic; Water | 2020 |
Reply to correspondence: Intradermal sterile water injection for acute renal colic pain. MS 23569R1.
Topics: Diclofenac; Humans; Injections, Intradermal; Pain; Renal Colic; Water | 2021 |
Myositis Ossificans of the Adductor Longus in a Soccer Player.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Groin; Hematoma; Humans; Magnetic Resonance Ima | 2020 |
Re: Gul A, Gul M. Intracutaneous sterile water injection for pain relief during extracorporeal shock wave lithotripsy: comparison with diclofenac sodium. Urolithiasis. 2020 Apr;48(2):103-108. doi:10.1007/s00240-019-01147-9. Epub 2019 Jul 5.
Topics: Diclofenac; Humans; Lithotripsy; Pain; Urolithiasis; Water | 2021 |
Transdermal Permeation and Skin Retention of Diclofenac and Etofenamate/Flufenamic Acid From Over-the-Counter Pain Relief Products.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Flufenamic Acid; Gel | 2021 |
Effects of Spirulina platensis on pain and inflammation in long Evans rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Diclofenac; Disease Models, Animal; Female; Formaldeh | 2020 |
The effective interplay of (non-) selective NSAIDs with neostigmine in animal models of analgesia and inflammation.
Topics: Acetic Acid; Analgesia; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dic | 2021 |
Intravenous Acetaminophen vs Intravenous Diclofenac in the Management of Painful Crisis in Sickle Cell Disease: Authors' Reply.
Topics: Acetaminophen; Administration, Intravenous; Anemia, Sickle Cell; Diclofenac; Humans; Pain | 2021 |
Intravenous Acetaminophen vs Intravenous Diclofenac in the Management of Painful Crisis in Sickle Cell Disease.
Topics: Acetaminophen; Administration, Intravenous; Anemia, Sickle Cell; Diclofenac; Humans; Pain | 2021 |
Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications.
Topics: Adverse Drug Reaction Reporting Systems; Analgesics; Anti-Bacterial Agents; Anti-Inflammatory Agents | 2017 |
Surgical suture braided with a diclofenac-loaded strand of poly(lactic-co-glycolic acid) for local, sustained pain mitigation.
Topics: Animals; Diclofenac; Lactic Acid; Pain; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolym | 2017 |
Layering of different materials to achieve optimal conditions for treatment of painful wounds.
Topics: Bandages; Biocompatible Materials; Cells, Cultured; Diclofenac; Fibroblasts; Humans; Lidocaine; Pain | 2017 |
NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Ibuprofen; Naproxen; Network | 2017 |
A case-history illustrates importance of knowledge of drug-interactions when pain-patients are prescribed non-pain drugs for co-morbidities.
Topics: Aged; Comorbidity; Diclofenac; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; F | 2017 |
Antinociceptive tolerance to NSAIDs in the anterior cingulate cortex is mediated via endogenous opioid mechanism.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Tolerance; Gyrus Cing | 2018 |
Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain.
Topics: Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Anxiety; Cohort | 2018 |
[In process].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Diclofenac; Hip; Humans; Knee; Pain; Treatment O | 2017 |
[Pharmacological profile of a novel nonhuman primate model of knee osteoarthritis].
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aprepitant; Diclofenac; Duloxe | 2018 |
Defective bone repair in diclofenac treated C57Bl6 mice with and without lipopolysaccharide induced systemic inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Endothelial Cells; Humans; Inflammatio | 2019 |
Analgesic Activity of Acid-Sensing Ion Channel 3 (ASIС3) Inhibitors: Sea Anemones Peptides Ugr9-1 and APETx2 versus Low Molecular Weight Compounds.
Topics: Acetic Acid; Acid Sensing Ion Channel Blockers; Acid Sensing Ion Channels; Analgesics; Animals; Biol | 2018 |
Factors affecting the results of analgesic therapy. Results of the Russian multicentre study of NOTE (NSAID: Open-label Trial of Efficacy).
Topics: Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Hum | 2018 |
Does format matter for comprehension of a facial affective scale and a numeric scale for pain by adults with Down syndrome?
Topics: Acetaminophen; Adult; Affect; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cog | 2013 |
Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Computer Simulation; Cyclooxygenase | 2014 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase | 2013 |
Comparison of the effects of dexketoprofen trometamol, meloxicam and diclofenac sodium on fibular fracture healing, kidney and liver: an experimental rat model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Diclofenac; Fibula; Fract | 2014 |
Comparison of the effects of crocin, safranal and diclofenac on local inflammation and inflammatory pain responses induced by carrageenan in rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Carotenoids; Carrageenan; Cyclohexenes; Diclofenac; D | 2013 |
The effects of Phα1β, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model.
Topics: Animals; Brain; Calcium Channel Blockers; Diclofenac; Disease Models, Animal; Dopamine; Fibromyalgia | 2014 |
P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; ATP Binding Cassette Transporter, Subfamily B, Mem | 2014 |
Antinociceptive tolerance to NSAIDs microinjected into dorsal hippocampus.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Diclofenac; | 2014 |
Optimization of aceclofenac solid dispersion using Box-Behnken design: in-vitro and in-vivo evaluation.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cellulose; C | 2014 |
Synthesis, hydrolysis kinetics and pharmacological evaluation of aceclofenac prodrugs.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2015 |
Synergistic effect of the interaction between curcumin and diclofenac on the formalin test in rats.
Topics: Analgesics; Animals; Curcumin; Diclofenac; Drug Synergism; Female; Formaldehyde; Pain; Pain Measurem | 2014 |
Clinical inquiry: does topical diclofenac relieve osteoarthritis pain?
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Osteoarthrit | 2015 |
Evaluation of antinociceptive activity of nanoliposome-encapsulated and free-form diclofenac in rats and mice.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Diclofenac; | 2015 |
Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats.
Topics: Adjuvants, Immunologic; Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxy | 2015 |
Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents.
Topics: Acetic Acid; Analgesics; Animals; Benzimidazoles; Diclofenac; Disease Models, Animal; Drug Evaluatio | 2015 |
Toona sinensis leaf extract has antinociceptive effect comparable with non-steroidal anti-inflammatory agents in mouse writhing test.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cycloox | 2015 |
Acute kidney failure associated with anaphylactic shock caused by diclofenac sodium.
Topics: Acute Kidney Injury; Anaphylaxis; Cyclooxygenase Inhibitors; Diclofenac; Humans; Injections, Intramu | 2015 |
Behavioral and neurochemical analysis of ongoing bone cancer pain in rats.
Topics: Adenocarcinoma; Analgesics, Opioid; Anesthetics, Local; Animals; Anti-Inflammatory Agents, Non-Stero | 2015 |
Design, synthesis and QSAR studies on a series of 2, 5-disubstituted- 1,3,4-oxadiazole derivatives of diclofenac and naproxen for analgesic and anti-inflammatory activity.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Design; Female; Infla | 2015 |
Prevalence, trends, patterns and associations of analgesic use in Germany.
Topics: Acetaminophen; Adolescent; Adult; Age Factors; Aged; Analgesics; Aspirin; Diclofenac; Drug Therapy; | 2015 |
Antiinflammatory and analgesic effects of Eurycoma longifolia extracts.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Aspirin; Cells, Cultured; Cyclooxygenase 2; Diclofena | 2016 |
Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: a new therapeutic approach for pain and inflammation.
Topics: Administration, Cutaneous; Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Common pain relievers may increase heart problems. High-dosage ibuprofen and diclofenac linked to elevated risk of death; naproxen, acetaminophen offer alternatives.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Ibuprofen; Naproxen; Pai | 2010 |
Association of terpinolene and diclofenac presents antinociceptive and anti-inflammatory synergistic effects in a model of chronic inflammation.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclohexane Monoterpe | 2016 |
Review: Some NSAIDs, notably diclofenac, improved knee or hip pain and function in osteoarthritis vs other NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Hip; Humans; Osteoarthritis, Knee; Pain | 2016 |
Diclofenac rectal suppository: an effective modality for perineal pain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Cohort Studies; Cross-Sectional St | 2016 |
Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Diclofenac; Drugs, Generic; Humans; | 2016 |
The application of ATR-FTIR spectroscopy and multivariate data analysis to study drug crystallisation in the stratum corneum.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Cluster Anal | 2017 |
Corticosteroid transdermal delivery significantly improves arthritis pain and functional disability.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Arthritis; Betamethasone Valerate; C-Reactive P | 2017 |
Primidone inhibits TRPM3 and attenuates thermal nociception in vivo.
Topics: Adrenergic Uptake Inhibitors; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium; | 2017 |
Anti-inflammatory and analgesic activities of some newly synthesized pyridinedicarbonitrile and benzopyranopyridine derivatives.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzopyrans; Carrageenan; Diclofenac; Disease Mode | 2008 |
New topical anti-inflammatory drugs may curb arthritis pain.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Diclofenac; Humans; Pai | 2008 |
Pharmacokinetics and pharmacodynamics of diclofenac in the presence and absence of glibenclamide in the rat.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Dic | 2008 |
Recurrent severe angioedema associated with imidapril and diclofenac.
Topics: Airway Obstruction; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, | 2008 |
[Summary of the practice guideline 'Urolithiasis' (first revision) from the Dutch College of General Practitioners].
Topics: Analgesics, Opioid; Diclofenac; Family Practice; Humans; Morphine; Netherlands; Pain; Practice Patte | 2008 |
Antinociceptive activity of methanolic extract of Epilobium hirsutum.
Topics: Acetic Acid; Analgesics; Analysis of Variance; Animals; Diclofenac; Epilobium; Male; Medicine, Tradi | 2007 |
Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.
Topics: Acetic Acid; Amidohydrolases; Animals; Benzamides; Carbamates; Cyclooxygenase Inhibitors; Diclofenac | 2009 |
Effects of analgesics on the plantar incision-induced drop of the noxious heat threshold measured with an increasing-temperature water bath in the rat.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Diclofenac; Disease Models, An | 2009 |
Treating osteoarthritis topically: Voltaren Gel for pain relief.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Osteoa | 2009 |
Delirium due to a drug-drug interaction of lithium and an NSAID.
Topics: Accidental Falls; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antidepressi | 2009 |
Anti-inflammatories and heart failure-identifying patients at risk.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents; Chondrosarcoma; Diclofenac; Heart Failure; Humans; Mal | 2009 |
Anti-inflammatory, analgesic and antipyretic activity of aqueous extract of fresh leaves of Coccinia indica.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Cucurbitacea | 2009 |
The selective metabotropic glutamate receptor 7 allosteric agonist AMN082 inhibits inflammatory pain-induced and incision-induced hypersensitivity in rat.
Topics: Allosteric Regulation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Carra | 2009 |
Prospective observational study of adverse drug reactions to diclofenac in children.
Topics: Adverse Drug Reaction Reporting Systems; Child; Child, Preschool; Confidence Intervals; Diclofenac; | 2009 |
Comparison of mechanical allodynia and the affective component of inflammatory pain in rats.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Celecoxib; Central Nervous System Agents; Diclo | 2010 |
Grading of monosodium iodoacetate-induced osteoarthritis reveals a concentration-dependent sensitization of nociceptors in the knee joint of the rat.
Topics: Action Potentials; Alkylating Agents; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; | 2009 |
Antioxidant, anti-inflammatory and analgesic potential of the Citrus decumana L. peel extract.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Citrus; Diclofenac; Dise | 2009 |
Topical diclofenac solution.
Topics: Activities of Daily Living; Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agent | 2009 |
Pharmacokinetic of diclofenac in the presence and absence of glibenclamide in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Diclofenac; | 2009 |
Preliminary studies on the antinociceptive activity of Vaccinium ashei berry in experimental animal models.
Topics: Acetic Acid; Analgesics; Animals; Anthocyanins; Blueberry Plants; Diclofenac; Disease Models, Animal | 2010 |
Analgesic and anti-inflammatory effects of Pistacia integerrima extracts in mice.
Topics: Abdominal Pain; Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Diclofenac; Dose-Respons | 2010 |
Synthesis, analgesic and anti-inflammatory activities of some novel pyrazolines derivatives.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Diclofenac; Drug Design; Edema; Hydrazines; Mice; Pai | 2010 |
Diclofenac patch: clinical applications beyond pain control.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Myofascial P | 2010 |
Time to significant pain reduction following DETP application vs placebo for acute soft tissue injuries.
Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Aged; Ankle Joint; Anti-Inflammatory Agen | 2010 |
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationsh | 2010 |
Effectiveness of doxazosin in the management of lower ureteral stones in male and female patients.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; | 2011 |
[Unilateral odynophagia in rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cooperative Behavior; Deglutition Disorders; Diagnosis, | 2011 |
Toxicities of raw Alocasia odora.
Topics: Adult; Airway Obstruction; Alocasia; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Di | 2011 |
Pain management of children and adolescents with sickle cell disease presenting to the emergency department.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Analgesics, Opioid; Anemia, Sickle Cell; Anti-I | 2011 |
Preemptive analgesic effects of midazolam and diclofenac in rat model.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Disease Models, Animal; Fo | 2011 |
Gastrointestinal tolerability of diclofenac epolamine topical patch 1.3%: a pooled analysis of 14 clinical studies.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Gastrointesti | 2011 |
Anti-inflammatory and analgesic activity of protocatechuic acid in rats and mice.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2011 |
Targeting A-type K(+) channels in primary sensory neurons for bone cancer pain in a rat model.
Topics: 4-Aminopyridine; Activating Transcription Factor 3; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2012 |
Evaluation of analgesic and anti-inflammatory activity of diospyros cordifolia extract.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; | 2011 |
Design, synthesis, computational and biological evaluation of some new hydrazino derivatives of DHA and pyranopyrazoles.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Carrageenan; Computational Biology; Cycl | 2012 |
Anti-inflammatory and analgesic potential of a novel steroidal derivative from Bryophyllum pinnatum.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Carrageenan; Diclofena | 2012 |
Evaluation of antinociceptive and anti-inflammatory activity of hydromethanol extract of Cocos nucifera L.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antioxidants; Cocos; Diclofenac; Disease Models, Anim | 2013 |
The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model.
Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzodioxoles; Carrageenan; Diclo | 2013 |
Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Female; | 2012 |
Anti-inflammatory and antinociceptive properties of dantrolene sodium in rats and mice.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dantrolene; | 2002 |
A new method of continuous maxillary nerve block with an indwelling catheter.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Lo | 2002 |
Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arachidonic Acids; Aspirin; Camp | 2002 |
Effect of resiniferatoxin on the noxious heat threshold temperature in the rat: a novel heat allodynia model sensitive to analgesics.
Topics: Acetaminophen; Analgesics; Animals; Diclofenac; Diterpenes; Dose-Response Relationship, Drug; Female | 2003 |
[Measurement of postoperative pain: analysis of the sensitivity of various self-evaluation instruments].
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans | 2003 |
The antinociceptive effect of iontophoretic direct application of diclofenac to arthritic knee-joints of rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Diclofenac; D | 2003 |
Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, No | 2003 |
Summaries for patients. Leeches to treat knee osteoarthritis.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Knee | 2003 |
Modulatory effect of cyclooxygenase inhibitors on sildenafil-induced antinociception.
Topics: Animals; Carrageenan; Cyclic GMP; Cyclooxygenase Inhibitors; Diclofenac; Drug Synergism; Enzyme Inhi | 2003 |
Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-methyl-3-substituted quinazolin-4-(3H)-ones.
Topics: Administration, Oral; Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Ster | 2003 |
Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.
Topics: Analysis of Variance; Animals; Behavior, Animal; Bone Density; Bone Neoplasms; Cyclooxygenase 2; Cyc | 2004 |
Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2,6-dichloroanilino) phenyl]acetic acid derivatives.
Topics: Acetates; Analgesics; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofena | 2004 |
[Systematic pain treatment following Colles' fracture].
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2004 |
[Transient osteoporosis of the hip in pregnancy: a report of three cases].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Bed Rest; Diagnosis, Differential; Diclofenac; Femal | 2004 |
[Prostate biopsy -- less pain through diclofenac].
Topics: Administration, Rectal; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibiotic P | 2004 |
[Rational therapy of urolithiasis in every-day practice].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Colic; Cyclooxygenase Inhibitors; Deamino Argin | 2004 |
Acid-induced pain and its modulation in humans.
Topics: Acid Sensing Ion Channels; Administration, Cutaneous; Adult; Amiloride; Analgesics; Anti-Inflammator | 2004 |
Synthesis, biological evaluation and kinetic studies of glyceride prodrugs of diclofenac.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Carrageenan; Chromatography, High Pressu | 2004 |
Efficacy and relevance of topical diclofenac for osteoarthritic pain.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Osteoarthritis | 2005 |
Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib.
Topics: Analgesics; Animals; Apamin; Behavior, Animal; Charybdotoxin; Diclofenac; Dose-Response Relationship | 2005 |
Diclofenac pretreatment for propofol.
Topics: Anesthetics, Intravenous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Fentanyl; Humans; Mid | 2005 |
Topical diclofenac for the treatment of eyeache in Miller-Fisher syndrome.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Eye Diseases; H | 2006 |
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; | 2006 |
[Paracetamol has the same effect as non-steroidal anti-inflammatory agents in acute musculoskeletal injuries].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans | 2006 |
Antiinflammatory and analgesic effects of Psidium guajava Linn. (Myrtaceae) leaf aqueous extract in rats and mice.
Topics: Acetic Acid; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Agents; Diclofenac; Female; | 2006 |
Antinociceptive effects of the aqueous extract of Brugmansia suaveolens flowers in mice.
Topics: Acetic Acid; Analgesics; Analysis of Variance; Animals; Diclofenac; Disease Models, Animal; Drug Eva | 2007 |
Spontaneous nociceptive behaviour in female mice with Freund's complete adjuvant- and carrageenan-induced monoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Behavior, Animal; Carrage | 2007 |
Oral administration of Ginkgo biloba extract, EGb-761 inhibits thermal hyperalgesia in rodent models of inflammatory and post-surgical pain.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Diclofenac; Dis | 2007 |
The local antinociceptive actions of nonsteroidal antiinflammatory drugs in the mouse radiant heat tail-flick test.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Dipyrone; Disease | 2007 |
Heat injury-induced drop of the noxious heat threshold measured with an increasing-temperature water bath: a novel rat thermal hyperalgesia model.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Diclofenac; Dose-Response Rela | 2007 |
[Painful ophthalmoplegia in children: Tolosa-Hunt syndrome or ophthalmoplegic migraine?].
Topics: Adolescent; Adrenal Cortex Hormones; Child, Preschool; Diclofenac; Female; Humans; Male; Migraine Di | 2007 |
Analgesic and antiinflammatory effects of mollic acid glucoside, a 1 alpha-hydroxycycloartenoid saponin extractive from Combretum molle R. Br. ex G. Don (Combretaceae) leaf.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Combretum; Diclofenac; Edema; Female; Hi | 2008 |
Antinociceptive effect from Davilla elliptica hydroalcoholic extract.
Topics: Administration, Oral; Analgesics; Animals; Arginine; Behavior, Animal; Brazil; Cyclooxygenase Inhibi | 2007 |
[Lumiracoxib--Prexigem].
Topics: Arthritis; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Pain | 2007 |
Control of pain during transrectal ultrasound-guided prostate biopsy: a prospective study comparing two methods.
Topics: Aged; Biopsy, Needle; Case-Control Studies; Diclofenac; Humans; Injections, Intramuscular; Lidocaine | 2007 |
Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Clinical | 2007 |
A diclofenac patch (Flector) for pain.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Administration | 2008 |
Diclofenac attenuates the regional effect of lambda-carrageenan on blood-brain barrier function and cytoarchitecture.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood-Brain Barrier; Brain; Carrageenan; Cyclooxyg | 2008 |
[Multicenter study on the use of injectable diclofenac in pain states: analysis of the clinical data on 1873 patients].
Topics: Adolescent; Adult; Aged; Diclofenac; Drug Evaluation; Drug Tolerance; Female; Humans; Injections, In | 1983 |
Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation.
Topics: Animals; Aspirin; Bradykinin; Bromelains; Cartilage, Articular; Cell Line; Concanavalin A; Depressio | 1994 |
[Muscle aches and biochemical changes following a ultra-marathon in the cold--modification by diclofenac].
Topics: Adult; C-Reactive Protein; Cold Temperature; Creatine Kinase; Diclofenac; Female; Humans; Male; Midd | 1994 |
Antinociceptive effects of non-steroidal anti-inflammatory drugs in a rat model of unilateral hindpaw inflammation.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose-Response Relationship | 1994 |
Suxamethonium-induced myalgia.
Topics: Diclofenac; Humans; Muscular Diseases; Pain; Succinylcholine | 1994 |
NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Cyclooxygena | 1993 |
Analgesia for ESWL.
Topics: Administration, Rectal; Analgesia; Diclofenac; Humans; Lithotripsy; Pain; Suppositories | 1993 |
Impairment of renal function after treatment of a burn patient with diclofenac, a non-steroidal antiinflammatory drug.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Burns; Diclofenac; Female; Humans; Pain; Renal Insuff | 1995 |
Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and associated spinal c-Fos expression in the rat.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Dexamethaso | 1996 |
The course of pain and the restriction of mobility in patients with shoulder complaints in general practice.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Middle Aged; Pain; | 1997 |
Diclofenac sodium for pain relief following laparoscopic sterilization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Female; Humans; Laparoscop | 1997 |
Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Beh | 1996 |
Reduction by antiinflammatory drugs of the response of corneal sensory nerve fibers to chemical irritation.
Topics: Acetic Acid; Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; | 1997 |
[Clinical thinking and decision making in practice. A patient with flank pain and anuria].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anuria; Diclofenac; Humans; Kidney Pelvis; Male; Middle Age | 1997 |
[Intramuscular injections of diclofenac].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Injections, Intramuscular; Pain | 1997 |
Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cycloox | 1998 |
Topical diclofenac sodium in the management of anesthetic abuse keratopathy.
Topics: Administration, Topical; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Corneal | 1998 |
Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose- | 1998 |
Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in mice.
Topics: Abdominal Muscles; Acetic Acid; Analgesics; Analgesics, Opioid; Animals; Capsaicin; Cyclooxygenase I | 1998 |
On the analgesic effect of sodium diclofenac in pain-induced functional impairment in the rat.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Diclofenac; Dose-Response Re | 1998 |
Analgesia for termination of pregnancy.
Topics: Abortion, Induced; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Ketorolac; P | 1999 |
[Symptomatic triangular bone. A case report].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Carpal Bones; Diclofenac; Humans; Immobilization; Ma | 1999 |
Analgesia in soft-tissue injury: current practice in Auckland is not supported by the available evidence.
Topics: Acetaminophen; Adult; Analgesia; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; | 1999 |
Glutamate and kynurenate in the rat central nervous system following treatments with tail ischaemia or diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Central Nervous System; Chromatography, High Press | 2000 |
Pharmacological and immunohistochemical characterization of a mouse model of acute herpetic pain.
Topics: Acetates; Amines; Amitriptyline; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; | 2000 |
Effect of dexamethasone plus vitamin B complex in the PIFIR model.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dexamethasone; Diclofena | 2000 |
Sildenafil increases diclofenac antinociception in the formalin test.
Topics: Analgesics; Animals; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Drug S | 2001 |
Non-steroidal hip arthropathy: case histories and differential diagnosis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Diclofena | 2001 |
Participation of COX, IL-1 beta and TNF alpha in formalin-induced inflammatory pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Celecoxib; Cyclooxygenase In | 2001 |
Central antinociceptive-analgesic effect of diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Humans; Nociceptors; Pain | 2002 |
Pharmacological evidence for the activation of K(+) channels by diclofenac.
Topics: 4-Aminopyridine; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; A | 2002 |
Neostigmine interactions with non steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Diclofenac; Disease Mod | 2002 |
Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test.
Topics: Analgesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Cyclooxyge | 2002 |
Antinociceptive, anti-inflammatory and acute toxicity effects of Zhumeria majdae extracts in mice and rats.
Topics: Acetic Acid; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Ag | 2002 |
Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the manage
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cohort Studies; Diclofenac; | 2002 |
[Study of the anti-inflammatory and analgesic actions of diclofenac in traumatology and orthopedic surgery].
Topics: Adult; Analgesics; Anti-Inflammatory Agents; Diclofenac; Female; Humans; Inflammation; Male; Middle | 1977 |
Localization of the central antinociceptive effects of diclofenac in the rat.
Topics: Animals; Brain; Diclofenac; Disease Models, Animal; Male; Microinjections; Pain; Periaqueductal Gray | 1992 |
Diclofenac does not modify morphine bioavailability in cancer patients.
Topics: Aged; Biological Availability; Chromatography, High Pressure Liquid; Diclofenac; Drug Interactions; | 1992 |
Muscle damage with diclofenac injections.
Topics: Diclofenac; Humans; Muscles; Pain | 1992 |
Morphine intoxication during acute reversible renal insufficiency.
Topics: Acute Kidney Injury; Aged; Bone Neoplasms; Diclofenac; Drug Therapy, Combination; Humans; Male; Morp | 1992 |
Pharmacological properties of five diclofenac metabolites identified in human plasma.
Topics: Animals; Arthritis, Experimental; Diclofenac; Dinoprostone; Edema; Humans; In Vitro Techniques; Macr | 1991 |
Clinical experiences in the treatment of pain in rheumatology.
Topics: Adult; Aged; Diclofenac; Female; Humans; Indomethacin; Male; Meclofenamic Acid; Middle Aged; Oxyphen | 1991 |
Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Benzoquinones; Capillary | 1991 |
Morphine intoxication during acute reversible renal insufficiency.
Topics: Acute Kidney Injury; Aged; Bone Neoplasms; Diclofenac; Humans; Male; Morphine; Pain; Poisoning; Pros | 1991 |
Acquired Brown's syndrome in systemic lupus erythematosus: another ocular manifestation.
Topics: Adult; Diclofenac; Diplopia; Fever; Humans; Hydroxychloroquine; Ibuprofen; Lupus Erythematosus, Syst | 1990 |
Pharmacology of diclofenac sodium.
Topics: Analgesics; Animals; Arachidonic Acid; Arachidonic Acids; Cyclooxygenase Inhibitors; Diclofenac; Dos | 1986 |
Behavioural and electrophysiological evidence for an analgesic effect of a non-steroidal anti-inflammatory agent, sodium diclofenac.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Diclofenac; Dose-Res | 1988 |
[Combination therapy of transcutaneous electric nerve stimulation and iontophoresis with benzydamine and diclofenac].
Topics: Benzydamine; Body Temperature; Combined Modality Therapy; Diclofenac; Electric Stimulation Therapy; | 1988 |
A new metabolite of diclofenac sodium in human plasma.
Topics: Adult; Animals; Biotransformation; Cattle; Chemical Phenomena; Chemistry; Diclofenac; Gas Chromatogr | 1988 |
[Efficacy of diclofenac continuous perfusion in hyperalgic bone metastases. Apropos of 20 cases treated at Gustave Roussy Institute].
Topics: Adult; Aged; Bone Neoplasms; Diclofenac; Female; Humans; Infusions, Intravenous; Male; Middle Aged; | 1988 |
Differentiation of peripheral and central effects of analgesic drugs.
Topics: Acetaminophen; Analgesics; Animals; Aspirin; Diclofenac; Male; Morphine; Pain; Rabbits; Reflex | 1985 |
Diclofenac sodium in the treatment of rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Diclofenac; Double-Blind Method; Female; Humans; Ibuprofen; Male; Mi | 1985 |
Diclofenac in the treatment of painful joints and traumatic tendinitis (including strains and sprains): a brief review.
Topics: Diclofenac; Flufenamic Acid; Humans; Ibuprofen; Indomethacin; Joint Diseases; Ketoprofen; Naproxen; | 1985 |